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Résumé en français  
Les vitamines B et les facteurs liés au métabolisme monocarboné (C1) aident à maintenir la 
synthèse de l’ADN, régulent l'expression des gènes, et peuvent affecter le risque de cancer. 
L'objectif général de cette thèse est d'étudier l'importance des biomarqueurs du C1 dans 
l'étiologie de trois cancers distincts qui diffèrent dans leur force d’association avec le 
tabagisme. Les articles inclus dans cette thèse ont été conduits au sein de deux études 
prospectives : l'étude prospective européenne sur la nutrition et le cancer (EPIC) et le 
consortium de cohortes du cancer du poumon (LC3). 
Dans l’article 1, nous avons étudié la relation entre les biomarqueurs du C1 et l'incidence ainsi 
que le pronostic du cancer de la sphère oto-rhino-laryngée (ORL) et de l'œsophage au sein de 
l'étude EPIC. Nous avons observé que les sujets ayant des concentrations élevées 
d'homocystéine avaient un risque accru de développer un cancer de la sphère ORL. 
Dans l’article 2, nous avons examiné la relation entre les biomarqueurs du C1 et l'incidence 
ainsi que le pronostic du carcinome à cellules rénales (CCR) au sein de l'étude EPIC. Nous avons 
constaté que les participants ayant des concentrations de vitamine B6 élevées avaient une 
diminution du risque de CCR avec un effet dose-réponse ainsi qu’une amélioration de la survie 
post-diagnostic. 
Dans l’article 3, nous avons étudié si les biomarqueurs du C1 sont associés au risque de cancer 
du poumon au sein de l'étude LC3. Dans l'ensemble, nous avons mis en exergue une faible 
association inverse, sans tendance claire, entre les concentrations de vitamine B6 et de folate 
et le risque du cancer du poumon. 
La principale conclusion de nos études est que les concentrations élevées de vitamine B6 sont 
associées à un risque plus faible de développer un CCR, et également à un meilleur pronostic 
chez les patients atteints de cette pathologie. Davantage d’études sont nécessaires afin 
d’évaluer si la vitamine B6 exerce une influence causale sur l’étiologie et la mortalité du CCR, 
ou si d'autres facteurs métaboliques sont impliqués. 
Mots clés: métabolisme monocarboné, cancer du poumon, cancer de la tête et du cou, 
carcinome à cellules rénales, EPIC, LC3, étude prospective. 
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English summary 
B-vitamins and factors related to one-carbon metabolism (OCM) pathway help to maintain 
DNA synthesis and regulate gene expression and may affect cancer risk. The overarching aim of 
this thesis is to investigate the importance of OCM biomarkers in the etiology of three distinct 
cancer sites that differed in their strength of association with smoking. Papers included in this 
thesis were conducted within two prospective studies, the European Prospective Investigation 
into nutrition and Cancer (EPIC) study and the Lung Cancer Cohort Consortium (LC3). 
In paper 1, we investigated if OCM biomarkers are associated with incidence and survival of 
cancer of the head and neck and esophagus in the EPIC study. We observed that subjects with 
higher concentrations of homocysteine had increased risk of developing head and neck cancer.  
In paper 2, we investigated if OCM biomarkers are associated with incidence and survival of 
renal cell carcinoma (RCC) in the EPIC study. We observed that study subjects with elevated 
vitamin B6 concentrations had lower risk of RCC in a dose-response fashion and improved 
survival following diagnosis.  
In paper 3, we investigated whether OCM factors are associated with lung cancer risk in the 
LC3 study. Overall, we observed a weak inverse association, with no clear trend, between 
concentrations of vitamin B6 and folate and risk of lung cancer.  
The most important conclusion is that elevated vitamin B6 concentrations are associated with 
lower risk of developing RCC, and also better prognosis among RCC cases. Further studies are 
warranted to evaluate if vitamin B6 exerts a causal influence on RCC etiology and mortality, or 
if other metabolic factors are involved. 
 
Key words: One-carbon metabolism, lung cancer, head and neck cancer, renal cell carcinoma, 
EPIC, LC3, prospective study 
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Résumé substantiel en français 
 
Les cancers liés au tabagisme sont définis comme les cancers causés par des expositions au 
tabac. À ce jour, plus de 3000 constituants ont été isolés à partir du tabac. Les avancées 
technologiques ont permis l'identification d'environ 70 substances cancérigènes dans la 
fumée du tabac, ainsi qu’une substance puissamment addictive, la nicotine. La fumée des 
produits du tabac, et en particulier des cigarettes est le facteur de risque le plus important 
pour le cancer. Il a été montré que cette exposition est clairement associée à un tiers de 
tous les cancers à l’échelle mondiale incluant les cancers du poumon (70-80% de tous les 
cas), de la tête et du cou (60-70%), du foie (50%) et du rein (30%). Ces connaissances ont été 
traduites par l’évitement du tabac et la mise en place de programmes de sevrage, ce qui a 
conduit à des réductions d’incidence de cancers liés au tabagisme (notamment le cancer du 
poumon) chez les hommes dans la plupart des pays européens. Même chez les sujets qui 
ont cessé de fumer, le risque à vie de cancer lié au tabagisme reste élevé. De plus, dans 
certaines populations où les campagnes anti-tabac ont été couronnées de succès, comme 
aux États-Unis, près de 50% des cas de cancer du poumon surviennent chez les non et 
anciens fumeurs. Il parait essentiel d’identifier des facteurs de risque afin d’en dégager des 
informations supplémentaires inter et intra groupes de fumeurs. Les conclusions mises en 
évidence revêtiraient un intérêt majeur pour la santé publique.  
L’alimentation et la nutrition sont supposées jouer un rôle fondamental dans le 
développement des cancers les plus courants. Il a été estimé qu’une mauvaise alimentation, 
en particulier une faible consommation de fruits et légumes, contribuerait à environ un tiers 
des cancers évitables. Les fruits et légumes sont des sources de vitamines B et d'autres 
micronutriments pour le métabolisme monocarboné (C1). Des carences et/ou déséquilibres 
de micronutriments dans la voie du C1 peuvent affecter le risque de cancer par le biais de 
multiples mécanismes tels que les méthylations anormales d'ADN ou des altérations dans 
les processus de réparation et de synthèse de l'ADN. Malgré un certain nombre d'études 
épidémiologiques suggérant un rôle possible du folate (vitamine B9) dans la prévention du 
cancer, en particulier le cancer colorectal, les preuves suggérant un lien de causalité entre le 
C1 et la carcinogenèse sont limitées. De fortes associations inverses entre des 
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concentrations pré-diagnostiques élevées de biomarqueurs du C1 (notamment la vitamine 
B6, le folate, et la méthionine) et le risque du cancer du poumon ont été récemment 
signalées dans une grande étude cas-témoins nichée au sein de l'étude EPIC. L'étude a 
notamment révélé des associations fortes et cohérentes parmi les non et anciens fumeurs, 
suggérant que les résultats n’étaient probablement pas dus au facteur de confusion qu’est 
le tabagisme. 
L'objectif général de cette thèse est d'étudier l'importance des biomarqueurs du C1 dans 
l'étiologie de trois cancer distincts (sphère ORL, rein et poumon) qui diffèrent dans leur 
force d’association avec le tabagisme. 
Dans l'article 1, nous avons étudié la relation entre les concentrations circulantes des 
facteurs du C1 et l’incidence ainsi que le pronostic du cancer de la sphère ORL et de 
l'œsophage. Un échantillon de 516 cas et 516 témoins appariés individuellement sur le pays, 
le sexe, la date de naissance, le pays et le prélèvement de sang a été recruté à partir de 
l’étude EPIC. Les concentrations plasmatiques de vitamines B2, B6, B9 (folate), B12, 
d'homocystéine et de méthionine ont été mesurées à partir d’échantillons pré-
diagnostiques sanguins. Nous avons remarqué que les sujets ayant des concentrations 
élevées d'homocystéine avaient un risque accru de développer un cancer de la tête et du 
cou. L'association positive de l'homocystéine était présente à la fois chez les non-fumeurs et 
les non-consommateurs d’alcool. Les concentrations circulantes des autres biomarqueurs ne 
présentaient aucun lien évident avec le risque ou la survie. 
Dans l'article 2, nous voulions évaluer l’ampleur avec laquelle l'homocystéine ou d'autres 
biomarqueurs inclus dans la voie du C1 pouvait être liée à l'incidence et au pronostic du 
carcinome à cellules rénales (CCR). Une raison supplémentaire d’étudier l'association entre 
les biomarqueurs du C1 et les CCR est que ce type de cancer présente une force 
d’association avec le tabagisme moindre comparé au cancer de la tête et du cou. Les 
concentrations plasmatiques de vitamines B2, B6, B9, B12, d’homocystéine et de 
méthionine ont été mesurées à partir d’échantillons pré-diagnostiques sanguins auprès de 
tous les participants de cette étude. Dans un premier temps nous avons recruté 556 paires 
cas-témoins au sein de la cohorte EPIC. Globalement, nous avons observé que les sujets 
d’EPIC ayant des concentrations de vitamine B6 élevées avaient moins de risque de CCR, de 
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manière dose-réponse, résultant à une diminution du risque approximative de 60%  lorsque 
les quartiles supérieurs et inférieurs de la population étaient comparés. Nous avons 
également remarqué une claire amélioration de la survie auprès des cas atteints de CCR 
ayant des concentrations de vitamine B6 plus élevées. Afin de s’assurer que la relation entre 
la vitamine B6 et le carcinome à cellules rénales n’était pas restreinte à l’étude EPIC, une 
étude de réplication a été menée dans une cohorte distincte d’Australie, la Melbourne 
Collaborative Cohort Study (MCCS) incluant 144 paires cas-témoins. Nous avons obtenu des 
résultats significativement similaires à ceux observés dans la cohorte EPIC concernant les 
risques de CCR ainsi que la mortalité par cancer. 
Dans l'article 3, nous voulions valider certaines conclusions antérieurement citées et 
observées au sein de la cohorte EPIC, impliquant de fortes associations inverses entre le 
folate, la vitamine B6 et la méthionine et le risque de cancer du poumon. Nous avons donc 
étudié l'association de ces trois biomarqueurs avec le risque de cancer du poumon au sein 
d’un vaste consortium, le consortium de cohortes du cancer du poumon (LC3). Ce dernier 
rassemble plusieurs populations d’Amérique, d’Europe, d’Asie et d’Australie. Au total, vingt 
études cas-témoins nichées ont contribué à cette étude avec des échantillons sanguins pré-
diagnostiques de vitamines B6, B9 et de méthionine mesurées auprès des 5 364 paires de 
cas-témoins. Les critères d'appariement étaient la cohorte d’appartenance, le sexe, la date 
du prélèvement de sang, la date de naissance et le statut tabagique. Dans l'ensemble, nous 
avons observé de faibles associations inverses, sans tendance claire, entre les 
concentrations de vitamine B6, de folate et le risque de cancer du poumon, associations 
principalement présentes chez les fumeurs anciens et quotidiens. Réciproquement, les 
fumeurs anciens et quotidiens ayant un déficit en concentrations circulantes de vitamine B6 
et de folate comparés à ceux ayant des concentrations normales ont montré une faible 
augmentation du risque du cancer du poumon. 
En résumé, nos études suggèrent que les concentrations circulantes d'homocystéine 
affectent le risque de développer un cancer de la tête et du cou. Ces résultats nouveaux 
doivent être répliqués dans d'autres études prospectives de grandes tailles ainsi que dans 
différentes populations éthniques. 
Les résultats de l'étude LC3 ne soutiennent pas l'association inverse entre les concentrations 
circulantes élevées de vitamine B6 et la diminution du risque de cancer du poumon, comme 
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précédemment indiqué dans l'étude EPIC du poumon. Cependant, nous avons remarqué  de 
fortes associations entre le déficit en vitamine B6 et le risque du cancer du poumon suivant 
les trois ans après le diagnostic chez des fumeurs quotidiens. Cette observation soulève 
l’hypothèse que la vitamine B6 circulante pourrait être un potentiel prédicteur de risque 
chez les fumeurs quotidiens ayant été diagnostiqués proches de l’échantillon sanguin. 
La principale conclusion de nos recherches est que les participants de l’étude EPIC ayant des 
concentrations circulantes de vitamine B6 élevées ont un moindre risque de développer un 
carcinome à cellules rénales tout en ayant un meilleur pronostic une fois cette maladie 
diagnostiquée. Cependant, des études complémentaires sont nécessaires pour évaluer si la 
vitamine B6 exerce une influence causale sur l’étiologie et la mortalité du CCR, ou si d'autres 
facteurs métaboliques sont impliqués. 
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Overview and aim 
Smoking-related cancers are defined as cancers caused by tobacco exposures. Over 3000 
constituents have been isolated from tobacco and advancing technologies have permitted 
the identification around 70 carcinogens in tobacco smoke to date, as well as a powerfully 
addictive substance, nicotine1. Approximately 1.1 billion people worldwide smoke with 
important sex-differences. In many countries, smoking rates are increasing in young women, 
with potentially grave consequences for cancer2. Smoking of tobacco products, and in 
particular cigarettes is the most important risk factor for cancer and has been shown to be 
clearly associated with about one in three of all cancers globally3, including lung (70-80% of 
all cases)4, head and neck (60-70%,)5, liver (50%)6 and kidney (30%)7. This knowledge has 
been translated into tobacco avoidance and cessation programs, which has led to 
reductions in smoking-related cancer (most notably lung cancer) incidence among men in 
most European countries8. While it has been observed that in populations where the large 
proportion of the population are no longer current smokers, the majority of smoking-
related cancer cases continue to occur among former smokers. In addition, survival from 
smoking-related cancers is poor, with 5-year mortality in the region of approximately 85% 
for lung cancer and 50% for other cancers sites such as head and neck cancer9. Identifying 
modifiable additional risk factors within and across smoking groups remains of great clinical 
and public health interest.   
Diet and nutrition are thought to play a fundamental role in the development of most 
common cancers10. It has been estimated that poor diet, in particular low intake of fruit and 
vegetables contribute to about one-third of preventable cancers11. Fruits and vegetables are 
sources of B-vitamins and other metabolites of the one-carbon metabolism (OCM) pathway. 
Deficiencies and/or imbalances of the micronutrients in the OCM pathway may impact 
cancer risk through multiple mechanisms such as aberrant DNA methylation patterns or 
DNA damage through an oxidative imbalance. Despite a number of epidemiological studies 
suggesting a possible role of folate (vitamin B9) in cancer prevention, particularly for 
colorectal cancer, evidence supporting a causal relationship between OCM and 
carcinogenesis is lacking. Strong inverse associations of elevated pre-diagnostic circulating 
concentrations of OCM biomarkers (in particular vitamin B6, folate, and also methionine) 
with lung cancer risk have been recently reported in a large nested case-control study within 
the European Prospective Investigation into Cancer and Nutrition (EPIC)12. The study found 
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strong and consistent associations for never- and former smokers, suggesting that the result 
was unlikely to be due to confounding by smoking.  
The overarching aim of this thesis is to investigate the importance of OCM biomarkers in the 
etiology of three distinct cancer sites (head and neck, kidney and lung) that differed in their 
strength of association with smoking. The head and neck cancer (HNC) and the renal cell 
carcinoma (RCC) studies investigated in EPIC cohort whether pre-diagnostic circulating 
markers of the one-carbon pathway including vitamin B2, vitamin B6, folate, vitamin B12, 
homocysteine and methionine are related to incidence and survival of cancer of the head 
and neck and squamous cell eosphagus (Chapter III), and RCC (Chapter IV), in a similar or 
different way as for lung cancer. The Lung Cancer Cohort Consortium (LC3) study (Chapter 
V) evaluated whether pre-diagnostic circulating concentrations of vitamin B6, folate and 
methionine are associated with lung cancer risk in a worldwide consortium of prospective 
cohort studies, in order to assess the generalisability of the recently published findings13.  
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Smoking related-cancers - epidemiologic evidence 
Lung cancer  
Incidence and mortality 
Lung cancer has been reported as the most common cancer globally, with approximately 
1,800,000 new cases diagnosed annually14. In 2012, lung cancer accounted for an estimated 
240,000 new cases in the United States (US), representing 15% of lung cancers worldwide14.  
However, incidence rates of lung cancer display remarkable variation across the world (see 
Figure 1)15. 
 
Figure 1. Age-standardized incidence and mortality rates (world) per 100,000 for lung cancer in 2012. Source: 
Globocan 201215. 
 
Among men, the highest estimated age-standardised incidence rates (ASR) are observed in 
Central and Eastern Europe (53.5 per 100,000), Eastern Asia (50.4 per 100,000) and North 
America (48.5 per 100,000) and  the lowest ASR are located in sub-Saharan Africa (4.8 per 
100,000)15. Similar to men, the highest incidence rates among women are also observed in 
North America (33.8 per 100,000) and Eastern Asia (19.2 per 100,000) while the lowest ASR 
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are also located in sub-Saharan Africa (2.5 per 100,000). When comparing incidence rates by 
sex, rates are generally lower in women than in men, mainly reflecting different historical 
exposure to tobacco smoking where women started smoking in large numbers several 
decades later than men16. However, recent trends show that lung cancer among women is 
increasing considerably in many countries including European countries17.     
 
Lung cancer has an enormous impact on worldwide mortality, estimated to be responsible 
for nearly 1.6 million deaths worldwide in 20122. Geographical patterns of mortality are 
quite similar to those of incidence for both sexes (see Figure 1) due to the rapid course of 
the disease after diagnosis, then reflecting the poor 5-year survival. Lung cancer mortality 
among men is decreasing in most Western countries, including many European countries, 
where the tobacco epidemic diminished after the middle of the last century17-19. By contrast, 
it has risen sharply in many low- and middle-income countries who were at an earlier stage 
in the smoking epidemic, such as China and Indonesia2. 
 
Lung cancer five-year relative survival rate for all stages combined is about 15% in the 
United States and Europe9 20 21. Survival is strongly influenced by histology and stage at 
diagnosis. The main histological types of lung cancer encompass small cell lung carcinoma 
(SCLC), squamous cell carcinoma (SCC), adenocarcinoma and large cell carcinoma (the latter 
three types being commonly referred as non-small cell lung carcinoma, or NSCLC). SCLC, 
representing less than 20% of the overall lung cancer burden, is usually classified as limited 
or extensive and is generally responsive to therapy22. In contrast, NSCLC representing over 
80% of lung cancers are categorized using the TNM Classification of Malignant Tumours into 
various stages23. Recent data from US (see Figure 2) shows that overall 5-year survival of 
lung cancer is over 20%. When stratifying by stage (see Figure 3), it has been observed that 
cases diagnosed at early stages have a 5-year survival ranging from 30%-60% (stage I and II). 
In contrast, cases diagnosed at a later stage (i.e. IV) have very poor prognosis with 5-year 
survival of below 5%.  
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Figure 2. Observed 5-years survival based in 
patients diagnosed with NSCLC in 2004-2009 on 
the SEER 9 areas (San Francisco, Connecticut, 
Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, 
and Atlanta), adapted from the SEER database9. 
 
 
 
 
 
 
 
 
 
 
 
 
Risk factors of lung cancer 
Epidemiological evidence of the association between tobacco smoking and cancer began to 
emerge in the 1920’s24 and by the 1950’s the causal relationship with lung cancer was 
established by Doll and Hill25 26. They reported that smokers who smoked 25 or more 
cigarettes per day had 50 times increased risk of lung cancer compared to non-smokers. This 
work was followed by several epidemiological studies, and by the mid-1960s, the causal 
association between lung cancer and smoking was recognized by public health and 
regulatory authorities. In 1986, the International Agency for Research on Cancer (IARC) 
monograph also reported the causality of tobacco smoking with lung cancer27. The excess 
risk of lung cancer among smokers relative to non-smokers depends on several aspects 
including intensity of smoking, duration of smoking, type of smoking product and age at 
start28 29.  
 
While tobacco exposure is well known to be strongly associated with lung cancer in ever 
smokers, there is still limited evidence of the causes of lung cancer in never. Secondhand 
smoke has been established as a major risk factor among never smokers30. Also, other 
factors including indoor pollutants (coal, wood fire indoors)31 32 and outdoor air pollution33 
may affect lung cancer development. 
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Figure 3. 5-year survival by stage for people 
diagnosed with lung cancer in 2004-2009 on the 
SEER 9 areas (San Francisco, Connecticut, Detroit, 
Hawaii, Iowa, New Mexico, Seattle, Utah, and 
Atlanta), adapted from the SEER database8. 
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Additional chemical substances have been linked to lung cancer, such as radon. According to 
the US Environmental Protection Agency (EPA), this radioactive gas causes about 20,000 
cases of lung cancer each year34 35. There is also convincing evidence from several ecological, 
case-control and cohort studies showing that arsenic in drinking water has a causal 
relationship with lung cancer36 37. Other substances found to increase lung cancer risk 
include asbestos and silica 37. 
 
Recent conclusion from the IARC monograph stated that there was possible but not 
established evidence for carcinogenicity of alcohol consumption with lung cancer38. 
However, it is difficult to disentangle the role of alcohol in lung cancer development given 
the strong correlation between alcohol drinking and tobacco smoking. Heavy drinkers tend 
to be heavy smokers suggesting that tobacco may be a confounding variable in the relation 
between alcohol and lung cancer. A recent meta-analysis among never smokers diagnosed 
with lung cancer suggested that alcohol does not play an independent role in lung cancer39.  
High consumption of fruit and vegetables might protect against lung cancer. While 
consistent inverse associations between dietary intake of fruit and lung cancer risk have 
been reported in both case-control and cohort studies 37 , the role of vegetables is less clear. 
A review of several  case-control studies have suggested a protective effect of high 
vegetable intake in lung cancer, but several prospective studies  did not support this 
hypothesis40. Possible reasons of this discrepancy might result from bias including 
misclassification of exposure, retrospective dietary assessment and variability in food 
consumption between absence and presence of the disease. Also, residual confounding by 
cigarette smoking might explain these results, as some of the studies investigating the 
relation of vegetables with lung cancer did not adjust for smoking.  
Several micronutrients have been investigated in relation to lung cancer and one of the 
most controversial is beta-carotene. Risk estimates from a polled analysis of case-control 
and cohort studies reported lower lung cancer incidence for participants having high beta-
carotene intake37. Thus, investigators hypothesised that beta-carotene may be related to 
lower lung cancer risk, and initiated randomized controlled trials (RCTs) were initiated in 
high lung cancer risk populations (middle-aged men that were smokers and/or exposed to 
asbestos). However, the Alpha-Tocopherol, Beta-Carotene, Prevention Cancer (ATBC) trial 
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reported that supplementation of beta-carotene increased lung cancer incidence37. An 
evaluation work from IARC concluded that high doses of beta-carotene supplements might 
not prevent lung cancer41. The World Cancer Research Fund/American Institute for Cancer 
Research (WCRF/AICR) and several health authorities do not recommend that smokers take 
supplemental doses of beta-carotene. Several other micronutrient including vitamin A and 
E, lycopene, zinc and alpha-carotene have been investigated in relation to lung cancer risk, 
but to date evidence is not conclusive of any protective effect for lung cancer37 42.  
 
 
Head and neck cancer  
Incidence and mortality 
Head and neck cancer (HNC) encompass a group of tumours, at various sites around oral 
cavity, larynx, oropharynx and hypopharynx43 44. Over 90% of head and neck cancers are 
squamous cell carcinoma (HNSCC), arising from the epithelial cells that line the mucosal 
surfaces of the head and neck45 (see Figure 4). 
 
 
Figure 4. Schematic of various head and neck malignancies. Source from Terese Winslow LLC. 
 
HNC is the sixth most common cancer type worldwide and affects nearly 650,000 individuals 
per year, and causes over 350,000 deaths46 47. The geographical inequalities in the burden of 
HNC are noticeable, with over 50 % of all cases occurring in developing countries15. 
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According to world estimations (see Figure 5), incidence rates of HNC are highest in 
Melanesia and South-Central Asia, in both sexes.  
 
Figure 5. Age-standardized incidence and mortality rates (world) per 100,000 for head and neck cancer (lip, 
oral cavity, larynx, nasopharynx and other pharynx) in 2012. Source: Globocan 201215. 
 
Globally, men are affected significantly more by HNC than women with a ratio ranging from 
2:1 to 4:115. However, incidence by sex varies with anatomic location and has been changing 
as the number of female smokers has increased over the last decades. The male-female 
ratio is currently about 8:1 for laryngeal cancer and approximately 2:1 for nasopharyngeal 
cancer15. 
 
Despite significant advances in multidisciplinary treatments of HNC including surgery, 
chemotherapy and radiation, the current 5-year survival rate from HNSCC of 50% has 
improved very little over the last 30 years48 49. Moreover, the prognosis is generally better 
for women compared to men and for neoplasms located in oral cavity and larynx than for 
those arising in the hypopharynx (see Figure 6).  
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Figure 6. 5-year relative survival of HNC subsites in US, adapted from the SEER database49. 
 
 
Risk factors of head and neck cancer 
Most HNC cases are attributable to tobacco smoking, alcohol drinking, and the established 
interaction between these two factors50. A positive association between tobacco smoking 
and HNC has been reported consistently in many studies1 27 50-52. Although the association 
with tobacco smoking is not as strong as with lung cancer, it remains very high with excess 
risk estimates among current smokers approaching 4 to 6-fold that among non-smokers1. 
Smoking is likely to be differentially associated with risk of subtypes of the HNC38 39 51 52. 
Both a recent meta-analysis of 28 case-control studies53 and a large cohort study from 
Netherlands (NLCS)54 reported that smoking was more strongly associated with laryngeal 
and oropharyngeal cancers than those from the oral cavity.  
Similarly, substantial epidemiologic evidence from the last three decades demonstrates that 
alcohol consumption increases risk of the HNC. Recently, the Monograph Working Group of 
IARC concluded that there “was sufficient evidence” for the carcinogenicity of alcohol in 
animals and classified alcoholic beverages as carcinogenic to humans55. In particular, the 
group confirmed, and newly established, the causal link between alcohol consumption and 
several cancers including the cancer of the oral cavity, pharynx, larynx and oesophagus38. 
Furthermore, several epidemiological studies showed a significant, positive, multiplicative 
interaction between tobacco smoking and alcohol consumption with HNC risk. As an 
example, the NLSC cohort reported that current smokers compared to never had higher risk 
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of HNC overall (relative risk [RR] 4.49, 95% CI 3.11-6.48) and that participants consuming 
≥30 grams of alcohol per day compared with abstinence had also  increased risk of HNC 
overall (RR = 2.74, 95% CI 1.85-4.06). When comparing participants smoking ≥ 20 cigarettes 
and drinking ≥30 g alcohol per day compared with never smokers abstaining from alcohol 
the RR was 8.28 (95% confidence interval [95% CI] 3.98-17.22 (interaction between 
categories of alcohol consumption and cigarette smoking was 0.03)54. Moreover, a positive 
association of tobacco smoking with HNC risk has been observed among non-drinkers and 
similarly alcohol consumption has been shown to increase risk of HNC among non-
smokers56. Other studies reported similar results which aim to support the independent role 
of tobacco smoking and alcohol intake in HNC development. 
 
Viral infection is a recognised risk factor for cancer of the head and neck. The association 
between Epstein-Barr virus infection and the development of head and neck cancer 
subtypes in particular nasopharyngeal cancer was first recognised in 196657. More recently, 
human papilloma virus (HPV) has attracted attention58, with recent observational studies 
finding it to be a strong risk factor for the development of head and neck cancer. In 
particular, there is substantial evidence for a role of HPV16 in the oropharyngeal cancer 
etiology38 59.  
 
Diet is estimated to contribute to about one-third of preventable cancers37 60. One of the 
most convincing pieces of epidemiological evidence for the role of dietary factors in cancer 
risk is the inverse relationship between the consumption of fruit and vegetables and HNC. 
Indeed, comprehensive evidence, both from case-control and cohort studies have shown 
that people with a low intake of fruit and vegetables have higher cancer incidence of the 
head and neck compared with those having a high fruit and vegetable intake37 61 62. 
Importantly, the last expert report from the World Cancer Research Fund (WCRF) stated 
that fruits, non-starchy vegetables, and foods containing carotenoids are probable 
decreased risk for HNC37. However, the evidence of the role of other food groups and the 
risk of HNC is inconsistent. Some epidemiological studies suggested that consumption of 
meat was associated with increased risk of  HNC37 63 64, whereas other have reported no 
Anouar Fanidi, 2016 
33 
 
association65 66. Despite the potential role of vegetable and fruit consumption in the etiology 
of HNC, residual confounding by smoking and alcohol is still a real concern.  
 
While it can be difficult to disentangle the exact role of micronutrients individually with 
HNC, experimental and observational studies suggested that vitamin C37 67, vitamin E37 68, 
and beta-carotene37 69 might reduce risk of HNC. Additionally, mainly retrospective studies 
have investigated folate and HNC risk, most reporting that higher dietary folate is inversely 
associated with HNC risk70. However, given the potential for reverse causality and recall bias 
to influence the results in retrospective case-control studies, it is difficult to interpret these 
results causally. 
 
Esopheageal cancer 
Incidence and mortality 
Esopheageal cancer is the eighth most common cancer worldwide, with an estimated 
450,000 new cases in 2012, and the sixth most common cause of cancer death with an 
estimated 400,000 deaths15. Cancer of the esophagus includes mostly two histologic types, 
esophagus squamous cell carcinoma (ESCC) and esophagus adenocarcinoma (EAC), although 
ESCC is the predominant histologic type of esophageal cancer worldwide71. Throughout this 
dissertation we will focus on ESCC. In 2012, ESCC accounted for an estimated 398,000 new 
incident cases worldwide with a global ASR of 5.2 per 100,000 (7.7 in men and 2.8 in 
women, see Figure 7). The highest incidence rates are observed in Eastern/ South-eastern 
Asia (13.6 in men and 4.3 in women), sub-Saharan Africa (6.4 in men and 4.0 in women), and 
Central Asia (5.9 in men and 3.6 in women). The lowest incidence rates occurred in North 
America (1.7 in men and 0.7 in women), and Southern Europe (2.4 in men and 0.4 in 
women)71. Furthermore, it has been reported that about 80% of ESCC occurred within what 
is named the “esophageal cancer belt,” an area extends from northeast China to the Middle 
East72.  
Globally, incidence rates of ESSC have been steadily declining in Western countries due to 
long-term reductions in alcohol intake and tobacco use in contrast to some Asian countries 
such as Taiwan where ESCC has been increasing, likely due to increase of tobacco and 
alcohol consumption73.  It has been also reported that ESCC incidence vary across ethnicities 
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with two to three times higher estimates in blacks than in whites, in particular in North 
America74. 
 
 
 
Figure 7. Age-standardised incidence rates per 100, 000 of oesophageal cancers by histological subtype, region 
and sex. AC, adenocarcinoma; SCC, squamous cell carcinoma. Source from Arnold M et al71. 
 
 
There is generally no difference reported in survival between the two histological types, EAC 
and ESCC75. Geographical patterns of mortality are quite similar to those of incidence for 
both sexes due to the rapid course of the disease after diagnosis, then reflecting very poor 
survival, with 5-year survival rates of 19% (2003-2009) in the USA72 and 12% (2000-2007) in 
Europe75.  
 
Risk factors of esophagus squamous cell carcinoma.  
The positive association between tobacco smoking and ESCC is well established. Cancer of 
the esophagus consistently occurs less frequently among participants who do not smoke, 
with supporting data from both control and cohort studies76-80. A recent prospective cohort 
study from Netherlands79 reported that current smokers had higher risk of ESSC compared 
with never smokers, the RR being 2.63 (95% CI 1.47-4.69). However, the risk of ESCC among 
current smokers can be much stronger. Fredman et al. showed in a large prospective US 
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cohort of 476,606 participants that compared with non-smokers, current smokers were at 
increased risk for ESCC with a hazard ratio (HR) equal to 9.27 (95% CI 4.04-21.29)76. 
 
Furthermore, the excess risk of ESCC among smokers relative to non-smokers depends on 
several aspects including smoking intensity and  duration of smoking81. A number of studies 
also observed that smokeless tobacco products and betel liquid (with or without tobacco) 
increased risk of ESCC, in particular in Asia82-84. 
 
The association between alcohol consumption and risk of ESCC has been described in many 
studies76-80 85 and showed consistent positive association between alcohol consumption and 
ESSC risk. As an example, a recent meta-analysis of 40 case-control and 13 cohort studies 
showed that that after adjusting for age, sex, and tobacco smoking the RR for the 
association between light alcohol drinking (12.5 g/d) and risk of ESCC was 1.38 (95% CI 1.14-
1.67). The RRs were 2.62 (95% CI 2.07-3.31) among moderate drinkers (>12.5–<50 g/d) and 
5.54 (95% CI 3.92-7.28) for high alcohol intake (50 g/d)86.  
 
Tobacco smoking and alcohol intake act also synergistically (effect arising from the two 
factors) in a multiplicative manner on ESCC. As an example, a recent meta-analysis reported 
the effects of alcohol consumption and tobacco use on ESCC, both alone and in 
combination87. They found that never smokers with alcohol use had increased risk of ESCC 
(odds ratio [OR] being 1.21, 95% CI 0.81-1.81), although this association was statistically 
nonsignificant, and that never drinkers with tobacco use had also increase risk of ESCC (OR 
1.36, 95% CI 1.14-1.61). This association was stronger when they looked both among alcohol 
and tobacco users with OR being 3.28 (95 % CI 2.11-5.08).  
 
There have been numerous studies assessing the relation between diet and nutrition with 
ESSC etiology. Many case-controls and cohort studies showed that high consumption of fruit 
and vegetables were inversely associated with ESCC risk37 88-90. As an example, a recent 
prospective cohort study of 38,790 Japanese men aged 45–74 years showed that 
participants with highest consumption of total fruit and vegetables compared to the lowest 
had around 50% decreased risk of ESCC (HR 0.52, 95% CI 0.30-0.88)91.  
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A number of epidemiological studies have investigated the relation between micronutrients 
including folate, beta-carotene, vitamin C and vitamin E, and ESCC risk37 92-94, and some have 
proved an inverse association88 95. Folate intake is one of the micronutrient that has been 
assessed in several studies and showed consistent results. In 2006, Larson C et al. reported 
from a meta-analysis that the summary relative risk for the highest versus the lowest 
category of folate intake was 0.66 (95% CI 0.53-0.83) for ESCC94. Similarly, a recent large 
prospective study including 492 293 participants found that those with low levels of folate 
intake compared to high levels had around 90% increased risk of ESCC, the RR being 1.91 
(95% CI 1.17-3.10)96.  
 
Over the past two decades, the HPV in ESCC has received increasing attention and several 
studies using various methods have confirmed the presence of HPV in ESCC97-100  . A recent 
case-control study from China showed that the presence of HPV in the esophagus was 
associated with increased risk of ESCC (OR 6.4, 95% CI 4.4-9.2)101. 
 
Body mass index, a surrogate indicator of obesity, has been inversely associated with the 
risk of ESCC in some investigations37 102, although issues remain regarding confounding by 
smoking as alternative explanations. However, a recent population-based case-control study 
comprising 287 ESCC cases and 1,544 controls reported that after adjusting for smoking the 
risk of ESCC was reduced by 35% (range, 23%-44%) per 5-unit increase in recent BMI103.   
 
 
Kidney cancer  
Incidence and mortality 
As for cancer of the head and neck and lung, incidence rates of kidney cancer vary greatly 
across the world (see Figure 8). In 2012, the incidence rate of kidney cancer was the highest 
in Europe, with Czech Republic rising the top ASR worldwide per 100,000 for both sexes 
(24.1 in men and 10.5 in women)15 . The lowest rates are observed in Asia (3.8 in men and 
1.9 in women) and in Africa (1.4 in men and 1.1 in women).  
In addition, stratifications by ethnic group as shown in United States indicate that African 
Americans and European Americans have on average two-fold higher ASR than Asian 
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Americans104. Figure 7 demonstrates also that men have approximately 2-fold higher kidney 
cancer incidence than women. 
 
 
Figure 8. Age-standardized incidence and mortality rates (world) per 100,000 for kidney cancer in 2012. Source: 
Globocan 201215. 
 
Renal cell carcinoma (RCC) is the predominant type of kidney cancer and accounts for 
approximately 80 to 85% of cases104. Four subtypes of RCC have been established: papillary, 
chromophobe, collecting duct, and clear-cell, the latter accounting over 85% of RCC.  
Compared to the cancer of the lung and the head and neck, survival estimates after cancer 
diagnosis is better. From the Surveillance, Epidemiology and End Results Program (SEER)9, 
over 65% of kidney and renal pelvis cancer are diagnosed at the local stage (i.e. early stage 
including stage I, IIA and IIB), and 5-year survival for localized kidney and renal pelvis cancer 
is about 90% in United State. Further, recent data from eight international centres (see 
Figure 9) show that cases diagnosed with clear-cell carcinoma at early stages (i.e. stage I and 
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II) have a 5-year survival over 80% whereas cases diagnosed at a later stage (i.e. III and IV) 
have poorer prognosis with 5-year survival below 50%105. 
 
 
 
Figure 9. Survival estimates in 4,063 patients with renal tumours according to histologic subtype and TNM 
stage. (A) TNM stage I to II. (B) TNM stage III to IV. Red dashed lines correspond to five-year survival. Source 
from Patard JJ et al.105. 
 
 
Risk factors of kidney cancer 
Kidney cancer is less affected by smoking exposure than lung and head and neck. However, 
this exposure is considered as a causal risk factor for kidney cancer104 106. Tobacco smoking 
has been consistently reported to be a risk factor for this type of cancer, with increased risks 
compared to never smokers in the order of 50%1 7. Several epidemiological studies showed a 
clear dose-response pattern resulting in two to three-fold risk differences between heavy 
smokers and people who have never smoked1 7 107. 
 
Obesity has been frequently studied in relation to cancer risk and different reports showed 
that this exposure increases the risk of kidney cancer37 108. In prospective studies conducted 
worldwide, overweight and obese individuals have an elevated risk of RCC in a dose-
response manner109-111. Furthermore, hypertension has been consistently associated with 
higher risk of kidney cancer104 112. Several observational studies have reported an 
association with a history of long-term hypertension, and cohort studies of blood pressure 
measurements taken at baseline have generally shown a positive dose-response 
5-years survival
Anouar Fanidi, 2016 
39 
 
relationship113-116. Despite the high correlation between obesity and hypertension, it has 
been suggested that these two risk factors alone may play an independent role in kidney 
cancer104 117. Furthermore, it has been pointed out that diabetes mellitus may increase 
kidney cancer risk, but results from case-controls as well cohort studies are not consistent104 
118. 
 
Despite alcohol intake being strongly positively related to cancer of the head and neck as 
previously shown, evidence from both case-control and cohort studies suggest that 
alcoholic drinks might protect against kidney cancer119 120. A recent meta-analysis of fifteen 
case-control studies observed an inverse association between alcohol consumption and RCC 
in both the overall alcohol intake group (OR 0.67, 95% CI 0.62-0.73) and subgroups analyses 
including sex, study design and geographical region123. A similar trend was observed in a 
meta-analysis of cohort studies involving over 750,000 subjects indicating that moderate 
alcohol consumption was associated with a lower risk (pooled multivariable RR 0.72, 95% CI 
0.60-0.86) of RCC overall and this inverse association was also seen among both women and 
men124.  
 
The evidence supporting dietary influences on kidney cancer etiology is less established 
than those observed for HNC.  However, a recent pooled analysis of 13 prospective studies 
reported significant inverse associations between combined intake of fruit and vegetables in 
relation to renal cell carcinoma, with a stronger association for fruit125. Despite a potential 
role of fruit and vegetable intake in RCC etiology, it is difficult to disentangle which 
micronutrient might be involved in those associations. Different epidemiological studies 
investigating the role of beta-carotene, lycopene and folate in relation to kidney 
carcinogenesis are weak, but seems to point out an inverse association between both 
carotene125-127 and vitamin E and kidney cancer128 129. 
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One-carbon metabolism: a candidate pathway 
As mentioned previously, dietary intake of fruit and vegetables has been associated with a 
potential decrease in risk among the three specific smoking-related cancer sites investigated 
in this dissertation. Fruit and vegetables are important dietary sources of B-vitamins and 
additional nutrients that are involved in the one-carbon pathway. Because these nutrients 
are important in maintaining DNA integrity and gene expression, they might have a 
potential role in preventing carcinogenesis, and present potential for cancer risk 
modification through changes in diet. 
Overview of the one-carbon metabolism (OCM) 
OCM encompasses a series of cyclical biochemical reactions that involve the transfer of one 
carbon unit (see Figure 10). OCM pathways can be viewed several modular units that 
comprise in particular two interconnected cycles: the folate cycle and the methionine cycle.  
 
Folate cycle 
Folate plays a central role in OCM as a source of methyl groups. The term folate represents 
all naturally occurring forms of vitamin B9 in foods such as meat, fruits, vegetables, grain 
products, legumes, bread and seeds 130, whereas folic acid is the synthetic form found in 
dietary supplements and fortified food.  
In cells, folate either from dietary intake or folic acid, is reduced by a series of enzymatic 
reactions, leading to the generation of dihydrofolate and then tetrahydrofolate (THF) which 
is the most important carrier of OCM groups. THF is later converted to 5,10-methylene-THF 
(me-THF) by serine hydroxymethyl transferase (SHMT). me-THF is then either reduced to 5-
methyltetrahydrofolate (mTHF) by methylenetetrahydrofolate reductase (MTHFR) or 
converted to 10-formyltetrahydrofolate (F-THF) through a sequence of steps. mTHF is 
demethylated to complete the folate cycle. After the demethylation of mTHF, the carbon is 
donated into the methionine cycle through the methylation of homocysteine to methionine 
by methionine synthase (MS) and its cofactor vitamin B12 (B12). 
Methionine cycle 
Methionine is an essential, amino acid and a precursor of S-adenosylmethionine (SAM), the 
primary methyl group donor for most biological methylations such as DNA, RNA, proteins, 
phospholipids, histones and neurotransmitters131 132. As shown in Figure 10, the methionine 
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cycle begins with homocysteine that accepts the carbon from the folate pool through mTHF 
to generate methionine. Methionine, through methionine adenyltransferase (MAT), is 
converted to S-adenosylmethionine (SAM), which is demethylated to form S-
adenosylhomocysteine (SAH). SAH is finally converted back to homocysteine, completing 
the methionine cycle. 
 
 
Figure 10. Overview of the OCM pathway. The OCM consists of the folate cycle (green) and the methionine 
cycle (gray). Cofactors are in purple and enzymes are in orange. SHMT: serine hydroxylmethyltransferase, TS: 
thymidylate synthase, MTHFR: methylenetetrahydrofolate reductase, MAT: methionine adenosyltransferase, 
CBS: cystathionine-synthase, CGL: cystathionine y-lyase, MS: methionine synthase, THF: tetrahydrofolate, me-
THF: 5,10-methylenetetrahydrofolate, mTHF: 5-methyltetrahydrofolate, F-THF:10-formyltetrahydrofolate, 
dTMP: deoxythymidine monophosphate, dUMP: deoxyuridine monophosphate, SAH: S-adenosylhomocysteine, 
SAM: S-adenosylmethionine, B2: riboflavin, B6: pyridoxal 5’-phosphate, B12: cobalamin, adapted from Locasale 
et al., 2013133. 
 
Vitamin B6 influence 
Vitamin B6 is abundant in food and its major sources come from whole grain, nuts, 
vegetables, bananas, milk and some types of meat130 134. In OCM, vitamin B6 is a co-factor of 
several enzymes (see Figure 10), including serine hydroxylmethyltransferase (SHMT), 
cystathionine β-synthase (CBS) and cystathionine γ-lyase (CGL).  
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OCM and carcinogenesis 
Many epidemiological studies have investigated OCM nutrients in relation to cancer. While 
some studies reported significant associations, the evidence to date is not clear. The 
biological mechanisms behind the association between OCM and carcinogenesis is still 
evolving. In this dissertation, we introduce two primary mechanisms by which one-carbon 
metabolism has been proposed to influence cancer development: 1) damage in DNA repair 
and DNA synthesis and 2) influence on gene expression via aberrant methylation pattern.  
 
DNA repair and DNA synthesis 
Folate is necessary for the de novo biosynthesis of purines and pyrimidines nucleotides, 
adequate of which is essential for genome stability135. 
Purine nucleotides are necessary for DNA synthesis. In the process of the de novo 
biosynthesis of purines, the methyl group is provided by F-THF (see Figure 10) and then 
incorporated into the purine ring producing the following nucleotides adenine and guanine. 
Insufficient methyl groups from OCM factors imbalances may induce impaired DNA 
synthesis and repair. Synthesis of pyrimidines occurs when me-THF methylates 
deoxyuridylate monophosphate (dUMP) to form deoxythymidylate monophosphate (dTMP), 
a reaction essential for DNA replication and repair136.  
It has been shown that mutations can occur either during the process of DNA repair, or 
during semiconservative DNA replication that leads to duplication of the cell genome137. In 
normal cells, a limited presence of folate reduces thymidylate from an imbalanced synthesis 
of dTMP (thymine) from dUMP (uracil) which leads in an increase in uracil content of DNA. 
This results in the incorporation of uracil into human DNA and which produces different 
types of genetic instability during DNA replication such as DNA strands breaks and 
chromosomal damage138. Thus, depletion of folate could not only block DNA repair capacity 
but also increase the need of DNA repair. In animal studies, this DNA and chromosomal 
damage has been shown to activate proto-oncogenes and inactivate tumour suppressor 
genes139, which are involved in cancer development. Knock et al. showed that low folate 
exposure increased intestinal tumorigenesis in mice through increased dUMP/dTMP ratio 
and DNA damage140. It has been also observed that a moderate dietary deficiency of folate 
increased incidence of colonic dysplasia and carcinoma in rats141.  
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While limited availability of folate in regular healthy cells could induce genetic instability, it 
has been suggested that folate may promote tumor progression after the neoplasm has 
been developed142. This controversial issue may be explained by the function of folate in 
nucleotide synthesis where tissues, including tumours, proliferate rapidly, and thus have an 
increased requirement for nucleotides. Then many cancers up-regulate folate receptors, 
and anti-folate drugs, such as 5-fluorouracil or methotrexate, are efficacious in treatment of 
cancer by blocking the DNA replication of cancer cells142 143.   
In addition, vitamin B6 imbalance may disturb different reactions in the OCM resulting also 
in dysregulation of DNA synthesis and DNA methylation, which leads to cancer 
development. It has been reported that vitamin B6 deficient subjects are thought to be 
more susceptible to DNA and chromosome breaks by a similar mechanism as described 
above. In vitamin B6 deficiency, availability of me-THF is decreased, reducing the 
methylation of dUMP and thereby increasing misincorporation of uracil, causing genomic 
instability. In vitro studies showed growth inhibition by vitamin B6 on different type of 
cancers144 145, including hepatoma cells of rat146. Most human studies on the association of 
vitamin B6 with carcinogenesis focused on colorectal cancer and have suggested that 
deficiency of vitamin B6 may increase risk147. However, since vitamin B6 is not solely 
dependent to the OCM pathway, this nutrient may also suppress carcinogenesis by reducing 
cell proliferation, angiogenesis, oxidative stress, inflammation, and nitric oxide synthesis148-
150. 
 
DNA methylation 
DNA methylation is an important epigenetic modification in mammals that confers an 
adequate regulation of gene expression, embryonic development and chromosome 
stability135 151 152. Epigenetics is defined as “the study of heritable changes in gene 
expression that occur without a change in DNA sequence”153, and unlike genetics, epigenetic 
changes are dynamic and reversible. In humans, DNA methylation is a covalent chemical 
modification, resulting in the addition of a methyl (-CH3) group at the carbon 5 position of 
the cytosine ring. This chemical modification can occur at millions of locations on the DNA 
sequence and occurs most of the time at CpG sites151. Between 70 to 80% of CpG 
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dinucleotides are methylated in mammals. CpG sites are generally dispersed in the genome 
non-uniformly, with the exception of short regions that are grouped in clusters and called 
‘CpG islands’152. These CpG islands rich in CpG are observed mostly in the promoter region 
of many genes and are in general unmethylated, whereas CpG sites dispersed non-uniformly 
are usually methylated under regular conditions. When methylation of promoter CpG 
islands occurs, transcription is inhibited and gene expression silenced152.   
 
DNA methylation and cancer 
Adequate DNA methylation is crucial for cell development and function, thus any anomalies 
in this process may lead to diverse diseases, including cancer. In fact, cells in cancer display 
a different methylome compared to normal cells. Interestingly, a decrease in genomic 
methylation at dispersed CpG sites and abnormal hypermethylation in gene promoter CpG 
islands are often observed in human cancers. The hypermethylation phenomena may 
contribute to silencing of tumor suppressors, whilst hypomethylation may activate 
oncogenes154. 
Regional increases in DNA methylation concentrations have been reported from many 
studies. Many genes have been found to be hypermethylated in cancer including p16, 
BRACA1 and RASSF1A155. Hypermethylation was reported in many types of human cancers 
including breast156 157, prostate 158, leukemia159 160 and lung161.  
Global loss of DNA methylation of the genome, termed hypomethylation, has been 
suggested to initiate carcinogenesis. Hypomethylation is observed among several 
malignancies162 163 including solid tumours such as prostate tumours164, metastatic 
hepatocellular cancers165, cervical cancers 163, and also in haematological malignancies 
including leukaemia166.  
DNA methylation levels may be tissue-specific because the variation among different tissues 
is substantial131 167. Some studies reported that DNA methylation levels in carcinogenic 
tissues did not differ from tissues characterised as benign or normal tissues surrounding 
carcinogenic tissues168 169.  
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OCM and methylation 
Many nutrients involved in the OCM including vitamin B6 (SHMT activity), vitamin B2 
(MTHFR stability) and vitamin B12 (MS function) 170 are important to maintain the one 
carbon flux, and deficiencies or imbalances of these biomarkers may lead to aberrant DNA 
methylation and subsequently carcinogenesis.  
The OCM, and thus DNA methylation, operate under the control of multiple influences. 
Moderate elevations in plasma homocysteine concentration have been reported to be 
associated with increased concentration of SAH, but not SAM, and increased SAH 
concentration has been associated with global DNA hypomethylation171. For example,  
several in vitro studies demonstrated a clear association between folate deficiency and DNA 
stability where it has been shown that deficiency of folate decreases genomic DNA 
methylation132. However, studies in humans have been inconclusive. Some suggest that 
altered folate status can affect global DNA methylation in humans172 173 whereas others 
reports no significant changes in DNA methylation in relation to folate concentrations174 175. 
In addition, it has been suggested that in vitamin B6 deficiency, DNA methylation is 
decreased because of less availability of SAM, the methyl group donor. Some studies have 
shown an association between B6 and hypermethylation176 177, but to date no studies have 
investigated the relation of hypomethylation with B6 deficiency.  
 
One-carbon pathway is a complex mechanism involving many factors. With an aim to 
further understand its relation in cancer, we conducted studies with a specific focus on 
some of the OCM cornerstones such as the B-vitamins involved in the folate cycle as well as 
the methionine and homocysteine engaged in methionine cycle. For clarity, OCM nutrients, 
factors or biomarkers refers in this dissertation to the combination of vitamin B2, vitamin 
B6, folate, vitamin B12, homocysteine and methionine. 
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Nutrients of the candidate pathway and smoking-related cancer  
 
Overview 
Among OCM biomarkers, folate is by far the most studied analyte in relation to cancer. Over 
the past decades, most human studies assessing the role of folate (measurement from 
dietary intake or blood) with carcinogenesis focused on colorectal cancer (CRC). The 
accumulative of epidemiologic and clinical evidence have reported about 20% to 40% 
decreased risk of CRC or adenoma in subjects with the highest dietary intake of folate 
compared to those being in the lowest intake, although the evidence is less consistent for 
circulating levels of folate178-180.  
 
OCM analytes and lung cancer  
Among OCM biomarkers, folate is also by far the most studied analyte in relation to lung 
cancer as previously shown for CRC. However, data on the effect of folate on the 
subsequent incidence of lung cancer are limited and inconclusive. Table 1 summarizes the 
literature on the selected OCM nutrients in relation to lung cancer risk. Inverse association 
of dietary folate intake with lung cancer risk have been reported in few case-control 
studies181 182. In contrast, a recent meta-analysis of nine cohort studies found a very small or 
no association with lung cancer risk183, and only one of the included studies alone reported 
a significant inverse association184. Dietary intake of other micronutrients related to the 
OCM pathway has been studied in relation to lung cancer development, including vitamin 
B2, B6, B12 and methionine, but no significant associations were found in those studies (see 
Table 1).  
Investigations on the relation between circulating concentrations of OCM factors with lung 
cancer risk have been assessed very sparsely in a prospective setting. The ATBC study was 
the first to evaluate whether pre-diagnostic circulating of B-vitamins (B6, B9 and B12) and 
homocysteine were associated with lung cancer risk. This nested case-control study of 300 
lung cancer cases and matched controls among Finnish male smokers did not find any clear 
association between circulating concentrations of folate, vitamin B12 and homocysteine and 
lung cancer risk185. However, subjects in the top quintiles of circulating concentrations of 
vitamin B6 had a two-fold decrease risk of lung cancer compared with those in the bottom 
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quintiles (OR 0.51; 95% CI 0.23-0.93). Ten years after the ATBC study on lung cancer, a 
nested case-control study of 899 cases and 1,770 controls from the EPIC cohort reported 
strong inverse associations between circulating concentrations of vitamin B6 and 
methionine independently to smoking status with lung cancer risk, resulting in 2.5-fold risk 
differences between the top and bottom 25% of the population13. Moreover, this study 
reported significant inverse association between circulating concentrations of folate and 
lung cancer risk. Overall, it remains unclear if factors of OCM pathway are important in lung 
cancer development. 
 
Table 1. Associations between OCM factors (vitamin B2, B6, B12, folate, methionine and 
homocysteine) and lung cancer risk 
Author  Year  Exposure Studies Subjects Resultsa 
Dietary assessment 
Yu-Fei 
Zhang et 
al.183    
2014 dietary folate 
intake 
meta-
analysis 
9 cohort 
studies  
High vs low dietary folate intake: RR 
= 0.92(0.84-1.01), p for trend= 0.08     
Per 100ug/day increment in folate 
lung cancer  RR= 0.99(0.97-1.01), p 
for trend0.31 
Yumie 
Takata et 
al.186   
2013 dietary folate  
intake 
 prospective 
cohort study 
359 lung 
cancer 
cases 
(men) 
highest vs. lowest quartile of dietary 
folate intake: HR=0.99 (0.70 – 1.40), 
p for trend= 0.92                                   
Dai WM et 
al.181 
2013 dietary folate 
intake  
meta-
analysis 
4,390 
lung  
cancer 
cases and   
6,138 
controls      
Overall inverse assocition of dietary 
foalte intake: OR=0.74 (0.65-0.84), p 
for trend <0.001                                          
Yumie 
Takata et 
al.187  
2012 dietary intake of 
B2, B6, folate, 
B12 and 
methionine  
 prospective 
cohort study 
359 lung 
cancer 
cases 
(women) 
highest vs. lowest quartile of dietary 
B2 intake: HR=0.62 (0.43-0.89), p 
for trend =0.03                                             
highest vs. lowest quartile of dietary 
B6 intake: HR=1.21 (0.84-1.74), p 
for trend =0.44                                             
highest vs. lowest quartile of dietary 
folate intake: HR=0.96 (0.70 – 1.32), 
p for trend = 0.79                                        
highest vs. lowest quartile of dietary 
B12 intake: HR=0.76 (0.55-1.05), p 
for trend =0.19                                             
highest vs. lowest quartile of dietary 
methionine intake: HR=0.87 (0.58-
1.29), p for trend =0.26                             
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Basset JK  
et al.188  
2012 dietary intake of 
B2, B6, folate, 
B12 and 
methionine  
prospective 
cohort study 
348 lung 
cancer 
cases 
highest vs. lowest quintile of dietary 
B2 intake: HR=0.79 (0.55-1.13), p 
for trend=0.15                                              
highest vs. lowest quintile of dietary 
B6 intake: HR=1.03 (0.74-1.43), p 
for trend=0.67                                              
highest vs. lowest quintile of dietary 
folate intake: HR=1.02 (0.69 – 1.50), 
p for trend = 0.60                                        
highest vs. lowest quintile of dietary 
B12 intake: HR=1.12 (0.79-1.59), p 
for trend=0.52                                              
highest vs. lowest quintile of dietary 
methionine: intake HR=0.93 (0.66-
1.31), p for trend=0.90   
Nina 
Roswall et 
al.189    
2010 dietary folate 
intake  
prospective 
cohort study 
721 lung 
cancer 
cases 
highest vs. lowest quartile of dietary 
folate intake:  RR=0.99 (0.79-1.23), 
p for trend=0.68   
Christopher 
G Slatore et 
al.190   
2008 dietary folate 
intake  
prospective 
cohort study 
521 lung 
cancer 
cases 
highest vs. lowest tertile of dietary 
folate intake: HR=0.99 (0.79-1.23), p 
for trend=0.68   
GC Kabat et 
al.191  
2008 dietary intake of 
B2, B6, folate, 
B12 and 
methionine  
prospective 
cohort study 
358 lung 
cancer 
cases 
(women) 
highest vs. lowest quintile of dietary 
B2 intake: RR=1.30 (0.94-1.80), p 
for trend=0.08                                              
highest vs. lowest quintile of dietary 
folate intake: RR=1.12 (0.83 – 1.52), 
p for trend = 0.43                                        
highest vs. lowest quintile of dietary 
methionine: intake RR=0.95 (0.69-
1.31), p for trend=0.76   
Eunyoung 
Cho et al.192    
2006 dietary folate 
intake                        
Totale folate 
intake  
pooled 
analysis            
(8 
prospectives 
studies)  
3,206 
lung 
cancer 
cases 
highest vs. lowest quintiles of 
dietary folate intake: RR=0.88 (0.74-
1.04), p for trend =0.08                             
highest vs. lowest quintiles of total 
folate intake: RR=1.02 (0.83-1.26), p 
for trend =0.51                   
Hongbing 
Shen  et 
al.182  
2003 dietary folate 
intake 
case-control 
study 
470 lung 
cancer 
cases and 
472 
matched 
controls 
(former 
smokers) 
dietary folate intake: OR=0.53 (0.35 
–0.80) (highest vs. lowest quartile), 
p for trend <0.001 
Jian-Min 
Yuan et 
al.193  
2003 dietary folate 
intake  
prospective 
cohort study 
482 lung 
cancer 
cases 
highest vs. lowest quintile of dietary 
folate intake: RR=0.82 (0.60 – 1.11)  
Laura E. 
Voorrips et 
al.194   
2000 dietary folate 
intake  
prospective 
cohort study 
939 lung 
cancer 
cases 
(men) 
highest vs. lowest quintile of dietary 
folate intake: RR=0.83 (0.39 – 1.75), 
p for trend = 0.03          
Elisa V. 
Bandera et 
al.184   
1997 dietary folate 
intake  
prospective 
cohort study 
395 lung 
cancer 
cases 
highest vs. lowest tertile of dietary 
folate intake: RR=0.70 (0.55 – 0.89), 
p for trend<0.001 
Circulating concentrations 
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Terry J. 
Hartamn et 
al.185  
2001 Serum of 
vitamin B6, 
folate and B12 
nested case-
control  
300 lung  
cancer 
cases and   
matched 
controls      
(male 
smokers) 
highest vs. lowest quintile of serum 
B6:           OR=0.51 (0.23-0.93), p for 
trend =0.02                                                   
highest vs. lowest quintile of serum 
folate:         OR=0.96 (0.52-1.72), p 
for trend =0.28                                             
highest vs. lowest quintile of serum 
B12:          OR=1.41 (0.80-2.50), p for 
trend =0.14                                                   
highest vs. lowest quintile of serum 
homocysteine:  OR=0.61 (0.32-1.17), 
p for trend =0.41                                         
Mattias 
Johansson  
et al.13  
2010 Serum of 
vitamin,B2, B6, 
folate, B12, 
methionine and 
homocysteine  
nested case-
control  
899 lung 
cancer 
cases and 
1,770 
matched 
controls 
highest vs. lowest quartile of serum 
B6: OR=0.44 (0.33-0.60), p for trend 
<0.001                                                            
highest vs. lowest quartile of serum 
methionine: OR=0.52 (0.39-0.69), p 
for trend <0.001                                          
highest vs. lowest quartile of serum 
folate: OR=0.68 (0.51-0.90), p for 
trend =0.001                                                 
highest vs. lowest quartile of serum 
B12: OR=1.35 (1.00-1.82), p for 
trend = 0.04                                              
highest vs. lowest quartile of serum 
B2: OR=0.99 (0.73-1.35), p for trend 
=0.81                                                              
highest vs. lowest quartile of serum 
homocysteine: OR=0.76 (0.54-1.07), 
p for trend =0.62                                         
Vitamin supplementation 
Stein Emil 
Vollset et 
al.195   
2013 folic acid 
supplementation 
meta-
analysis (13 
RCTs*) 
272 lung 
cancers       
Overall folic acid vs. Non-folic acid 
group: RR= 1.08 (0.86 – 1.35), p for 
trend = 0.37     
Marta 
Ebbing et 
al.196   
2009 folic acid and B6 
supplementation 
meta-
analysis (2 
RCTs*) 
92 lung 
cancers 
Overall folic acid vs. Non-folic acid 
group: HR= 1.59 (0.92 – 2.75)                 
Overall vitamin B6 vs. Non-vitamin 
B6 group: HR= 1.06 (0.62 – 1.82)   
*RCTs= randomized clinical trials 
a Multivariate-adjusted OR,RR or HR and 95% confidence intervals (CIs) in parentheses 
 
 
OCM factors and head and neck cancer 
While little evidence have emerged on food groups linked to specific cancer sites, cancer of 
the head and neck consistently occurs less frequently among subject with high consumption 
of vegetables and fruit, with supporting data from both case-control62 and prospective 
studies61 197. To date, very few epidemiological studies - mainly case-control studies - 
assessed the association between B-vitamins and HNC. Results of these studies are 
summarized in Table 2. Overall, some case-control studies reported no or little relationship 
between intake of folate and vitamin B6 with HNC risk92 198 199 where as other studies 
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indicated a significant inverse association69 200-202. Furthermore, a recent pooled analysis of 
individual data from ten case-control studies participating in the International Head and 
Neck Cancer Epidemiology (INHANCE) Consortium and including over 5,000 cases and 
13,000 controls, reported that high levels of folate intake compared to those with low levels 
were found to be inversely associated with overall oropharyngeal cancer risk70. The other 
OCM nutrients measured by dietary intake, including vitamin B2, B12 and methionine, did 
not reveal any clear association with HNC risk.  
Only a few retrospective case-control studies have reported on circulating OCM biomarkers 
and HNC risk, most indicating lower folate concentrations and higher homocysteine 
concentrations among cases than among controls203-206. However, recall bias and reverse 
causality is particularly a concern because the nutrient (from dietary questionnaire or blood 
measurement) is assessed after diagnosis for cancer cases and thus, it is difficult to interpret 
those studies in the context of cancer etiology. 
 
Table 2. Associations between OCM factors (vitamin B2, B6, B12, folate, methionine and 
homocysteine) and the head and neck cancer risk 
Author  Year  Exposure Studies Subjects Resultsa 
Dietary assessment 
Carlotta 
Galeone 
et al.70 
2014 dietary intake of 
folate 
case-
control  
5,127 cancers of 
oral cavity and 
pharynx and 
13,249 controls 
highest vs. lowest quintile of dietary 
folate intake: OR=0.65 (0.43- 0.99), p 
for trend =0.04  
Keitaro 
Matsuo et 
al.201 
2012 dietary intake of 
folate 
case-
control  
409 HNC cases highest vs. lowest quartile of dietary 
folate intake: OR=0.53 (0.36- 0.77), p 
for trend <0.001  
D. Aune et 
al.92 
2011 dietary folate  
intake 
case-
control  
798 UADT* 
cancer cases 
and 2,032 
controls                   
283 cancer 
cases of oral 
cavity and 
pharynx                   
281 larynx 
cancers 
highest vs. lowest quartile of dietary 
folate intake: OR=0.41 (0.26 – 0.65), p 
for trend <0.0001                                            
highest vs. lowest quartile of dietary 
folate intake: OR=0.49 (0.24 – 0.98), p 
for trend =0.04                                                 
highest vs. lowest quartile of dietary 
folate intake: OR=0.54 (0.27 – 1.10), p 
for trend =0.07                                        
C. 
Pelucchi 
et al.202 
2003 dietary intake of 
folate and 
methionine    
case-
control  
749 cancer 
cases of the oral 
cavity and 
pharynx and 
1,772 controls  
highest vs. lowest tertile of dietary 
folate intake: OR=0.53 (0.40-0.69), p 
for trend <0.001                                              
highest vs. lowest tertile of dietary 
methionine intake: OR=1.14 (0.87-
1.50), p for trend =0.33                                  
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Etore 
Bidoli et 
al.200 
2003 dietary intake of 
B2, B6 and folate 
case-
control  
527 laryngeal 
cancer cases 
and 1,297 
controls  
highest vs. lowest quintile of dietary 
B2 intake: OR=1.00 (0.70- 1.50), p for 
trend =0.05                                                        
highest vs. lowest quintile of dietary 
B6 intake: OR=0.60 (0.40- 0.90), p for 
trend <0.05                                        
highest vs. lowest quintile of dietary 
folate intake: OR=0.40 (0.20- 0.60), p 
for trend <0.01                                                 
Stephanie 
J. 
Weinstein 
et al.199   
2002 dietary intake of 
folate  and 
methionine  
case-
control  
341 oral 
cancers cases 
and 521 
controls  
highest vs. lowest quartile of dietary 
folate intake: OR=0.60 (0.40-1.00), p 
for trend =0.05                                                 
highest vs. lowest quartile of dietary 
methionine intake: OR=1.40 (0.90-
2.20), p for trend =0.21                                  
Eva Negri 
et al.69  
2000 dietary intake of 
B2, B6 and folate 
case-
control  
754 oral cancer 
cases and 1,775 
controls 
highest vs. lowest tertile of dietary B2 
intake OR=0.64 (0.40-1.01), p for 
trend =0.09                                                        
highest vs. lowest tertile of dietary B6 
intake OR=0.27 (0.15-0.50), p for 
trend <0.0001                                                   
highest vs. lowest tertile of dietary 
folate intake: OR=0.32 (0.20 – 0.52), p 
for trend <0.0001                                            
E. De 
Stefani et 
al.198  
1999 dietary intake of 
B2, B6, folate 
and B12  
case-
control  
133  UADT* 
cancer cases 
and 383 
controls 
highest vs. lowest tertile of dietary B2 
intake: OR=2.00 (1.10-3.5), p for trend 
=0.04                                                            
highest vs. lowest tertile of dietary B6 
intake: OR=0.80 (0.50-1.40), p for 
trend =0.16                                                       
highest vs. lowest tertile of dietary 
folate intake: OR=0.90 (0.50 – 1.60), p 
for trend = 0.90                                                
highest vs. lowest tertile of dietary 
B12 intake: OR=1.80 (1.00-3.2), p for 
trend =0.05                                                        
Vitamin supplementation 
Stein Emil 
Vollset et 
al.195 
2013 folic acid 
supplementation 
meta-
analysis 
(13 
RCTs**) 
29 cancers of 
the lip, mouth 
and pharynx           
Overall folic acid vs. Non-folic acid 
group RR= 1.38 (0.66 – 2.86), p for 
trend = 0.26     
*UADT =upper aero digestive tract; RCTs**= randomized clinical trials 
a Multivariate-adjusted OR or RR and 95% confidence intervals (CIs) in parentheses 
 
 
OCM factors and esophageal squamous cell carcinoma 
Evidence on the association between the selected OCM micronutrients in this dissertation 
and cancer risk of the squamous cell esophagus has been limited and is summarized in Table 
3. Globally, most of epidemiological studies were case-control studies and assessed the 
association between folate intake and ESCC risk. Three independent retrospective case-
control studies93 207 208 did not find any clear association between folate intake and risk of 
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ESCC. Surprisingly, a meta-analysis comprising four case-control studies showed a significant 
inverse association between folate intake and ESCC risk with a summary relative risk when 
comparing the highest versus the lowest category of folate intake being 0.66 (95% CI 0.53-
0.83)94. Similarly, a recent large prospective study including 492 293 participants found that 
those with low levels of folate intake compared to high levels had around 90% increased risk 
of ESCC, the relative risk being 1.91 (95% CI 1.17-3.10)96. We did not find any study assessing 
the relation of circulating concentrations of B-vitamins and related metabolites of the OCM 
with ESCC.  
 
Table 3. Associations between OCM biomarkers factors (vitamin B2, B6, folate and 
methionine) and esophageal squamous cell carcinoma risk 
Author  Year  Exposure Studies Subjects Resultsa 
Linda 
M. 
Brown 
et al.207 
1998 dietary intake 
of B2 and 
folate 
case-
control  
114 ESCC cases 
and 681 controls 
(whites) 
highest vs. lowest quartile of dietary 
B2 intake OR=0.90, p for trend =0.42       
highest vs. lowest quartile of dietary 
folate intake OR=0.70, p for trend 
=0.63                                                               
        219 ESCC cases  
and 557 controls 
(blacks) 
highest vs. lowest quartile of dietary 
B2 intake OR=1.20, p for trend =0.67       
highest vs. lowest quartile of dietary 
folate intake OR=1.10, p for trend 
=0.85                                                               
Susan T. 
Mayne 
et al.208 
2001 dietary folate,  
intake 
case-
control  
206 ESCC cases 
and 687 controls    
75th vs. 25th of dietary B2 intake 
OR=1.26 (0.84-1.89)                                     
75th vs. 25th of dietary B6 intake 
OR=0.45 (0.30-0.69)                                     
75th vs. 25th of dietary folate intake 
OR =0.58 (0.39-0.86)                                    
75th vs. 25th of dietary B12  intake 
OR=1.51 (1.15-2.00)                                     
C. 
Galeone 
et al.93 
2005 dietary intake 
of B6, folate 
and 
methionine 
case-
control  
351 ESCC cases 
and 875 controls  
highest vs. lowest tertile of dietary B6 
intake OR=0.88 (0.60-1.31), p for trend 
=0.55                                                            
highest vs. lowest tertile of dietary 
folate  intake OR=0.68 (0.46-1.00), p 
for trend =0.05                                              
highest vs. lowest tertile of dietary 
methionine intake OR=1.11 (0.76-
1.62), p for trend =0.58                               
Susanna 
C. 
Larsson 
et al.94 
2006 dietary intake 
of folate 
meta-
analysis (4 
case-
control 
studies) 
929 ESCC cases highest vs. lowest category of dietary 
folate intake OR=0.66 (0.53- 0.83) 
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Q Xiao 
et al.96 
2014 dietary intake 
of B6,foalte, 
B12 and 
methionine 
prospective 
cohort  
185 ESCC cases 1th quintiles vs. 3rd quintile of dietary 
B6 intake: RR=1.38 (0.91 – 2.12), p for 
trend =0.01                                                    
1th quintiles vs. 3rd quintile of dietary 
folate intake: RR=1.91 (1.17 – 3.10), p 
for trend =0.02                                              
1th quintiles vs. 3rd quintile of dietary 
B12 intake: RR=1.21 (0.78 – 1.87), p 
for trend =0.13                                              
1th quintiles vs. 3rd quintile of dietary 
methionine intake: RR=1.45 (0.91 – 
2.31), p for trend =0.16                               
ESCC= esopahgus squamous cell carcinoma 
a Multivariate-adjusted OR or RR and 95% confidence intervals (CIs) in parentheses 
 
 
OCM factors and kidney cancer 
Although the relation between fruit and vegetable intake with kidney cancer is intriguing 
and consistently observed in both retrospective and prospective case-control studies, the 
associations between micronutrients from dietary intake related to the OCM  with kidney 
cancer are few and inconsistent. To date, only four studies (two retrospective case-control 
studies and two prospective cohorts) have investigated intake of OCM nutrients, including 
vitamin B2, B6, B12, folate and methionine, in relation to risk of kidney cancer (see Table 3). 
As a whole, these studies found little evidence that higher intakes of nutrients related to 
OCM lower risks of RCC and concluded that those OCM nutrients may have little influence 
on kidney carcinogenesis209-211.  
Circulating concentrations of B-vitamins have been assessed in relation to multiple cancers, 
but only one study with a prospective design has been published regarding RCC to date212. 
The ATBC study investigated the association between serum OCM biomarkers (folate, 
vitamin B2, B6, B12, cysteine and homocysteine) and risk of RCC. This nested case-control 
study of 224 case-control pairs did not find any clear association between those biomarkers 
and RCC risk. A role of OCM in renal cell development is biologically plausible, but evidence 
regarding such a role is limited.  
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Table 4. Associations between OCM factors (vitamin B2, B6, B12, folate, methionine and 
homocysteine) and kidney cancer risk 
Author  Year  Exposure Studies Subjects Resultsa 
Dietary assessment 
Kaye E. 
Brock et 
al.210   
2012 dietary folate  
intake 
case-control 323 RCC* 
cases and 
1,827 
matched 
controls 
highest vs. lowest quartile of 
dietary folate intake: OR=0.80 
(0.50 – 1.20), p for trend= 0.12       
Christina 
Bosseti et 
al.209 
2006 dietary intake 
of B2, B6 and 
folate 
case-control  767 RCC* 
cases and 
1,534 
matched 
controls 
highest vs. lowest quintile of 
dietary B2 intake: OR=0.88 
(0.66-1.19)                                            
highest vs. lowest quintile of 
dietary B6 intake: OR=0.85 
(0.64-1.13)                                            
highest vs. lowest quintile of 
dietary folate intake: OR=0.85 
(0.64 – 1.12)                                         
Eunyoung 
Cho et 
al.211 
2013 Total intake 
of B6, folate, 
B12 and 
methionine        
pooled analysis        
(2 prospective 
studies) 
436 RCC* 
cases 
highest vs. lowest quintile of 
total B6 intake: RR=0.88 (0.65-
1.19), p for trend=0.55                      
highest vs. lowest quintile of 
total folate intake: RR=0.84 
(0.60 – 1.18), p for trend = 0.52      
highest vs. lowest quintile of 
total B12 intake: RR=1.24 (0.90-
1.70), p for trend=0.61                      
highest vs. lowest quintile of 
total methionine: intake 
RR=1.29 (0.93-1.78), p for 
trend=0.10  
Circulating concentrations 
Todd M. 
Gibson et 
al.212 
2010 Serum of 
vitamin,B2, 
B6, folate, 
B12, and 
homocysteine  
nested case-
control  
224 RCC* 
cases and 
224 
matched 
controls 
highest vs. lowest quartile of 
serum B2: OR=0.76 (0.42-1.40), 
p for trend =0.68                                
highest vs. lowest quartile of 
serum B6: OR=1.33 (0.73-2.42), 
p for trend =0.43                                 
highest vs. lowest quartile of 
serum folate: OR=0.67 (0.37-
1.20), p for trend =0.19                     
highest vs. lowest quartile of 
serum B12: OR=0.87 (0.46-
1.63), p for trend =0.98                     
highest vs. lowest quartile of 
serum homocysteine: OR=0.92 
(0.51-1.66),                               p for 
trend = 0.60                                          
RCC*= renal cell carcinoma 
a Multivariate-adjusted OR or RR and 95% confidence intervals (CIs) in parentheses 
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Study designs in analytical epidemiology 
 
Descriptive epidemiology concentrates on describing events (events or outcomes mostly 
refer to diseases) in population by characteristics related to time, place and individual213. 
From those observations, hypotheses are generated and tested through analytical 
approach. The principal objective of analytic epidemiology is to determine causes and 
effects, or the “why?” and the “how?” , through investigation of exposure and disease at the 
individual level214. A definition of this approach was further developed by Rothman et al.215, 
pointing that analytical epidemiology aims to evaluate whether particular exposure such as 
a diet or a biomarker, is associated or not to an event such as cancer, and then whether this 
association is independent. However, even if the association between the exposure and the 
event is statistically significant, causation is not necessarily present due to possible artefact, 
confounding, chance, or bias216. Nowadays, experimental and observational studies (mainly 
cohort and case-control studies) are the principal designs used in analytical epidemiology.  
 
Experimental studies 
The specific characteristic of experimental studies is that the investigator controls the 
allocation of exposures to study subjects. Experimental studies, in particular clinical trials 
are superior to observational studies in the evidence hierarchy217. The reference of 
experimental studies is RCTs, where participants are randomly allocated to the groups (e.g. 
exposure or placebo). One advantage of such design is that potential unknown confounders 
are maintained symmetrically within the groups, and the comparability of the groups is 
maintained throughout the investigation. Thus, properly executed, RCT is the superior 
methodology to demonstrate causality and clinical efficacy of preventive and therapeutic 
procedures in the clinical setting. 
Until now, the main focus of experimental studies of B-vitamins and cancer prevention has 
been on folate and colorectal cancer. Three RCTs of folate supplementation investigated 
whether it may prevent colorectal adenomas among high-risk population, but failed to 
identify a protective effect218-220. Although RCTs may restrict confounding, they have several 
limitations including; (1) limited size, limited number of cancers that occur in the follow-up 
period; (2) the exposure such as supplementation is randomized over a relatively short 
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period (usually shorter than few years); and (3) they are unrelated to lifelong nutrient levels 
prior to the study. 
While the RCT may be considered as the “gold standard” of scientific studies, this design is 
not always suitable in epidemiological research, mainly because of ethical issues. It would 
for instance not be ethical to study the impact of a potential dangerous substance e.g. 
arsenic on kidney cancer by allocating arsenic to the exposed group and a placebo to the 
control group. Furthermore, RCTs overall are very costly and it may not be feasible to 
conduct them over many years.  
In contrast to RCTs where investigators record outcome in relation to exposure that has 
been allocated in some random fashion, in observational studies, researchers limit 
themselves to observing the outcome in people who are already segregated into different 
exposure groups. The two main nonexperimental, observational study designs are cohort 
and case-control studies. 
 
Cohort studies 
According to Breslow and Day221, cohort studies are longitudinal studies and start by 
identifying a group of individuals about whom certain exposure information is collected; the 
group is then followed forward in time to ascertain the occurrence of the disease(s) of 
interest, so that for each individual prior exposure information can be related to subsequent 
disease experience. Later, Rothman and Greenland222 termed cohort as group (s) of subjects 
followed over time who share a common experience or status. For example, this could be a 
generation defined by the same period of birth, a group carrying a genetic trait (i.e. Down 
syndrome), a specific population who undergone special exposure (i.e. the Chernobyl 
cohort), or subjects gathered on a geographical basis (the Framingham cohort). 
In public health, one the main objectives of cohort studies is to determine circumstances of 
disease occurrence and progression. First cohort investigations enrolled to assess the 
relation between risk factors and a disease of interest emerged during the 1950s in United-
States223 and in Grand Britain25 224. These studies were first devoted to evaluate the 
associations already strongly suggested by case-control studies or case-cohort studies. As an 
example, the British Doctors' Study from Doll and Hill was designed to assess the role of 
tobacco smoking on cancer mortality224. Usually, the cohort study design is referred to 
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exposed/unexposed studies because at least two groups of subjects (one exposed to a 
factor and the other not), without having initially the event, are followed and compared to 
the incidence of this event. The principle of this comparison is not far from experimental 
studies, although the exposition is not allocated in some random fashion by the 
investigators.  
Once enrolled, all cohort members are classified according to their exposure status at the 
baseline (initial) examination, and these statuses can be updated during further 
examinations at different times throughout follow-up of participants.  
 
Cohort participants can arise from different population sources. Cohort can originate 
entirely, or almost entirely, from a population defined geographically and temporally. For 
example, Hoffamns et al. carried out a cohort study” among the entire 1932 male birth 
cohort to investigate the impact of body mass index at the age of 18 on survival during the 
subsequent 32-year time interval225. However, it is more usual that the cohort is arising 
from a fraction or a sample of the population defined geographically and temporally. One 
well-known example concerns a cohort study that was initiated in the late 1940s, the 
Framingham Study, where participants were recruited in Framingham, Massachusetts. 6,507 
adult subjects were selected to participate from a total list of 18,000 residents aged 35 to 59 
years old in order to investigate risk factors of coronary heart disease223.  
 
In order to correctly estimate the incidence of the disease(s) and its determinants, it is 
crucial to obtain accurate quality information regarding the disease occurrence. To ensure 
this quality information, document such as clinical records or death certificate of the 
participant are compared to previous documents recorded in interviews. In addition to 
validating the diagnosis of the disease, this comparison method permits to improve 
information regarding diagnosis characteristics, such as specific histological types in a 
cancer. A significant challenge in cohort studies is the validation of the cause of death, 
where either the physician is directly interviewed or information are collected from clinical 
records. Nevertheless, it is usually unfeasible to collect data on event for all members of the 
cohort due to some reasons including lost to follow-up (prior to the date of event) or death 
(from unrelated causes). 
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The design of a cohort study can vary and be prospective or retrospective. In a prospective 
cohort study, none of the participants have developed any of the event(s) of interest at 
study enrolment whereas in a retrospective cohort study (or historical study), exposure(s) 
and event (s) occurred before participants are enrolled in the study, and this specific cohort 
design can be defined for example from historic records. 
In epidemiological methods, we can also differentiate closed cohorts from open cohorts. 
The main difference between these two types of cohorts is how membership is fixed. In a 
closed cohort, memberships are fixed and no participant can be added to the cohort once 
this latter started.  Even if the size of the closed cohort diminishes due to death or loss to 
follow-up, no additional participant is further included. For example, people who were living 
in Hiroshima and Nagasaki when the atomic bombs were dropped in 1945 are part of a 
cohort whose membership started at the date of this nuclear disaster226, and no additional 
membership was included through time. These subjects remain in the cohort until they die. 
In contrast, open cohorts who dominate cancer epidemiology and form the conceptual basis 
for most case-control studies, are dynamic with members leaving or being added to the 
cohort. Rothman et al. has been given typical examples of open cohorts, in particular state 
cancer registries215. Every time a resident will be diagnosed with a cancer, he or she will be 
added to the cohort. Also, if the resident immigrates in another country or die, he or she can 
also leave the cohort.  
 
In cohort studies, time is a key element and the concept of “person-time” is fundamental for 
design and analysis. Person-time corresponds to the number of study subjects and the time 
they are followed, or more explicitly the sum of all times contributed in a study by subjects 
at risk of a disease. Let’s assume for example that we have some participants exposed to 
arsenic water and were followed since they were exposed until the date of diagnosis, loss to 
follow-up, death or end of the study (censured date). Among those, 5 were followed 5 years 
and 10 were followed 2 years. This gives us a total person-time equal to 45 person-years 
(5*5 + 10*2 = 45).    
In cohort design, person-time is necessary to estimate disease risk between exposed and 
unexposed participants. The estimation can be relative that is about the degree by which 
the exposure increases risk (relative risk), or absolute that is about how much difference in 
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risk is there between the exposed and unexposed participants (attributable risk). The 
relative risk provides an idea of what is the strength of the association between the 
exposure and the disease which can guide for any potential causal relationship. Attributable 
risk indicates the burden of disease that an exposure displays in a population, which 
emphasize its public health impact213.  
Many books and articles have reported on advantages and disadvantages of cohort 
studies215 222 227. In general, the main advantages are: exposures collected pre-diagnostically 
permit to avoid recall bias or reverse causality; they have the power to examine rare 
exposure and multiple events; incidence rates of disease in exposed and unexposed 
individuals can be determined. However, the cohort study design is not exempt of 
limitations such as (1) data on exposure and/or specimens for exposure analysis must be 
collected on the entire cohort (in prospective designs) at baseline which leads to cost issues 
and time consuming, (2) presence of bias from loss to follow-up (selection bias) between 
case and controls might induce the presence of an indirect non-causal association, and from 
outcome information being influenced by knowledge of exposures (information bias), (3) 
need to follow large number of subjects for long time to get enough statistical power , and 
(4) are limited for studies with rare events or long induction period. 
 
Case-control studies 
Case-control studies are defined as those studies which compare the frequency of patients 
having the disease (cases) with subjects free of disease (controls) with regards to prior 
exposure(s) or characteristic(s)213. Case–control studies often constitute one of the first 
approaches to study the etiology of a disease or condition. The major objective of a case-
control study is to strengthen hypothesized causal relationships by providing accurate and 
effective estimates.  
Many epidemiological works reported on principal case-control methodologies213 215 222 227 
and include specification of the study hypothesis, definition and selection of cases and 
controls, collection of information, analysis and interpretation. 
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As with any other type of design, the study hypothesis as to be clearly defined earlier in 
order to avoid design weaknesses and problems when interpreting the results215.  
A case-control study begins with the identification of cases which has to be ideally 
representative of all cases observed in a determined and identified population. Cases are 
selected on the basis of the disease and not the exposure. A case must be precisely and 
explicitly defined227. Objective evidence confirming the diagnosis of cases is usually 
advisable, even though the study must separate with some cases. For example, in cancer 
epidemiology, cancer cases are often defined thanks to the International Classification of 
Diseases (ICD) codes which confirm diagnosis of new incident cancer cases and limit 
ambiguity. Selection bias were raised by Rothman et al. when selecting all prevalent cases 
because those cases may not be representative of all cases215. For instance, the sub-
population of prevalent cases with a short duration will be excluded from the entire group 
of prevalent cases because of either death or recovery and hence this might bias the 
relation between the exposure and the outcome. If documentation of incident cases is 
limited and non-precise this could lead to dilute the case group with some non-cases and 
the probability to discover real risk differences between cases and controls are diminished.  
After cases identification, an important work has to be conducted for the selection of 
controls.  Some epidemiologists noted that ideally controls should be directly sampled from 
the source population in order to have a well-representative selection. However, there are 
some debates pointing out that comparability of controls with cases might be more 
efficient. Rothman et al. discussed these two directions and argued that priority need to be 
done on the comparability of controls with the cases and that representativeness of the 
population is less important215. However, increasing attention on many levels is observed 
when considering population dimension. Conducting a population-based case-control study 
need generalisability, and to rich this, controls should be randomly selected from the 
disease free members of the same population from which all incident cases were drawn227. 
We could imagine for example all the newly diagnosed lung cancer cases in the catchment 
area of Lyon, assuming that they come from a regional cancer registry. Ideally, controls 
would suitably be drawn from the population of the same area within the same groups of 
age and sex than the cases. Sometimes, controls can also be drawn from hospitals although 
they are considered less suitable than population controls as they can lead to bias arising 
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from the factors which lead individual to use health care services. In addition to population 
and hospital, controls can be selected from other sources such as neighbours, friends, or 
relatives, although control selection should always be motivated by the assumption227. 
An important aspect of case-control studies consists in determining the start and duration of 
exposure for cases and for controls. Several methodologies are used when recording data. 
Data on the relevant exposures can be obtained by telephone interview, by questionnaire, 
by face to face interview, by examining medical, occupational or other records, or by taking 
biological samples. Whatever method is chosen, it is crucial to guaranty that validated tools 
are used by trained investigators in the collection of data, and that such investigators should 
be “blind” (where possible) to the hypothesis under study and to the case/control status of 
the study participant. Even though this may be complex to realize in practice, strict 
procedures should be followed in order to limit bias from investigators (influence the cases 
and controls to remember exposures) and to maximized data collection.  
 
Since the number of cases and controls is determined by the group conducting the research 
in traditional case-control studies, incidence rate ratio cannot be measured.  However, if 
well-conducted, a case-control study can provide close estimates (odds ratio) of cohort 
studies (relative risk). The odds ratio is determined by the ratio of the odds of an exposure 
in the case group to the odds of an exposure in the control group215. Confidence interval for 
each odds ratio must be calculated in order to provide information on the precision of the 
estimates.  
In addition, several statistical analysis methods are used in case-control studies in order to 
control for confounding or to evaluate interactions222. Measurement error and missing data 
are not rare in retrospective case-control studies and this can affect results.  Sensitivity 
analysis which aims to quantitatively explore uncertainty in interpreting results has been 
proposed as one way of addressing these biases215 228.  
 
Several methodological design books in epidemiology have been discussed limitations of 
case-controls studies213 215 222 227 229. When interpreting results, one should take into account 
potential biases including information bias in the data collection, selection bias in the 
selection of cases and controls, and oblivion of confounding factors216. For example, in 
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traditional case-control studies, cases will usually report the exposure information after 
learning of their diagnosis. Then, diagnosis may produce differential abilities in repotting, for 
example, by improving memory which might increase sensitivity among cases, or by 
inducing more false memory and this reduce sensitivity. These characteristics are examples 
or recall bias. However, recall bias can be limited by keeping the study participants unaware 
of the hypotheses under study.  
If cases and controls are not representative of the source population from where cases 
arisen, this could induce distortion in the results (selection bias). Despite approaches in 
selecting population-based controls which limit this type of bias, clear and precise 
monitoring need to be performed on response rates and participation bias227. 
Another concern in case-control studies it that diagnosis related behavioural or pre-
malignant changes may affect the exposure, such as biomarkers close to diagnosis, i.e. as 
would be expected by reverse causality230. 
One of the major issue when conducting analytical epidemiology and in particular case-
control study is question related to validity and precision. First, several methods can help in 
improving results precision or diminishing random errors by obtaining large sample size 
population (using pre-study power analysis) or by improving study design (for example 
matching control group with cases with respect to certain characteristics other than the 
exposure under study such as age or sex). In addition, one could think to validate results 
internally by conducting several sensitivity analysis (accuracy of measurement), and also to 
validate them externally by conducting the same study outside that population 
(generalisability of findings)231.  
In addition, confounding is a considerable important issue in nonexperimental research. On 
the simplest level, confounding is a confusion of effects of the exposure of interest231. The 
distortion introduced by a confounding factor can lead to over- or underestimation of an 
association, or consequently more, can change the direction of the association. It is 
therefore essential to control for confounding throughout each investigation notably in 
observational study designs compared to intervention studies.  
 
Although traditional case-control designs are more likely to have bias and incorrect 
inference compared to cohort studies, several epidemiologists highlighted important 
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advantages of case-control designs including that they are cost-effective, easy to conduct, 
relatively quick,  very suitable for rare events (e.g. cancer), and there is no participant that 
can be loss to follow-up215 227 230. If well-designed and well-conducted, case-control studies 
permit to evaluate multiples hypotheses and interactions which can make this design 
efficient.  
 
Nested case-control studies 
We explained previously that in traditional case-control studies, controls should be selected 
to be representative of the study population source from which the cases were drawn. If 
they are not, selection bias will be introduced. A variant of case-control studies, named 
“nested case-control studies”, permit readily to accomplish this selection. As the name 
implies, a nested case-control study is a case-control study nested within a cohort, in which 
the cases and the controls arise from a clearly defined population, the cohort. However, in 
order to be able to adapt such design, it is important to enumerate times of entry and exit 
known for all members in order to list each risk set. These risk sets are necessary to ensure a 
rough representativeness when using sampling methods.  In general, the selection method 
mostly used in nested case-control study is the incidence density sampling229. This method 
aims to sampled controls from the risk set at the time each case is diagnosed and that this 
risk set is completely independent from the other risk sets. In order to improve 
comparability between cases and controls, they might be matched on various demographic 
characteristics such as sex, age, or year of recruitment. Importantly, a control being sampled 
from the population at time t could become afterwards a case a time t+n, and also the same 
participant could be sampled more than once as a control. Figure 11 shows a simple 
situation of two risk sets. For the first case (risk set n°1) 4 controls are eligible for the 
matching and for the second case (risk set n°2) only 2 controls remained eligible. Similar 
density sampling methods were applied throughout the different nested case-controls 
studies used in this dissertation. 
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Figure 11. Representation of risk sets in nested case-control designs. 
 
When using this approach for case-control matching, the association estimate (odds ratio) 
from the nested case-control design is an unbiased estimate of constant incidence rate ratio 
from the cohort232. As an example, Hak E et al. and colleagues compared relative and 
absolute estimates of associations in an influenza vaccine study using both cohort and 
nested case-control designs233.  After selection of different ratios (1:1 to 1:4) of cases and 
matched controls, it has been observed that the nested case-control design provided valid 
and precise estimates of associations compared to the full-cohort analysis. 
Because the nested design conserves the validity of the prospective study, bias due to the 
difference in recall and bias of the disease modifying biological characteristics as mentioned 
for traditional case-control designs are avoided. Also, nested case-control studies compared 
to cohort design are more efficient in a way that they can give similar statistical and 
significant estimation with a smaller sample size than required for analysis in cohorts. By 
selecting a sample of control(s) for each case, the number of participants for whom 
exposure information needs to be collected, such as a biomarker, is reduced, which might 
decrease cost and logistics compared to obtain the exposure of interest in the entire 
cohort234. However, important data including baseline characteristics must be collected at 
enrolment for all participants in the cohort making the costs of nested design more likely 
higher than a traditional case-control study.  
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In line with the advantages of the nested design, in particular time and cost, we conducted 
several nested case-controls studies in order to contribute in understanding the role of OCM 
biomarkers in relation to smoking-related cancers. 
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Data sources 
The European Prospective Investigation into nutrition and Cancer (EPIC)   
Overview of cohort  
In 1992, the International Agency for Research on Cancer (IARC) initiated a comprehensive 
collaboration across Europe, the EPIC cohort, a multi-centre prospective cohort study in 
Western Europe12 235. The main objective of the study was to investigate the etiology of 
human cancer of various sites in relation to nutritional and other lifestyle factors, further 
motivated by difficulties in measuring dietary exposures and the need for very large 
prospective studies in order to establish associations between these factors and disease. 
Originally, seven EPIC countries were included in the project including France, Germany, 
Greece, Italy, The Netherlands, Spain and the United Kingdom. These core countries were 
subsequently followed by three Nordic countries, Denmark, Sweden and Norway comprising 
in total 10 countries and 23 individual centres across Europe (see Figure 12). 
 
 
Figure 12. EPIC study collaborating centres. 
 
The enrolment of participants from all EPIC centres took place between 1992 and 2000.  In 
general, women and men aged 35 to 70 years were invited to participate either by mail or in 
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person. In total, the EPIC study has recruited 521,330 participants from all participating 
centres.  
 
Study population and data collection  
Individuals who agreed to participate signed an informed agreement and received two 
questionnaires on dietary and lifestyle variables, respectively. As a whole, subjects 
completed questionnaires at home and were then invited to a study centres for additional 
examination including anthropometric measurements and blood samples donation. From all 
participants recruited in the EPIC cohort, 385,747 provided blood samples, which were 
collected to a standardised protocol. After the blood draw, fractions of blood (plasma, 
serum, erythrocytes and buffy coat for DNA) were aliquoted into several 0.5 mL straws. One 
set containing half of the straws was stored locally and the remaining straws were 
transported to IARC biobank (Lyon) for storage in liquid nitrogen (-196°C). However, with 
exception of the Danish and Umeå (Sweden) samples that were stored in plastic tubes 
locally. The Danish samples were stored in liquid nitrogen tanks in the biobank of The 
Danish Cancer Society in Copenhagen, and the samples from the Umeå study centre were 
stored in -80°C freezers in Umeå.  
 
Different methods of dietary assessment were adopted in the EPIC cohort. First, extensive 
self-administrated quantitative dietary questionnaires, containing more than 250 food items 
and estimating individual average portions systematically, were used in several countries 
including northern Italy, The Netherlands, Germany and Greece (where dietary 
questionnaires were interviewer-administered). Questionnaires, similar in content to the 
self-administered quantitative dietary questionnaires but structured by meals, were used in 
Spain, France and Ragusa (south Italy). To increase compliance, the centres in Spain and 
Ragusa performed a face-to-face dietary interview using a computerised dietary program, 
whereas the dietary questionnaire was self-reported in France. 
Then, semi-quantitative food-frequency questionnaires (with the same standard portion(s) 
assigned to all subjects) were used in Denmark, Norway, Naples in Italy and Umea˚ in 
Sweden. Finally, combined dietary methods were used in the UK and Malmö (Sweden). The 
two British centres used both a semi-quantitative food-frequency questionnaire and a 7-day 
record, whereas a method combining a short non-quantitative food-frequency 
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questionnaire with a 14-day record on hot meals (lunches and dinners) was developed in 
Malmö. 
 
The ascertainment of cases within EPIC reflects the predominant pattern of diagnosis in the 
general population because the majority of cohort’s subjects were invited from the general 
adult population residing in a giving town or geographical area. Incident cancer cases were 
identified at regular intervals through population-based cancer registries (Denmark, Italy 
except Naples, the Netherlands, Norway, Spain, Sweden and United Kingdom) or by active 
follow-up (France, Germany, Greece and Naples), which involved a combination of methods, 
including review of health insurance records, cancer and pathology registries, as well as 
direct contact with participants and their next-of-kin. 
Mortality data, including vital status, cause of death, and date of death, were obtained from 
mortality registries at the regional or national level. Subjects were followed up from study 
entry until cancer diagnosis (except non-melanoma skin cancer), death, emigration, or the 
end of the follow-up period for the relevant study centre. End of follow-up was defined as 
the latest date of complete follow-up for both cancer incidence and vital status and varied 
between study centres from December 2004 to June 2010. Vital status at follow-up is over 
98% complete. 
 
The Lung Cancer Cohort Consortium (LC3) 
Overview of cohorts  
The LC3 was initially created in 2011. This initiative followed an investigation within the EPIC 
study where it was reported strong associations between circulating concentrations of 
vitamin B6, folate and methionine and lung cancer risk13. The overarching objectives of this 
large consortium are two-fold; (1) to evaluate potential etiological risk factors of lung cancer 
over and above smoking history, and (2) to develop extensive risk prediction models using 
biomarkers in multiple cohorts. The LC3 was initiated in the collaboration of several cohorts 
participating in the National Cancer Institute (NCI). All cohorts with at least 150 lung cancer 
cases having prospectively collected questionnaire data and either plasma or serum samples 
were invited to participate to the consortium. Many cohorts fulfilled those criteria and 
accepted to participate, and to date, the LC3 includes 20 prospective cohorts with a 
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combined study population of over 2,000,000 participants from North America, Europe, Asia 
and Australia, and are listed in the table below. Further design information and follow-up 
procedures of each cohort are provided in Appendix 1.  
 
Table 5. Characteristics of participating cohorts and lung cancer cases with serum/plasma 
available 
Nb. Full Cohort name Abbr. Representative   (co-applicant) Location  Enrolment  
Cohort 
size 
Cohorts recruited in US  
1 Women´s Health Initiative WHI Ross Prentice Fred Hutchinson CRC 1994-1998 161,808 
2 Southern Community Cohort Study SCCS 
Qiuyin Cai        
Shiman Qu   
Vanderbilt 
University 
Medical Center 
2002-2009 86,000 
3 
Prostate, Lung, Colorectal 
and Ovarian  Cancer 
Screening Trial 
PLCO Neil Caporaso DCP/DCEG, NCI, US 1993-2001 155,000 
4 NY Univ. Women Health Study NYUWHS 
Alan Arslan       
Anne 
Zeleniuch-
Jacquotte 
NYU School of 
Medicine 1985-1991 14,274 
5 ACS Cancer Prevention Study-II  CPS-II 
Victoria 
Stavens          
Marji 
McCullough 
American Cancer 
Society 1992 184,190 
6 Clue studies1974 CLUE (CLUE I) & 1989 (CLUE II) CLUE 
Kala 
Visvanathan 
John Hopkins 
Bloomberg 
School of Public 
Health 
1974 &1989 50,000 
7 Multiethnic Cohort Study MEC 
Loic le 
Marchand        
Lynne Wilkens 
Cancer Research 
Center, 
University of Hawaii 
2001-2007 215,000 
8 Women’s Health Study WHS Shuming Zhang 
Brigham and 
Women's 
Hospital / Harvard 
Uni 
1992-1995 39,876 
9 Nurses' Health Study NHS I Jiali Han         Xuehong Zhang 
Brigham and 
Women's 
Hospital / Harvard 
Uni 
1989 32,826 
10 Health Professionnals Follow-up Study HPFS Jiali Han  Harvard University 1993 18,159 
11 Physicians health study I & II PHS I+II 
Jing Ma          
Howard Sesso 
Brigham and 
Women's 
Hospital 
1982-1983      
1997-2000 29,071 
Cohorts recruited in Europe/ Australia 
12 Melbourne Colloborative Cohort Study MCCS 
Gianluca Severi   
Graham Gilles 
Cancer 
Epidemiology 
Centre / Victoria 
1990-1994 41,514 
14 Malmö Diet and Cancer MDCS Jonas Manjer Lund University, 1991-1996 28,098 
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study Sweden 
15 Northern Sweden Health and Disease Cohort NSHDC 
Mikael 
Johansson        
Kjell Grankvist 
Umeå University, 
Sweden 1985-onward 99,100 
16 
Alpha-Tocopherol, Beta-
Carotene Cancer 
Prevention Study 
ATBC 
Demetrius 
Albanes     
Stepahnie 
Weinstein 
DCEG, NCI, US 1985 29,133 
17 The HUNT study HUNT 
Arnulf 
Langhammer     
Kristian Hveem 
HUNT Biosciences, 
Norway 1995-1997 100,00 
Cohorts recruited in Asia 
18 Shanghai Cohort Study SCS Jian-Min Yuan University of Minnesota 1986-1989 18,244 
19 Singapore Chinese Health Study SCHS 
Lesley M. 
Butler 
University of 
Minnesota 1993-1998 63,257 
20 Shanghai Men’s Health Study SMHS Xiao-Ou Shu 
Vanderbilt 
University 2001-2006 61,500 
21 Shanghai Women’s Health Study SWHS Wei Zheng 
Vanderbilt 
University 1996-2000 74,942 
 
Study population and data collection 
In total, the consortium included 11,399 incident lung cancer cases with available pre-
diagnostic blood samples. Of these, we selected a subsample of 5,545 cases, comprising all 
incident cases among never smoking participants (n=1336), and a random selection of the 
cases diagnosed among former and current smoking participants. A standardised data base 
dictionary was sent to each cohort and we requested a standardized set of covariates for 
each study subject, including variables on (1) anthropometric and demographic variables 
such as weight, height, ethnicity, smoking status, educational attainment; (2) dietary intake 
variables such as vegetables, fruit, vitamins supplements; (3)  clinical variables such as 
tumour stage, histology, date of diagnosis, and (4)  follow-up information such as date of 
death and cause of death. All plasma and serum samples were sent and centralized to the 
Bevital AS laboratory in Bergen, Norway, and once on site they were kept at -80°C. A 
minimum of 500 μL of blood fraction (plasma or serum) from all participating subjects in 
each individual cohort was requested.  
 
Biochemical analyses 
All serum/plasma samples from the studies were shipped and centralized to Bergen under 
appropriate conditions, using established protocols (e.g sent on dry ice). Sample volume 
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requirements have been minimized by using a combination of microbiological assays and 
mass-spectrometry based methods, and sample handling was carried out by robotic 
workstations ensuring high sample throughput. Measurements performed at Bevital have 
been used in several high profile, recently published epidemiological studies13 236-238. All 
biochemical analyses of circulating OCM biomarkers were performed at the the Bevital A/S 
laboratory (http://www.bevital.no) in Bergen, Norway. Plasma from all study participants 
were analyzed on four analytical platforms (platforms B, C, D, and F). Concentration 
measurements of plasma vitamin B2 (riboflavin), vitamin B6 (measured as pyridoxal 5’-
phosphate [PLP], its active form), vitamin B9 (folate), vitamin B12 (cobalamin), total 
homocysteine, and methionine were provided in HNC (Chapter III) and RCC (Chapter IV) 
studies. LC3 study (Chapter V) comprised plasma/serum measurement concentrations of 
vitamin B6, folate and methionine. All case and control participants were successfully 
analysed, for at least one of the biomarker. Circulating cotinine was also measured as an 
indicator of recent smoking behaviour in each study. Circulating vitamin B2, vitamin B6, 
homocysteine, methionine, and cotinine were determined by mass spectrometry–based 
methods (liquid chromatography coupled to tandem mass spectrometry; gas 
chromatography coupled to tandem mass spectrometry - LC-MS/MS, GC-MS/MS)239 240. 
Microbiological methods were used to determine concentrations of folate (Lactobacillus 
casei)241 and vitamin B12 (Lactobacillus leichmannii)242.  
The detection limit, and within-day and between-day coefficients of variations (Cvs) using 
these methods are low for all of the biomarkers239 240. For HNC and RCC studies, CVs within 
and between batches were, respectively, 6 and 11% for vitamin B2, 3% and 6% for vitamin 
B6, 4% and 5% for folate and vitamin B12, 1% and 3% for methionine, and 1%and 2% for 
homocysteine. The CVs within and between batches of biomarkers studied in LC3 study 
were, respectively, 3 and 7% for vitamin B6, 4 and 5% for folate and 1 and 3% for 
methionine. 
All samples were analysed with similar methods in batches of 86 and quality control 
included six calibration samples, two control samples, and one blank sample in each batch. 
For each study, all serum or plasma samples were kept at -80°C and all cancer cases and 
their individual matched controls were analysed together within the same batches in 
random order. The laboratory staff was blinded to the case–control status of the blood 
samples. The raw data from the separate platforms and analysis sets were merged, handled 
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and controlled by specifically designed software. Outliers were identified by the ratio of 
concentrations as measured by the different platforms. Unlikely combinations of values 
were flagged by installed macros. This increases accuracy and precision, minimizes the 
possibility of assay interference and ensures adequate sample handling and logistics. The 
system also generated summary statistics and printouts of selected samples. These routines 
for data handling ensured efficiency and reduced the chance of logistic problems and 
human errors. 
In the LC3 study, about 1,000 repeat blood samples from subjects were additionally 
measured in order to estimate the within person variation in each biomarker. These repeat 
samples came from two participating cohorts which are the CSP (390 repeat samples) and 
NSHDS (600 repeat samples) studies.  The sample size of repeat samples have been 
designed to select approximately one third of repeat samples collected within a short time 
of each other (< 1 year), as well as one third collected around 3 to 5 years of each other, and 
one third within 10 years or more of each other.  
 
 
Statistical methods 
Standard statistical methods, such as linear and logistic regression, were used throughout 
the different studies of this thesis in order to investigate various relationships. The strength 
of associations was estimated by OR. P-values were assessed as indicators of associations, 
and p-values of less than 0.05 were considered statistically significant.  
Throughout the papers included in this thesis, we conducted initial analyses involving 
extensive assessments of demographic variables such as age, smoking status, body mass 
index (BMI) and factor related to socio economical status as well as for dietary intake of fruit 
and vegetables. Also, the relation of lifestyle and dietary factors with biomarker 
concentrations were assessed using linear models, adjusted for age, sex, country and other 
covariates if necessary. Subsequent statistical analysis included estimation of RR by 
calculating OR, using both conditional and unconditional logistic regression. In the three 
studies of this thesis, risk analysis involved calculating quartiles of circulating concentration 
for each biomarker of interest based on their distribution among all matched control 
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participants. Because of the substantial variation of circulating biomarkers across continent 
in LC3 study (Chapter V), quartiles were additionally based on the distribution among all 
controls of each continent (United States [US], Europe and Australia combined [EU/AU], and 
Asia). OR and 95% CI for participants in the second, third, and fourth quartiles were 
calculated relative to the first quartile using conditional logistic regression, conditioning on 
individual case sets. Unconditional logistic regression were also used mostly in HNC and RCC 
studies for stratified analysis or in order to increase the statistical power (since we had 
about half controls who were not matched to the cases, see Selection of cases and controls 
in Chapter III and IV) and further evaluate the consistency of any association observed in 
conditional logistic regression. 
In order to evaluate whether deficiency of the OCM biomarkers of interest in LC3 study are 
harmful for lung cancer etiology, we conducted analyses by using clinical cut-points for 
deficiency of vitamin B6 and folate. Because methionine deficiency is very poorly 
documented, we could not conduct such analysis. We have considered vitamin B6 deficiency 
as circulating vitamin B6 concentration less than 20nmol/L, compared with normal range, 
defined as ≥ 20nmol/L243. Folate was classified as deficient (<7 nmol/L), moderate deficiency 
(7 to 13 nmol/L), or normal (≥ 13 nmol/L)244. For these additional analyses in the LC3 study, 
we also used conditional logistic regression to estimate RRs by calculating ORs and 95% CI of 
lung cancer risk for deficiency relative to normal concentrations.  
To assess potential effect modification throughout the studies, we performed stratified 
analyses by different variables including place of recruitment (country or continent), sex, 
smoking status, age at diagnosis, time from blood draw to diagnosis.  
In order to investigate if OCM biomarkers were related to cancer survival probability of the 
head and neck and kidney, estimation of hazard ratios (HRs) for all-cause mortality for cases 
were calculated using Cox proportional hazards models (Chapter III and IV, respectively). 
Time since diagnosis was used as the timescale, and all models were adjusted for age at 
diagnosis, sex, and country and additional variables when it was relevant. 
We adjusted overall analysis by cotinine (in quartiles) within each study, by smoking status 
(in HNC and RCC studies), and further smoking variables when available, including duration 
of smoking and average cigarettes smoked per day. Further potential confounders, including 
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alcohol consumption, BMI, educational attainment, hypertension and dietary intake were 
included in our analyses where necessary.  
For estimated interclass correlations of repeat measurements in the LC3 study, we used 
spearman correlation methods215.  
All statistical analyses were conducted using SAS 9.2 (Cary, NC)245 (Chapter III, IV and V), 
Stata 12.1 for Linux (Stata Corporation)246 (Chapter IV), R version 3.1.3247 (Chapter V), and 
Stan version 2.6.0248 (Chapter V).  
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Objective 
Although our group has recently reported strong inverse associations between circulating 
concentrations of OCM biomarkers, in particular vitamin B6, folate and methionine, with 
risk of lung cancer, the risk association of OCM biomarkers in other smoking related-cancers 
remains to be demonstrated.  
In this Chapter we primarily aim to investigate whether pre-diagnostic circulating 
concentrations of vitamin B2, vitamin B6, folate, vitamin B12, methionine and homocysteine 
are associated with onset and survival of HNC. Additionally, we investigated the relation of 
those OCM factors with ESCC risk and mortality.  
 
Selection of cases and controls 
This study was nested in the EPIC cohort and further study design information has been 
described previously in Chapter II (see Material and Methods, Study population and data 
collection). 
In this study, 1,273 subjects diagnosed with incident head and neck or oesophagus cancers 
where identified from nine EPIC sub-cohorts contributing to this nested case-control study. 
These cancer cases were defined on the basis of the International Classification of Diseases 
for Oncology, Second Edition (ICD-O-2), and included: oral cavity (ICD C02.0-C02.9, C04.0-
C04.9, C03.0-C03.9, C05.0-C06.9, C14.0-C14.9), oropharynx (C01.9, C02.4, C09.0-C10.9), 
hypopharynx (C13.0- C13.9), larynx (C32.0-C32.9), and oesophagus (C15.0-C15.9). Criteria of 
exclusion included cases who (1) did not donate a blood sample (n=152), (2) did not have 
enough plasma available for biochemical analysis (n=20), (3) had a history of another cancer 
(n=158, except non melanoma skin cancer), (4) were not histologically confirmed, were 
prevalent at the time of blood donation, or did not have questionnaire information available 
(n=22), (5) cases from Denmark (n=288) because of flooding of the Danish biobank, and the 
Malmo centre in Sweden (n=101) who did not participate in this study. We thought also to 
exclude adenocarcinoma of the head and neck (n=16) because the etiology of 
adenocarcinoma and SCC are likely to differ and the vast majority of the HNC are SCC. After 
all participant exclusions, 516 cancer cases of the head and neck and oesophagus remained 
eligible in this study.  
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For each case, one control was randomly chosen from appropriate risk sets consisting of all 
cohort members alive and free of cancer (except non-melanoma skin cancer) at the time 
(and hence age) of diagnosis of the index case. Matching criteria were country, sex, date of 
blood collection (±1 month, relaxed to ±5 months for sets without available controls), and 
date of birth (±1 year, relaxed to ±5 years for sets without available control participants). An 
additional control group (control group 2, n=479) was included in the HNC study. This 
control group 2 was matched to cases of the study on RCC (from Chapter IV) using similar 
matching criteria.  Control group 2 participated essentially to unconditional and stratified 
analyses in order to assess the consistency of any association and increase the statistical 
power.  
 
Biochemical analyses 
All biomarkers were sent on dry ice to the Bevital A/S laboratory, in Bergen, Norway. 
Because the studies of this thesis share common biochemical methods, details of the 
biochemical analyses have been provided previously in Chapter II (see Material and 
Methods, Biochemical analyses). 
 
Statistical analyses 
Throughout this study, we used both conditional and unconditional logistic regression in 
order to investigate circulating OCM biomarkers in relation to cancer risk of the HNC and 
ESCC. Hazard ratios for all-cause mortality for HNC and ESCC cases were calculated using 
Cox proportional hazard regression models. These calculations were performed using SAS 
9.2. More details in statistical methods are provided in Chapter II (see Material and 
Methods, Statistical methods). 
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Objective 
In the previous chapter, we found that participants having higher circulating concentrations 
of homocysteine had elevated risk of HNC. We wanted then to evaluate the extent to which 
homocysteine or other biomarkers included in the OCM pathway may be related to the 
incidence and survival of RCC. An additional reason for studying the association between 
OCM biomarkers and RCC was that this specific cancer site had less strength of association 
with smoking compared to HNC. 
 
Selection of cases and controls 
As for the HNC study, the RCC case-control study nested within the EPIC cohort used similar 
selection methods and further study design information has been described previously in 
Chapter II (see Material and Methods, Study population and data collection). 
In this study, we initially identified 905 cases from 10 participating countries within EPIC 
that were diagnosed with RCC as C64.9 according to the International Classification of 
Diseases for Oncology, Second Edition (ICD-O-2). We excluded prevalent cases and cases 
with a prior history of another cancer (n = 85, except non melanoma skin cancer), cases who 
did not donate a blood sample (n = 153), were not histologically confirmed (n = 27), did not 
have questionnaire information available (n = 6), and cases from the Malmö centre that did 
not participate in this study (n = 64), leaving 570 eligible RCC cases. 
As in HNC study, one control was randomly chosen for each case in RCC study, from 
appropriate risk sets consisting of all cohort members alive and free of cancer (except non-
melanoma skin cancer) at the time (and hence age) of diagnosis of the index case. The 
matching criteria is the same of the HNC studies being country, sex, date of blood collection 
(±1 month, relaxed to ±5 months for sets without available controls), and date of birth (±1 
year, relaxed to ±5 years for sets without available control participants).  
As previously explained for the HNC study, we also included a control group 2 (n=553) 
unmatched to the RCC incident cases but matched to cases of the HNC study (Chapter III). 
Similar matching criteria for the control group 2 compared to the RCC matched controls 
were also used. This control group 2 participated to unconditional and stratified analyses to 
assess the consistency of any association and increase the statistical power.  
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Replication study 
The first analyses from the EPIC sub-sample in the RCC study showed strong inverse 
association between circulating vitamin B6 and risk of renal cell carcinoma. In order to 
determine if this association was restricted to the EPIC study population, a replication study 
was conducted in a separate cohort, the Melbourne Collaborative Cohort Study (MCCS). The 
MCCS is a prospective cohort study of 41,514 women and men aged 40 to 79 years at the 
time of recruitment which took place between 1990 and 1994 in Melbourne, Australia. 
Following blood draw, plasma fractions were stored in liquid nitrogen tanks at -196°C. 
Incident cancer diagnoses were identified via routine linkage to the Victorian Cancer 
Registry (VCR). There is a statutory requirement that all cancers diagnosed in the state of 
Victoria (the state in which Melbourne is situated), excluding non-melanoma skin cancer be 
reported to the VCR. Vital status and cause of death information were obtained via linkage 
to the National Death Index of Australia.  
The nested case-control study from MCCS counted a total of 144 case-control matched 
pairs. We ensured that incident cases and controls were selected using the same protocol as 
the EPIC cohort. As a note, data from the MCCS study were used as an independent 
replication analysis and then were not pooled with the EPIC data. 
 
Biochemical analyses 
Biochemical procedures used in this study are identical to the HNC study (Chapter II), and 
details of the biochemical analyses have been provided previously in Chapter II (see 
Material and Methods, Biochemical analyses). 
Statistical analyses 
In this study, we used similar statistical methods to the HNC study including conditional and 
unconditional logistic regression to investigate the association of OCM biomarkers with RCC 
risk. Hazard ratios for all-cause mortality for RCC cases were calculated using Cox 
proportional hazard regression models. Model based estimates of the survival function by 
biomarker quartiles were calculated using flexible parametric survival models. These 
calculations were performed using SAS 9.2 and Stata 12.1 for Linux.  More details for 
statistical analyses are provided in Chapter II (see Material and Methods, Statistical 
methods). 
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Objective 
In addition to investigate whether OCM biomarkers were associated with other smoking-
related cancers than lung cancer, we wanted to externally validate and support some 
previous findings from the EPIC lung cancer study13. We then further investigated the 
association between circulating concentrations of vitamin B6, folate and methionine with 
lung cancer risk in the LC3 study which gather multiple populations from America, Europe, 
Asia and Australia.   
 
Selection of cases and controls 
In total, twenty nested case-control studies contributed in this study, gathering over 5,500 
case-control pairs. Further study design information of each participated cohort is described 
in Appendix 1. Lung cancer cases were defined on the basis of the International 
Classification of Disease for Oncology, Second Edition (ICD-O-2), and included invasive 
cancers coded as C34.0-C34-9. After excluding cases who were not correctly matched on 
smoking status (n=124 cases), who had insufficient plasma samples (n=42), or had a revised 
date of diagnosis prior to blood draw (n=13), 5,364 lung cancer cases and their matched 
controls remained eligible. 
For each case, one control was randomly chosen from risk-sets consisting of all cohort 
members alive and free of cancer (except non-melanoma skin cancer) at the time of 
diagnosis of the index case. Matching criteria were cohort, sex, date of blood collection (± 1 
month, relaxed to ± 3 months for sets without available controls), and date of birth (± 1 
year, relaxed to ± 3 years). To adequately control for confounding by tobacco exposure 
controls were also matched for 3 categories of smoking status including never smoker, 
short/long term quitters among former smokers (< 10 years/ 10+ years since quitting), and 
light/heavy smokers among current smokers (< 15 years/ 15+ cigarettes per day). 
 
Data harmonization 
The LC3 consortium was led by our group, the Genetic Epidemiology Group, at the 
International Agency for Research on Cancer. Once the consortium started, I was strongly 
involved in the coordination of biosample shipments. We created a data dictionary (see 
Appendix 2) which was sent to all participated cohorts including epidemiological and clinical 
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variables. With support from Dr Brennan and Dr Johansson, I mostly coordinated and led 
the data management of the LC3 study database by completing the study database 
including biochemical, epidemiological and clinical data for all participating cohorts, and 
harmonizing the baseline data. The LC3 database includes 44 biomarkers and over 200 
variables for over 12,000 participants. 
 
Biochemical analyses 
All biosamples from the LC3 study were also sent on dry ice to the Bevital A/S laboratory, in 
Bergen, Norway, which permit us to have a good comparability with the two previous 
studies (Chapter III and IV). Additional biochemical analysis information has been provided 
previously in Chapter II (see Material and Methods, Biochemical analyses). 
 
Statistical analyses 
In the LC3 study we used conditional logistic regression in order to investigate circulating 
OCM biomarkers in relation to lung cancer risk. In addition, hierarchical linear models were 
used to describe within- and between-cohort differences in (log) concentrations of each 
biomarker by demographic and host factors.  These calculations were performed using SAS 
9.2, R version 3.1.3 and Stan version 2.6.0. Supplementary statistical details are provided in 
Chapter II (see Material and Methods, Statistical methods). 
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Abstract 
Background – Circulating concentrations of B-vitamins and factors related to one-carbon 
metabolism have been found to be strongly inversely associated with lung cancer risk in the 
European Prospective Investigation into Cancer and Nutrition (EPIC) study. The extent to 
which these associations are present in other study populations is unknown.  
Methods – Within 20 prospective cohorts from the NCI Cohort Consortium, a nested case-
control study was designed including 5,364 incident lung cancer cases and 5,364 controls 
that were individually matched to cases by age, sex, cohort, and smoking status. Centralized 
biochemical analyses were performed to measure circulating concentrations of vitamin B6, 
folate and methionine, as well as cotinine as an indicator of recent tobacco exposure. The 
association between these biomarkers and lung cancer risk was evaluated using conditional 
logistic regression models.  
Results – Participants with higher circulating concentrations of vitamin B6 and folate had a 
modestly decreased risk of lung cancer risk overall, the odds ratio when comparing the top 
and bottom fourths [OR4vs1] being 0.88 (95% confidence interval [95% CI], 0.78-1.00) and 
0.86 (95% CI 0.74-0.99), respectively. We found stronger associations among for men (OR4vs1 
0.74; 95% CI 0.62-0.89 for vitamin B6, OR4vs1 0.75; 95% CI 0.61-0.93 for folate) and ever 
smokers (OR4vs1 0.79; 95% CI 0.68-0.91 for vitamin B6, OR4vs1 0.85; 95% CI 0.72-0.99 for 
folate). We further noted that the association of folate was restricted to Europe/Australia 
and Asia, whilst no clear association was observed for the United-States. Circulating 
concentrations of methionine were not associated with lung cancer risk overall or in 
important subgroups. 
Conclusion – Although confounding by tobacco exposure or reverse causation cannot be 
ruled out, these study results are consistent with a small decrease in lung cancer risk in ever 
smokers who avoid low concentrations of circulating folate and vitamin B6. 
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Introduction 
The most important and effective means for lung cancer control is by reducing the number 
of people who smoke tobacco products. However, even among subjects who have quit 
smoking, the lifetime risk of lung cancer remains high,249-251 and in some regions where anti-
tobacco campaigns have been successful, such as the US, a large proportion of lung cancer 
cases now occurs among former and never smokers. Given these considerations, exploring 
additional means of primary prevention of lung cancer is important for subgroups of high 
risk–in particular former smokers–who seek additional means to further reduce their risk.  
One-carbon metabolism (OCM) encompasses a series of biochemical reactions involving B-
vitamins that are essential to ensure balanced DNA synthesis and methylation,133 180 and 
changes in specific OCM factors have been implicated in cancer development.132 180 195 If 
imbalances in B-vitamins such as folate (B9) and vitamin B6 are proved to be causally 
implicated in lung cancer etiology, they would provide an appealing target for 
chemoprevention as they are modifiable by changes in diet or supplementation.145 252 
Only two prospective studies have been published on lung cancer and circulating 
biomarkers of OCM, the EPIC study13 and the Alpha-Tocopherol, Beta-Carotene, Prevention 
Cancer (ATBC) study of smoking men,185 both of which reported an inverse association 
between circulating vitamin B6 and lung cancer risk. In particular, the EPIC nested case-
control study of 899 cases and 1,770 controls reported that the inverse association of 
vitamin B6 with lung cancer risk was strong and consistent regardless of tobacco smoking 
history, and also reported strong inverse associations of methionine and folate with risk.13  
In order to provide conclusive evidence on the importance of circulating B-vitamins and lung 
cancer risk, we initiated the Lung Cancer Cohort Consortium (LC3) with a combined cohort 
population of over 2,000,000 participants from North America, Europe, Asian, and Australia, 
to retrieve blood samples and conduct biochemical analysis on over 5,000 case-controls 
pairs.  
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 Material and Methods 
Study population 
We invited all prospective cohort studies with cryopreserved baseline plasma and serum 
samples that in 2009 were members in the US National Cancer Institute (NCI) Cohort 
Consortium to participate in the study. Twenty cohorts fulfilled those criteria and accepted 
to participate, resulting in a combined cohort population of over 2,000,000 participants 
from North America, Europe, Asia and Australia. Brief details on design of the cohorts and 
their follow-up procedures are provided in the Supplementary methods.  
Selection of cases and controls 
Lung cancer cases were defined on the basis of the International Classification of Diseases 
for Oncology, Second Edition (ICD-O-2), and included all invasive cancers coded as C34.0-
C34-9. We selected a total 5,545 lung cancer cases, and in order optimize the statistical 
power in smoking stratified analyses, never and former smoking cases were oversampled. 
For each case, one control was matched by cohort, sex, date of blood collection (± 1 month, 
relaxed to ± 3 months for sets without available controls), and date of birth (± 1 year, 
relaxed to ± 3 years), as well as smoking status in 5 categories; never smokers, short and 
long term quitters among former smokers (<10 years, ?10 years since quitting), and light 
and heavy smokers among current smokers (< 15 years, ?15 cigarettes per day). After 
various exclusions (see Supplementary methods), 5,364 lung cancer case-control pairs 
remained eligible for the risk analysis. 
Biochemical analyses 
Concentrations of vitamin B6, methionine and cotinine were determined by mass 
spectrometry based methods (LC-MS/MS, GC-MS/MS),239 240 and microbiological methods 
were used to determine concentrations of folate (Lactobacillus casei).241 Further details are 
provided in Supplementary methods.  
Statistical analyses 
Hierarchical linear models were used to describe the variation in average biomarker 
concentrations between the cohorts, and the extent to which these could be explained by 
differences in baseline characteristics. Relative risks of lung cancer were estimated by 
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calculating odds ratios (OR) and 95% confidence intervals (CI) using conditional logistic 
regression (conditioning on matched case-control sets) with the first quartile as the 
referent. Additional covariates were included to account for confounding by risk factors, 
including indicators of educational attainment (in six categories) and tobacco exposure (in 
addition to matching to smoking status by design: cotinine concentrations [quartiles defined 
in current smokers]). Including additional covariates of body mass index (BMI) and alcohol 
intake did not appreciably alter the results and were not included in the final models. As a 
sensitivity analysis, we fitted models that were additionally adjusted for smoking duration or 
pack-years of smoking among ever smokers. All risk analyses were conducted overall, and 
stratified by smoking status and region (US, EU/AU, Asia).  
As an indication of the overall statistical strength of association between each biomarker 
and risk, we calculated a p-value for trend by including the base-2 logarithm (log2) of the 
biomarker concentration as a continuous variable in a separate conditional logistic 
regression model. The same approach was used in stratified risk analyses according to other 
pre-defined demographic characteristics and risk factors. OR estimates per log2 unit (log2 
OR) may be interpreted as the relative risk associated with a doubling in the concentration 
of a circulating biomarker.  
All statistical analyses were conducted using SAS 9.2 (Cary, North Carolina),245 R version 
3.1.3247 or Stan version 2.9.0.248  
Additional details on the statistical methods are provided in the Supplementary methods.  
Results  
Baseline Characteristics 
Baseline characteristics of the study subjects separated by geographic areas are shown in 
Table 1. The final study population included 5,364 lung cancer cases and 5,364 individually 
matched controls. Median age at cohort enrolment was 63 years and the median time 
between blood draw and lung cancer diagnosis was 6.3 years. Because we oversampled 
never and former smokers, approximately half of the study population were current 
smokers at recruitment (2,519 case-control pairs, 47%), whereas the other half were either 
former (1,518 case-control pairs, 28%) or never smokers (1,327 case-control pairs, 25%). 
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Overall, 46% of the participants were women, though the sex distribution varied by region, 
the US cohorts contributing more women and the cohorts from Europe and Asia contributed 
more men. 
Variation in circulating biomarkers 
There was substantial between-cohort variation in concentrations of all biomarkers (Table 
1), in particular for folate and vitamin B6 concentrations that were substantially higher in US 
cohorts than for EU/AU or Asian cohorts. This could only partly be explained by differences 
in age, sex, smoking status, or BMI (Figure 1). For circulating vitamin B6 and methionine, the 
between-cohort variability was similar before and after covariate adjustment (Figure 1). 
Conversely, for circulating folate, adjustment for age, sex, smoking status, and BMI reduced 
the between-cohort variability, the sd being 0.70 (90% CI 0.54-0.97) without adjustment and 
0.44 (90% CI 0.32-0.65) with adjustment. 
Risk analysis overall and stratified by region 
Participants with higher circulating vitamin B6 and folate had an approximate 20% lower risk 
of lung cancer overall (Table 2 and 3), the odds ratio when comparing the top and bottom 
quartiles [OR4vs1] being 0.81 for vitamin B6 (95% CI 0.72-0.92) and 0.80 for folate (95% CI 
0.70-0.92). These OR estimates were slightly attenuated after adjustment for circulating 
cotinine and education (OR4vs1 0.88, 95% CI 0.78-1.00 for vitamin B6 and OR4vs1 0.86, 95% CI 
0.74-0.99 for folate). We did not observe any clear association between circulating 
methionine and risk of lung cancer, the overall OR4vs1 being 0.95 (95%, 0.85-1.07, Table 4). 
Among participants with available information on smoking duration and pack-years of 
smoking (90% of ever smokers), further adjustment by continuous number of years of 
smoking or pack-years of smoking did not notably affect the estimates (Supplementary 
Table 1-4).  
In risk analyses stratified by region (Table 2-4), the overall inverse associations of vitamin B6 
and folate were mainly driven by Asian and EU/AU participants. The adjusted OR4vs1 for 
vitamin B6 was 0.82 in the Asian cohorts (95% CI 0.65-1.02) and 0.78 for the EU/AU cohorts 
(95% CI 0.62-1.00), and 0.95 for the US cohorts (95% CI 0.80-1.13). Similarly, for folate, the 
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adjusted OR4vs1 was 0.84 for the Asian cohorts (95% CI 0.68-1.03) and 0.77 for the EU/AU 
cohorts (95% CI 0.60-0.99), and 0.95 for the US cohorts (95% CI 0.78-1.15).  
Risk analysis stratified by smoking status and sex 
In analyses stratified by smoking status, we observed an inverse association between 
vitamin B6 and overall risk for former (OR4vs1 0.72, 95% CI 0.57-0.91) and current smokers 
(OR4vs1 0.79, 95% CI 0.65-0.95) (Table 2). Folate was also inversely associated with risk for 
former (OR4vs1 0.66, 95% CI 0.51-0.85), but not for current smokers (OR4vs1 0.97, 95% CI 0.77-
1.21) (Table 3). When analyzing ever smokers overall (i.e. former and current smokers 
combined), we observed an inverse association for circulating vitamin B6 (OR4vs1 0.79, 95% 
CI 0.88-0.91) and folate (OR4vs1 0.85, 95% CI 0.72-0.99). Of note, whilst no clear association 
was seen between folate and risk for never smokers (OR4vs1 0.86, 95% CI 0.63-1.17), we 
observed a positive association between vitamin B6 and risk for never smokers, the OR4vs1 
being 1.51 (95% CI 1.14-2.01) (Table 2).  
Further analyses stratified by sex showed that any inverse association between folate or 
vitamin B6 and lung cancer risk was restricted to ever smokers and men. First, the 
association of vitamin B6 in men (OR4vs1 0.74, 95% CI 0.62-0.89) was consistently observed in 
cohorts from each region (Table 2), with similar observations for folate (overall OR4vs1 0.75; 
95% CI 0.61-0.93) (Table 3). Conversely, no association was seen among for women overall, 
nor for women separated by region (Table 2-3).  
Stratified risk analysis by demographic and diagnostic parameters 
To assess potential of effect modification, we fitted models that included interaction terms 
between circulating folate or vitamin B6 and various covariates (Supplementary Figures 1-8). 
Gender modified the associations between circulating concentrations of vitamin B6 and 
folate and lung cancer risk (Pheterogeneity ≤0.05, Supplementary Tables 1 and 4). When 
assessing blood samples taken up to 10 years prior to diagnosis, we observed that the 
overall inverse association between vitamin B6 and lung cancer risk was driven by cases 
diagnosed closer to blood draw (Pheterogeneity = 0.001, Supplementary Figure 1), as well as by 
former (ORlog2 0.81; 95% CI 0.70-0.90, Supplementary Figure 3) and current smokers (ORlog2 
0.79; 95% CI 0.69-0.91, Supplementary Figure 4). Stratified analyses by histology showed a 
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stronger inverse association between vitamin B6 and folate and risk of lung squamous cell 
cancer (ORlog2 0.86; 95% CI 0.77-0.95 for vitamin B6 and ORlog2 0.88; 95% CI 0.78-0.98 for 
folate) than for other histological types (Supplementary Figures 1 and 5). Stratified analysis 
by period of blood collection before and after 1996 when folate fortification of food items 
took effect in US did not reveal any discernable difference in lung cancer risk for circulating 
folate (Supplementary Figure 12). The associations between biomarker concentrations and 
lung cancer risk for individual cohorts are presented in Supplementary Figures 9-11. We also 
estimated the potential risk increase associated with being clinically deficient in vitamin B6 
and folate, and observed a 23% increase in risk of lung cancer for those deficient in vitamin 
B6 (OR = 1.23, 95% CI 1.09-1.38) that was more apparent for being diagnosed with 
squamous cell cancer (OR=1.54, 95% CI 1.18-2.02), and also those for developing lung 
cancer within the first 3 years following blood collection (OR=1.83, 95% CI 1.42-2.36) 
(Supplementary Figure 13). Similarly, for folate we observed an increased risk for those 
classified as deficient (OR=1.27, 95% CI 1.07-1.49, Supplementary Figure 14). Further 
stratified analyses are presented in Supplementary Figures 13 and 14.  
Discussion  
Our aim was to evaluate the associations between lung cancer risk and circulating 
concentrations of folate, vitamin B6, and methionine, within a consortium of 20 prospective 
cohorts from the US, Europe, Asia and Australia. We found that individuals with low 
concentrations of vitamin B6 and folate have a small risk increase of lung cancer, particularly 
among men, current and former smokers, and participants living outside the United States. 
Previous studies and the Lung Cancer Cohort Consortium (LC3) 
To date, this is the largest cohort consortium initiative for which circulating biomarkers 
where assessed in relation to a single cancer outcome with coordinated biochemical 
analysis conducted in one centralized laboratory. The background to this study was the 
initial findings from the EPIC cohort involving 899 lung cancer cases and 1,770 controls.13 
The EPIC study reported a strong inverse association between vitamin B6 and lung cancer 
regardless of smoking history, and additionally, found similar inverse associations with risk 
for folate and methionine. The results of the EPIC study were noteworthy as they suggested 
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a potentially important role of the one-carbon metabolism pathway in lung cancer etiology, 
in addition to tobacco exposure. Along with additional evidence from the ATBC cohort,185 
this motivated the organization of the Lung Cancer Cohort Consortium (LC3) in order to 
conclusively evaluate the extent to which these findings translate into other populations 
from Asia, the United States, Europe and Australia.  
Interpreting the results  
The current study discerned relatively weak inverse associations between folate, vitamin B6 
and lung cancer risk overall, associations that differed substantially between groups of 
different tobacco exposure history. For former and current smokers, we observed slightly 
lower risk among for those study participants with higher concentrations of folate and 
vitamin B6 compared to those having lower concentrations. This inverse association for lung 
cancer risk with vitamin B6 or folate can also be interpreted as an increased risk among 
participants in the lowest category of concentrations compared to those in the remaining 
three higher categories (Tables 2 and 3). In contrast, methionine was not clearly associated 
with risk overall or in any important subgroup. 
Previous studies have shown that being a current smoker is clearly associated with lower 
circulating concentrations of folate and vitamin B6,13 and our analysis confirms this relation 
(data not shown). This highlights the importance of carefully accounting for tobacco 
exposure in risk analyses of B-vitamins and lung cancer. We used circulating cotinine, an 
objective and accurate measure of current tobacco exposure,253 and the weak inverse 
associations of vitamin B6 and folate with lung cancer risk remained after adjusting for 
cotinine. Further accounting for smoking duration and intensity did not substantively alter 
the OR estimates. In contrast to current smokers, former smokers tend to have similar 
circulating B-vitamin concentrations as never smokers.13 This suggests that the potential 
confounding effect of tobacco exposure on the associations between circulating vitamin 
B6/folate and lung cancer risk is of less concern for former smokers than for current 
smokers. Despite these considerations, and given the important impact of both past and 
current tobacco exposure on lung cancer risk, our results do not allow ruling out 
confounding by tobacco smoking as a possible explanation for the observed associations.  
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Another potential explanation for the observed association of vitamin B6 with risk is reverse 
causation. In analysis stratified on smoking status, we observed a gradually stronger inverse 
association between vitamin B6 and risk of lung cancer in both former and current smokers 
when measured in blood drawn closer to diagnosis (Supplementary Figure 1, 3 and 4), 
results that would be consistent with pre-clinical metabolic changes due to the underlying 
disease progression. In contrast, no such clear relation by time from blood draw to diagnosis 
was observed for folate.  
On the whole, we interpret these results as being consistent with a small benefit in terms of 
lung cancer risk for smokers who avoid low circulating concentrations of vitamin B6 and 
folate, but cannot rule out the possibility that residual confounding by tobacco exposure 
and/or reverse causation due to the disease progression, underlie their associations with 
risk.  
The most notable difference between our results and those from the previous EPIC study 
was for never smokers, where vitamin B6 was positively associated with risk among for 
women in the current study, the opposite of what was observed in the previous EPIC study. 
The reason for this stark discrepancy is unclear and not explained by differences in study 
characteristics.  
Study strengths and limitations 
Strengths of this study included the large study sample of 5,364 case-control pairs, the 
prospective study design and the use of pre-diagnostic plasma or serum, the centralized 
biochemical analysis with a robust quality control protocol, and the wide participation of 
cohorts from different geographical regions. We benefitted from over-sampling never and 
former smokers, as well as matching by history of tobacco exposure, thus allowing for well-
powered stratified analysis. However, this oversampling also meant that the individual 
cohorts provided different proportions of subjects by smoking status. For instance, the WHI 
only contributed never smoking women and the ATBC study only contributed current 
smoking men. Another particular feature of this study was that circulating vitamin B6 and 
folate varied substantially across cohorts and continents. Indeed, US participants had about 
65% higher B6 and almost three-fold the median folate concentrations of European and 
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Asian study participants (see Table 1). A likely explanation of this is that up to 50% of U.S. 
citizens aged 50 years or more regularly consume dietary supplements such as multi-vitamin 
pills,254 and because of the folate fortification in the US.255 Differences in baseline 
characteristics only partially accounted for these differences, and this means that we could 
not efficiently compare participants at extremes of the distribution of folate concentrations 
because the controls were matched to cases within the same cohort, and we were reluctant 
to break that matching.  
Study implications and conclusions 
This study highlights the importance of re-evaluating promising associations of 
putative risk factors indicated in initial studies across multiple study populations in a 
coordinated fashion. The LC3 clearly demonstrates that it is feasible to gather cohorts from 
around the world and provide robust information on disease risk association before 
resorting to intervention studies that are costly and risk harming the study participants. 
Whilst our results were consistent with a modest decrease in lung cancer risk among former 
and current smokers who avoid low circulating concentrations of vitamin B6 and folate, we 
could not rule out the possibility that confounding due to tobacco or reverse causation may 
explain these associations. Given that any potential beneficial effect of vitamin B6 or folate–
if real–is likely to be small, our findings do not support the conduct of additional prevention 
studies with the view of using B-vitamins for primary prevention of lung cancer.  
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Figure 1. Estimated between-cohort variation in mean concentration of vitamin B6, folate, and 
methionine. Before (left) and after (right) adjustment for age, sex, smoking status, and BMI. Histograms show 
the posterior distribution of the overall mean and standard deviation (SD) of the cohort-specific intercepts. 
The "caterpillar plots" show the estimated cohort-specific mean concentrations, along with 50% and 90% 
credible intervals (thick and thin bars, respectively).  
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The one-carbon metabolism and smoking-related cancers 
 
Recall on objectives 
Over the past two decades, the role of one-carbon metabolism (OCM) in cancer has 
received considerable attention. Circulating B-vitamins and related analytes have been 
assessed prospectively for multiple cancer sites including colorectal256-259, prostate237 238, 
and breast cancer260-263, although the evidence is inconsistent. To date, data examining 
associations of OCM deficiency/ imbalance and smoking related cancers are sparse, and my 
thesis aims to fill this knowledge gap. In order to achieve this, circulating OCM biomarkers 
were examined in relation to three specific cancer sites that differed in their strength of 
association with smoking.  
 
Summary of the results  
One-carbon metabolism and head and neck cancer etiology and outcome (Chapter III) 
To the best of our knowledge, this was the first prospective study assessing the association 
between circulating OCM biomarkers and risk of the head and neck cancer (HNC). Only a 
few retrospective case-control studies had been published and reported lower circulating 
concentrations of folate and higher concentrations of homocysteine in cases than in 
controls203-206. In this study, we observed that subjects in the top quartile of circulating 
concentrations of homocysteine had a two-fold increase in risk of HNC compared with those 
in the bottom quartile. The positive association of homocysteine was present both among 
never-smokers and non-alcohol consumers.  
Furthermore, we observed that participants with high circulating concentrations of folate 
had overall lower risk of HNC. Because folate and homocysteine are inversely correlated in 
the OCM pathway135, we cannot exclude the possibility that the folate association with risk 
is underlying the positive association of homocysteine with HNC risk. Mutually adjusted 
conditional analysis (data not shown) indicated that these risk associations were not 
independent, homocysteine accounting for the association of folate, but not vice-versa. 
However, the inverse folate association with HNC risk was not as consistent as that of 
homocysteine, and when performing different sensitivity analyses, the positive 
homocysteine association with risk was not materially affected whereas the folate
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association was attenuated and no longer significant. This finding might not support for a 
decrease of HNC risk in participants having elevated dietary intake of folate, as seen in 
previous epidemiological studies69 200-202.  
Overall, the results from Chapter II indicate that circulating homocysteine affects the risk of 
developing squamous cell carcinoma of the head and neck. 
 
One-carbon metabolism and renal cell carcinoma etiology and outcome (Chapter IV)  
Evidence on the role of vitamin B6 in RCC is limited, , and to date, only one prospective 
study assessing circulating concentrations of vitamin B6 and RCC risk has been published212, 
and did not report any clear association. 
In contrast, our study showed that subjects from the EPIC cohort with elevated vitamin B6 
concentrations had lower risk of RCC, in a dose-response fashion, resulting in two to three-
fold risk differences between the top and the bottom quartiles of the population. We also 
observed a clear improved survival among cases with higher vitamin B6 concentrations. 
Subsequent replication of the EPIC results using the independent MCCS cohort from 
Melbourne, Australia, yielded nearly identical associations for both RCC risk as well as for 
cancer mortality.   
Because the RCC study from the EPIC cohort and the previous study from the ATBC study 
are different in term of study design (population-based observational study vs trial) and 
populations sources (10 European countries vs Finish men smokers) and also because these 
two studies used different biological measurement methods to measure circulating vitamin 
B6 (liquid chromatography/tandem mass spectrometry vs the tyrosine decarboxylase assay), 
we cannot exclude that  these study differences might explain this discordance in the 
findings.   
One of the main questions that arose following the findings from the RCC study was 
whether the association of circulating vitamin B6 with survival was also present among 
participants having blood measurement at diagnosis. In order to investigate this, our group 
analyzed plasma from 630 newly diagnosed RCC cases from Central and Eastern Europe 
(Muller DC et al, in press Plos One, 09/2015) and found that the hazard of death was three 
times lower among those in the highest compared with the lowest fourth of vitamin B6 
concentrations after taking into account disease stage.  
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Together, these studies strongly suggest that circulating concentrations of vitamin B6 are 
inversely related to both RCC risk and mortality.  
 
One-carbon metabolism and lung cancer etiology in the LC3 (Chapter V)  
This large consortium of lung cancers, the LC3 study, was based on previous results from 
EPIC cohort where a strong dose-response association between circulating vitamin B6 and 
lung cancer risk was reported including among never smokers13.  
In the current study, the LC3 study, we observed a weak inverse association, with no clear 
trend, between circulating concentrations of folate and B6 and lung cancer risk, and this 
association was mainly present among ever smoking study participants. Similarly, men and 
former smokers who were deficient in circulating vitamin B6 and folate showed a marginal 
increased risk of lung cancer compared to those with normal levels. The observed results 
from LC3 study did not confirm the reported results from the previous EPIC lung study.  
However, it is not straightforward to compare our results with those of the EPIC lung study 
because the EPIC cohort was conducted mainly in Western European countries whereas the 
LC3 study is more diverse, and included four continents, several ethnic backgrounds and 
sex-specific cohorts. It would seem clear that the discordant results between the studies 
cannot be readily explained by differences in baseline characteristics such as sex or smoking 
status. It is possible that unobserved differences between the cohorts might partially 
account for the discrepant results. 
One particular feature of the LC3 study is that circulating vitamin B6 and folate varied 
substantially across cohorts and continents; American participants displayed almost three-
fold higher median folate concentrations and 1.5-fold higher median vitamin B6 
concentrations compare to both the European and Asian participants. This drastic variation 
complicated comparisons, as well as pooling of data across continents and cohorts. In 
addition, the sizable sample size of 5,364 case-control pairs quickly diminished when 
stratifying by continent and smoking status resulting in reduced statistical power in some 
important subgroups such as never smoking men.  
Furthermore, when looking for deficiency, we noted a relatively small proportion among US 
participants being deficient in circulating folate (2% being below 7 nmol/L) and vitamin B6 
(10% being below 20 nmol/L) compare to European/Australian and Asian participants. 
Speculatively, the lack of variability from deficiency to excess of these biomarkers might be 
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a potential explanation of the null association observed among US participants when 
evaluating the relation of deficiency with lung cancer risk, and therefore cannot rule out the 
possibility that low circulating of folate and vitamin B6 may lead to stronger increased risk of 
lung cancer compared to what we found in the LC3 study.  
 
Results from the LC3 study suggest that ever smoking study participants with elevated 
circulating vitamin B6 and folate had a slight decreased risk in lung cancer, and they should 
avoid deficiency both in circulating folate and vitamin B6, but cannot rule out that tobacco 
exposure may explain this result. 
 
 
Observations across the studies 
Tobacco exposure 
Because the control of confounding by smoking depends on accurate smoking history, and 
because some misclassification of the true smoking history is unavoidable, investigations of 
smoking related-cancers overall are difficult to conduct. Moreover, the proportion of 
cancers explained by smoking, i.e. the attributable fraction, differs among cancer histology 
and cancer sites, as for the three cancers examined in this thesis. While tobacco smoking 
dramatically increases the risk of lung cancer, the risk increase is moderate for HNC and 
weaker for RCC. As such, residual confounding by smoking is difficult to exclude, in 
particular for lung cancer.  
In HNC study, the association between homocysteine and HNC risk was observed among 
both never and current smokers, suggesting that residual confounding due to tobacco 
smoking might not explain the association with risk. 
In RCC study, the test of interaction between smoking exposures and vitamin B6 revealed 
that the inverse association between circulating concentrations of vitamin B6 and RCC risk 
was prominent among current compared to never- and former smokers, although a non-
significant inverse association among the two latter strata was observed. However, current 
smokers have about 30 to 50% higher risk of RCC compared to never smokers1 7, and given 
that the association of circulating vitamin B6 indicated 2 to 3-fold increased risk among 
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current smokers compared to never smokers, it would seem unlikely that confounding by 
smoking can explain the observed results.  
In LC3 study, associations were mainly observed among ever smokers. We attempted to 
control for confounding by tobacco exposure by matching by detailed smoking status. In 
addition, circulating cotinine, which is an indicator of current smoking intensity and is 
known to explain lung cancer risk beyond that captured by questionnaire information253, 
was also included to control tobacco smoking among current smokers in each study of this 
dissertation. Even though we took all possible measure to account for residual confounding 
by tobacco exposure, we cannot completely rule out the possibility that it may still partially 
account for the observed associations of lung cancer.  
While we observed an inverse association between circulating vitamin B6 and lung cancer 
risk among ever smokers, the vitamin B6 association surprisingly tend to be positively 
associated to lung cancer among never smokers. We do not know exactly the reason for this 
discrepant results but this could be due to the difference of comparability between never 
smoking lung cancer cases and controls. While ever smoking cases and controls shared a 
similar strong risk factor that lead to lung cancer development, we might miss comparability 
of exposures between never smoking lung cancer cases and controls. Lung cancer among 
never smokers is low30 and to date, the descriptive epidemiology of never smokers is 
limited, although several risk factors have been suggested including second hand smoke30 33, 
occupational exposure32 264, asbestos exposure265, and genetic factors266. It is possible that 
never smoker participants diagnosed with lung cancer in LC3 study were related to these 
previous or unknown risk factors, which may account for these surprising findings among 
non-smokers. However, we did not have such information in the LC3 study, and therefore 
this complicates the comparability between never smoking lung cancers cases and controls, 
even though they were matched by relevant confounding including age, sex and cohort. 
Assembling further studies on never smoking lung cancers will ensure a better assessment 
of their risk factors.  
 
 
Other potential confounders 
A potential explanation of the results observed throughout the studies of this thesis is that 
underlying preclinical disease may affect concentrations of OCM biomarkers. However, the 
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associations observed in HNC and RCC studies were stable over the 10-year of follow-up 
after blood collection. In the same two studies, our estimates did not change appreciably 
after excluding cases with their matched controls who were diagnosed within 1 or 2 years 
after blood draw, which would seem to exclude any possible reverse causation bias. 
Furthermore, the observed associations throughout the three studies of this thesis are 
unlikely to be explained by the other OCM biomarkers because our estimates were not 
affected after controlling for them, either one-at-time or simultaneously.  
 
As mentioned in the beginning of this thesis, major sources of one-carbon nutrients and 
related vitamins are many and include fruits and green leafy vegetables (folate) as well as 
fortified cereals and whole grains (vitamin B6). Thus, one could ask whether food intake 
affects circulating OCM biomarkers or cancer development. As example from the RCC study, 
we observed no association between vitamin B6 estimated from food frequency 
questionnaire (FFQ) and risk of RCC, in contrast to the strong association from circulating 
concentrations. There are suggestive explanations that could explain this discrepancy. First, 
is that blood measurement reflects more accurately vitamin B6 intake than estimates from 
self-reported questionnaires. Although measurement correction error models have been 
developed267, misclassification of dietary intake is still a major concern in dietary 
assessment. Moreover, in RCC study, the correlation between vitamin B6 intake from FFQ 
and plasma vitamin B6 was very modest (0.17), an observation very similar to multiple 
previous studies268 269. Also, adjusting for fruit, vegetables, nuts and seed, that are rich in 
vitamin B6, did not attenuate our estimates suggesting that food rich in vitamin B6 are 
unlikely to explain our results. 
A second explanation is that circulating vitamin B6 varies significantly between cases and 
controls not due to differences in food intake but from diverse biological processes including 
absorption or catabolism of the circulating micronutrients. This could induce lower 
concentrations among cases participants even if their food consumption was similar to 
controls. Accordingly, results of this would mean that modification through diet might not 
be a good candidate for reducing cancer incidence. If it turns out that relations with vitamin 
B6 are causal, it would be very important to identify which of these two interpretations is 
true.   
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When we were able to capture the relation of food intake rich on B-vitamins in the HNC and 
RCC studies (Chapter III and IV), data provided by the LC3 cohorts was incomplete and did 
not permit us to control for such exposure. Also, we had partial information on 
supplementation used (dietary or vitamins) that is very common among US population270.  It 
is plausible that in the LC3 study, US participants with the highest circulating of B-vitamins 
tend to be healthier with important use supplement minerals and vitamins. Numerous 
studies have shown that supplement use is associated with a healthier lifestyle. For 
example, it was reported that supplement users compared to non-users have higher 
education and incomes and are more likely to be physically active. In contrast, they are less 
likely to be tobacco or alcohol consumers compared to non-users271. Because (1) the design 
of LC3 study is prospective, (2) cases and controls were carefully matched on sex, age, 
cohort and smoking status, and (3) we adjusted by well-known risk factors of lung cancer, 
confounding effect may be reduced and any bias would be non-differential. However, we 
could not assure adjustment and cannot exclude the possibility that this missing information 
on dietary intake and vitamin supplementation affected our estimates in the LC3 study.  
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Main strengths and limitations 
This entire dissertation is based on prospective studies, which are known to be the best 
design in term of observational epidemiology. Indeed, in retrospective case-control studies 
reversed causality and confounding by treatment are particularly a concern because the 
exposure is assessed at or after diagnosis of cancer cases which lead to many biases. In HNC, 
RCC and LC3 studies, cases were enrolled prior to their cancer diagnosis with information on 
different variables including baseline characteristics variables as well as biomarker 
measurements. Thus, this minimizes the chance that any differences between cases and 
controls are caused by existing tumors and are therefore better designed than retrospective 
case-control studies to investigate cancer etiology. 
However, prospective studies are large enterprises and demand consequent efforts in order 
to obtain large sample size populations. One approach to deal with, it is to conduct a case-
control study nested within a cohort which has similar precision of prospective cohorts but 
costs less. Our group had the great opportunity to conduct two nested case-control studies 
(HNC and RCC studies) from one of the largest single prospective cohorts worldwide, the 
EPIC cohort, reaching about 520,000 participants of whom almost 360,000 donated a blood 
sample. Furthermore, different collaborations and efforts permitted our group to form the 
biggest cohort consortium of lung cancers to date which gathered twenty nested case-
control studies and coordinate over 12,000 prospective blood analyses of biomarkers.   
 
Despite EPIC and LC3 studies have strengths in terms of sample size, methods for recording 
participants information were not always similar. For example, the EPIC cohort includes 10 
European countries, and in some of them, incident cancer case identification and follow-up 
were based on cancer registers where as in other countries used a combination of methods 
including health insurance records, cancer and pathology registries, as well as direct contact 
participants and their next-of-kin. This issue was also observed in the LC3 study (See 
Supplementary Methods of LC3 study). It is also important to note that some of the sub-
populations from EPIC and LC3 tend to be healthier than the overall population, thus 
limiting generalizability. For instance, the NHS or the PHS studies are composed exclusively 
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of nurses and physicians respectively, or the UK center in the EPIC cohort is mainly 
composed of vegetarians.  
Furthermore, as indicated in the LC3 study, large differences in folate and vitamin B6 
concentrations were observed across the cohorts and continents. This observation 
underlines the large lifestyle differences inherent within this consortium. While this 
observation could permit to assess a larger range of exposure values, it might also raise the 
issue if unknown life-style related factor interacts with the exposure of interest. In other 
words, an association found in one sub-population (e.g. SWHS study which is composed 
mainly of Chinese never smoking women) might not be identified in another (e.g. the ATBC 
study composed of Finish men smokers) because of different exposure to unknown 
interacting factors. 
As indicated in HNC and RCC studies, OCM biomarkers were measured from a single blood 
sample drawn in adulthood and therefore may be imperfect estimates of underlying 
historical exposure. Intra-individual variation may still be important through time and thus 
having only one precise measure of recent exposure could lead to misclassification of true 
underlying historical exposure. However, because cases and controls were matched on 
blood draw they should not have differential misclassification bias. Furthermore, in the LC3 
study we looked explicitly on the variability, the intra-individual variation of biomarkers 
across two samples, and repeat testing indicated an intra-class correlation (ICC) greater than 
0.6 for both circulating vitamin B6 and folate, which suggests a reliable collinearity. 
Importantly, biosample measurements were centralized and took place in a single 
laboratory for all studies, including the LC3 study, thus minimizing systematic inter-
laboratory variation. Coefficients of variations within and between batches were low for all 
OCM biomarkers measured across our studies. 
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Future directions  
 
Findings from the three studies in this dissertation expanded our scientific knowledge on 
the potential role of OCM biomarkers in smoking-related cancer etiology and outcome. 
However, it is difficult to disentangle the role of each micronutrient independently of the 
other in relation to the outcome because the one-carbon pathway is a complex mechanism 
in which many vitamins and related metabolites interact together. In line with other 
studies13, we observed for example that circulating folate increases circulation of both 
vitamin B2 and B6, or lower the folate levels increase the concentrations of homocysteine. It 
won’t be surprising that these biomarkers might be correlated with some other OCM 
analytes. In order to better understand the interactions between OCM nutrients, one could 
look at additional cornerstones of the OCM pathway such as glycine or serine which were 
recently found necessary and sufficient for cell transformation and malignancy133. In line 
with this hypothesis, I recently generated some preliminary analyses using the same 
datasets and observed interesting results indicating that circulating concentrations of both 
serine and glycine were significantly and inversely associated to HNC risk.  
This thesis is composed of three studies with different cancer sites and suggests different 
associations. First, the HNC study indicates potential role of homocysteine and folate with 
cancer of the head and neck, although the results are preliminary and hence it is difficult to 
make any conclusion. These novel findings need to be replicated in other sufficiently-
powered prospective studies as well as in different ethnic populations. 
Second, the RCC study strongly suggests that circulating concentrations of vitamin B6 are 
inversely related to both RCC risk and mortality. In addition to the RCC study, an 
independent new study from our group (Muller DC et al., personal communication) strongly 
supports the survival benefit of vitamin B6 after diagnosis of RCC. Even though our findings 
are strong and consistent they need to be replicated in other future large-scale prospective 
studies as well as in some other ethnic groups than Western. One could envisage in a near 
future to gather studies across the globe as it was done within lung cancer cohort 
consortium. This will contribute to our understanding of the role of circulating vitamin B6 in 
cancer risk and survival, and its exact role in the pathogenesis of this cancer. However, even 
if our observations regarding circulating vitamin B6 are shown to be causal, it might not be 
straightforward to confirm that OCM pathway is implicated in this relation. Indeed, multiple 
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pathways implicated in cancer development are dependent on vitamin B6, examples of 
which include the tryptophan metabolism pathway, which is involved in immune function 
and inflammatory processes272-274, as well as cell proliferation, angiogenesis, and oxidative 
stress149, the latter being particularly relevant in smoking-related cancers. For example, 
inflammation can be the underlying cause of RCC etiology and outcome whereas circulating 
vitamin B6 is only an indicator of inflammation and thus, have no direct and independent 
role in carcinogenesis and survival.  
RCTs could help to elucidate these interpretations. However, it is unlikely that intervention 
trials of vitamin B6 with RCC would be advisable in a very near future because (1) we do not 
have enough evidence to date to potentially induce an harm to the patient, (2) recent 
pooled analysis of two randomized trials reported no benefits for all cancer combined 
among participants randomized to receive vitamin B6196, and (3) a large number of study 
participants would be required to have a relevant statistical power due to the complexity to 
evaluate impact of vitamin B6 separately controlling for the other nutrient status or/and 
genetic variation.  
One promising alternative which could help in elucidating the role of vitamin B6 in RCC 
without going through an intervention study is the Mendelian Randomization (MR) 
approach. This method aims to identify gene variants associated independently with 
exposure (i.e. with B6 vitamin concentration), and test whether there is an association 
between any such gene variants and disease status. Given that allocation of gene variants at 
meiosis is largely at random, and that such variants should not be associated with lifestyle 
factors, an independent association between a gene variant and disease status should only 
occur if it is a true causal association and would therefore provide strong evidence of 
causality. Conclusive examples of this method include the role of cholesterol for coronary 
heart disease275 or folate concentrations in mothers and neural tube defects in offspring276. 
Then, identifying further genetic variants that influence circulating vitamin B6 through large 
collaborative studies and investigate their relation to RCC risk will be also a major topic in 
the near future.  
Third, although findings from LC3 study did not support the strong inverse association 
between higher circulating vitamin B6 and decreased risk lung cancer, as previously 
reported in the EPIC lung study13, circulating vitamin B6 may contribute in risk prediction of 
lung cancer. One of the final analysis in the LC3 study indicated that circulating vitamin B6 
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displays a compatible association across all the cohort consortium with that previously seen 
in two European cohorts (ATBC and EPIC)13 185 in current smokers diagnosed close to blood 
draw, with a 2-fold risk increase for lung cancer happening within 3 years for participants 
who we defined as vitamin B6 deficient. This observation might support circulating vitamin 
B6 as a potential useful lung cancer risk predictor close to blood draw. 
 
The rational for using biomarker is to measure more adequately the biologically relevant 
exposure. Most biomarkers from both prospective and retrospective studies rely on a single 
serum or plasma sample, which only provides an estimate of biomarker exposure over the 
previous days.  As it was evoked previously, one approach to assess temporal changes and 
to better estimate long-life exposure is to study samples from each subject obtained at 
several time points.  However, given financial and logistic issues this won’t be possible for all 
participants of studies, in particular for a cohort. A compromise is to repeat sample 
measurements for a representative and large enough fraction of the original cohort, as we 
did in the LC3 study (Chapter IV).  Alternatively, one could think on a single blood sample 
which gives a good estimation of a medium- long-term nutrient status. For example, blood 
cell folate concentrations respond slowly to changes in folate intake because the 
erythrocytes, which have a 120-day lifespan, accumulate folate only during 
erythropoiesis277. Biomarkers represent to date an important tool in cancer epidemiology 
and, advances technologies are rapid and will facilitate the application of the markers to 
large sample size studies.   
In conclusion, one-carbon metabolism is a complicated pathway, and there are a number of 
gaps in our understanding its relation to cancer, in particular smoking-related cancers. 
Findings from this thesis research contributed evidence to fill these gaps.  This dissertation is 
a first “pillar” in my long research aim to better understand the OCM implication in the 
etiology of smoking-related cancers.  
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APPENDICES 
Appendix 1- Supplementary methods of LC3 cohorts 
 
Study population 
We invited all prospective cohort studies that in 2009 were members in the US National Cancer 
Institute (NCI) Cohort Consortium to participate in the study. Additional inclusion criteria included the 
occurrence of at least 200 incident lung cancer cases with baseline questionnaire data and either 
plasma or serum samples cryopreserved at <80°C available. Twenty cohorts fulfilled those criteria and 
accepted to participate, resulting in a combined cohort population of over 2,000,000 participants from 
North America, Europe, Asia and Australia.  
Selection of cases and controls 
Lung cancer cases were defined on the basis of the International Classification of Diseases for Oncology, 
Second Edition (ICD-O-2), and included all invasive cancers coded as C34.0-C34-9. Altogether, 11,399 
incident lung cancer cases with pre-diagnostic blood samples were identified from the participating 
cohorts. We selected a total 5,545 lung cancer cases, and in order optimize the statistical power in 
smoking stratified analyses, never and former smoking cases were oversampled. For each case, one 
control was randomly chosen from risk-sets consisting of all cohort members alive and free of cancer 
(except non-melanoma skin cancer) at the time of diagnosis of the index case. Matching criteria were 
cohort, sex, date of blood collection (± 1 month, relaxed to ± 3 months for sets without available 
controls), and date of birth (± 1 year, relaxed to ± 3 years), as well as smoking status in 5 categories; 
never smokers, short and long term quitters among former smokers (<10 years, ?10 years since 
quitting), and light and heavy smokers among current smokers (< 15 years, ?15 cigarettes per day). 
After excluding cases who were not correctly matched on smoking status (n=124 cases), who had 
insufficient plasma samples (n=42), or had a revised date of diagnosis prior to blood draw (n=13), 5,364 
lung cancer case-control pairs remained eligible for the risk analysis. 
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Brief description of the participating cohorts in the Lung Cancer Cohort Consortium 
US cohorts 
The Women’s Health Initiative (WHI) 
WHI is a long-term health study of 161,808 post-menopausal women aged 50 to 79 years at 40 clinical 
centers throughout the U.S.  WHI comprises a Clinical Trial (CT) component (68,132 women), and an 
Observational Study (OS) component (93,676 women), and has included several extension studies.  
Some detailed descriptions of WHI have been previously presented278 279.The CT evaluated two forms 
of postmenopausal hormone therapy, a low-fat dietary pattern intervention, and calcium and vitamin D 
supplementation in a randomized, controlled fashion, in a partial factorial design. The hormone therapy 
component findings led to major reductions in the use of hormone therapy worldwide, and are thought 
to have led to noteworthy reductions in breast cancer incidence. 
In the present study lung cancer cases occurring during the follow-up of WHI cohorts since enrolment 
(1993-1998) among non-smoking women, were matched 1-1 to corresponding non-smoking lung 
cancer free controls, for serum and DNA analyte comparisons.  
The Southern Community Cohort Study (SCCS) 
The Southern Community Cohort Study (SCCS)280 is a prospective cohort of African and non-African 
Americans which during 2002-2009 enrolled approximately 86,000 residents aged 40-79 years across 
12 southern states.  Recruitment occurred mainly at community health centers, institutions providing 
basic health services primarily to the medically uninsured, so that the cohort includes many adults of 
lower income and educational status.  Each study participant completed a detailed baseline 
questionnaire, and nearly 90% provided a biologic specimen (approximately 45% a blood sample and 
45% buccal cells). Follow-up of the cohort is conducted by linkage to national mortality registers and to 
state cancer registries. Included in this study are 240 incident African American lung cancer cases and 
240 individually matched African American cohort members without lung cancer at the index date 
selected by incidence density sampling. 
Prostate, Lung, Colorectal and Ovarian  Cancer Screening Trial (PLCO) 
The PLCO study, a randomized trial aimed at evaluating the efficacy of screening in reducing cancer 
mortality, recruited approximately 155,000 men and women age 55 to 74 years from 1992 to 2001281. 
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Screening for lung cancer among participants in the intervention arm included a chest x-ray at baseline 
followed by either three annual x-rays (for current or former smokers at enrollment) or two annual x-
rays (for never smokers); participants in the control arm received routine health care. Screening-arm 
participants provided data on sociodemographic factors, smoking behavior, anthropometric 
characteristics, medical history, and family history of cancer, as well as blood samples annually for the 
first 6 years of the study (baseline [T0] and T1 through T5). Lung cancers were ascertained through 
annual questionnaires mailed to the participants, and positive reports were followed up by abstracting 
medical records or death certificates. Follow-up in the trial as of July 2009 was 96.7%. 
We conducted a nested case-control study within the screening arm of the PLCO trial. As of December 
31, 2004, 898 lung cancers were diagnosed among the 77,464 participants. Patients were excluded 
because of missing baseline questionnaire, previous history of any cancer, diagnosis of multiple cancers 
during follow-up, missing smoking information at baseline, missing consent for utilization of biologic 
specimens for etiologic studies, or unavailability/insufficient quantity of serum or DNA specimens. 
Hemolyzed vials were excluded.  We included 450 confirmed lung cancer patients and 450 matched 
controls in this study sampled from the intervention arm. 
Controls were individuals free of cancer at the time of a case's lung cancer diagnosis. Controls were 
individually matched to lung cancer patients on sex, date of birth +/- 1 year with a possible relaxation 
to 5 years, race, study year of blood draw, date of blood draw +/- 1 month (with a possible relaxation to 
3/6 months), time of blood draw (6AM-9AM, 9AM-12PM, other), smoking categories (smoking status at 
enrollment, never, former, or current smoker; cumulative amount of smoking (0 to 29, 30 to 39, 40 to 
49, and 50+ pack-years), with additional matching for time since quitting (< 15 years and ≥ 15 years) for 
former smokers, cigarettes per day smoked, and number of days in the study.  
The New York University Women’s Health Study (NYUWHS) 
The New York University Women’s Health Study (NYUWHS) is a prospective cohort study of women 
enrolled at a mammography screening center in New York City. From March 1985 through June 1991, 
14,274 women between the ages of 34 and 65 were enrolled in the study. Because the original focus of 
the study was endogenous hormones and breast cancer, women who had taken hormone medications 
in the 6 months preceding baseline enrolment were not eligible for the study. 
At the time of enrolment, data on demographics, anthropometric measures, medical history, 
reproductive and lifestyle variables were collected through self-administered questionnaires after 
written informed consent was obtained. Incident lung cancer cases were identified through active 
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follow-up of the cohort conducted with questionnaires mailed approximately every two to four years 
and record linkages with state tumor registries in New York, New Jersey, and Florida, as well as record 
linkage with the National Death Index (NDI).  Medical records were obtained to verify reported cancer 
outcomes. A total of 171 incident lung cancer cases and 171 individually matched controls were 
included for this analysis. 
The American Cancer Society Cancer Prevention Study-II (CPS-II) Nutrition Cohort  
The ACS Study-II is a prospective study of cancer incidence and mortality among 86,404 men and 
97,786 women.  The CPS-II Nutrition Cohort, which is described in detail elsewhere282, was initiated in 
1992 as a subgroup of CPS-II, a prospective study of cancer mortality involving approximately 1.2 
million Americans begun in 1982.  Participants in the CPS-II Nutrition Cohort were recruited from CPS-II 
members who resided in 21 states and were between the ages of 50 and 74 years.  At enrollment in 
1992/1993, participants completed a self-administered questionnaire that included demographic, 
medical, dietary, and lifestyle information.  Follow-up questionnaires were sent to all living Nutrition 
Cohort members in 1997, and every two years after this to update exposure information and to 
ascertain newly diagnosed cancers.   Between June 1998 and June 2001, blood samples were collected 
from a subset of CPS-II Nutrition Cohort participants (21,965 women and 17,411 men).   
Incident lung cancer cases were identified through self-report on a follow-up questionnaire, linkage 
with state cancer registries, or death certificates.  Self-reported cancers were verified through medical 
records.  200 incident lung cancer cases and 200 matched controls from the CPS-II Nutrition Cohort 
were provided for this analysis. 
The Campaign Against Cancer and Stroke (CLUE I) and the Campaign Against Cancer and Heart 
Disease (CLUE II). 
The CLUE studies include two large cohorts of volunteers from Washington County, Maryland that were 
enrolled in 1974 and 1989, respectively.  CLUE I was conducted in Washington County, Maryland, in the 
fall of 1974. Brief health histories and blood pressures were taken and 15 ml of blood was drawn from 
26,147 volunteers (23,951 were residents of Washington County) at the time of enrollment. Linkage of 
the records from this program to those of a private census in the summer of 1975 indicated that almost 
a third of the adult population of the county had participated. CLUE II was an outgrowth of CLUE I 
conducted from May through October in 1989. As in CLUE I, a brief health history was obtained and 20 
ml of blood was drawn. A blood sample was collected from 32,894 volunteers at the time of enrollment 
(25,076 were residents of Washington County). Participants were also given a food frequency 
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questionnaire to complete at home and were asked to return it with a toenail clipping of the large toe 
for trace metal assays. Comparisons with published figures from the 1990 Census indicted that 
approximately 30 percent of adult residents had participated.  
The Multiethnic Cohort (MEC) 
The MEC includes over 215,000 men and women aged 45-75 years at recruitment from five different 
racial/ethnic groups (African Americans, Japanese Americans, Native Hawaiians, Latinos and European 
Americans) in Hawaii and California283. The cohort was assembled in 1993-1996 by mailing a self-
administered, 26-page questionnaire to obtain extensive information on demographics, medical and 
reproductive histories, medication use, family history of various cancers, physical activity and diet. 
Identification of incident cancer cases is by regular linkage with the Hawaii, Los Angeles County and 
California SEER registries. From 1995 to 2001, blood collection was conducted from incident cases with 
breast, prostate, or colorectal cancers, as well as a random sample of cohort participants to serve as 
controls in genomic nested case-control studies (participation rate 72% and 63%, respectively). In 
addition, from 2001 to 2006, blood was also collected prospectively, without regard for cancer 
diagnosis, from willing cohort participants. Approximately 67,000 gave a blood sample (participation 
rate 43%).  All incident lung cancer cases diagnosed before 2010 with a pre-diagnostic blood sample 
were considered for inclusion in this study. Each case was matched to a control based on study site, 
sex, age, race/ethnicity, smoking status, hours of fasting, and date and time of blood draw. 
Women’s Health Study (WHS) 
The WHS was a randomized trial of low-dose aspirin, vitamin E, and beta-carotene in the primary 
prevention of cardiovascular disease and cancer beginning in 1992 among 39,876 female US health 
professionals aged ≥45 years284. Information on major clinical, lifestyle, and dietary factors was 
collected via self-reports on baseline questionnaires. Women also provided baseline bloods. During 
more than two decades of follow-up, WHS participants reporting new cases of cancer on annual follow-
up questionnaires were confirmed by medical record review by the WHS Endpoints Committee. 
Reports of cancer were confirmed on the basis of pathology or cytology reports or, rarely, strong 
clinical and radiologic or laboratory marker evidence when a pathology or cytology review was not 
conducted. Only confirmed cases of lung cancer were included in the present analyses, which were 
matched with eligible controls. 
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Physicians’ Health Study (PHS) 
The PHS I began in 1982 as a randomized trial of aspirin and beta-carotene for the primary prevention 
of heart disease and cancer among 22,071 male, Caucasian physicians initially aged 40 to 84 years285, 
followed by the PHS II trial beginning in 1997 to evaluate beta-carotene, vitamin C, vitamin E, and a 
daily multivitamin on the prevention of cancer, CVD, and other endpoints. The PHS II included 14,641 
men, with 7,641 participants from the PHS I plus 7,000 new physicians, for a total of 29,071 PHS 
participants286. A wide range of demographic, clinical, and lifestyle factors were assessed via baseline 
questionnaires, along with baseline bloods. PHS participants reported major clinical endpoints, 
including cancer, yearly in a mailed questionnaire and postcards every six months. Self-reported, 
incident lung cancer cases were confirmed through medical record review by the PHS Endpoints 
Committee in included in the present analyses. 
The Nurses’ Health Study (NHS) 
The Nurses’ Health Study (NHS)287 288 was established in 1976, when 121,700 married female registered 
nurses aged 30 to 55 years residing in 11 States in the U.S. completed and returned a self-administered 
questionnaire. Questionnaires have been mailed to participants in both cohorts every 2 years since 
baseline to collect updated information on demographics, lifestyle factors, medical history, and disease 
outcomes. A semi quantitative food frequency questionnaire (FFQ) was administered to obtain 
information on usual dietary intake over the previous year. The reproducibility and validity of the FFQs 
have been established289-293. The FFQ was first administered in 1980 in the NHS, and were repeated 
almost every 4 years thereafter. For each food item, the questionnaire specified a common serving size 
and queried respondents on average intake during the previous year; responses in 9 categories ranged 
from almost never to 6 or more per day. Most nutritional variables measured by these FFQs have been 
developed, tested, and refined by our group over the past 30 years 
(https://regepi.bwh.harvard.edu/health/).  
The follow-up rate has been greater than 90%. The institutional review board at the Brigham and 
Women’s Hospital approved the study. As approved by the committee, return of the questionnaires 
was considered to imply informed consent. Cases of lung cancer were self-reported by the participants 
or identified on their death certificates and were subsequently confirmed by medical records. 
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Health Professionnals Follow-up Study (HPFS) 
The Health Professionals Follow-up Study (HPFS)294 is an ongoing cohort study of 51,529 U.S. male 
professionals who were aged 40 to 75 years at baseline in 1986. Questionnaires have been mailed to 
participants in both cohorts every 2 years since baseline to collect updated information on 
demographics, lifestyle factors, mwedical history, and disease outcomes. The follow-up rate has been 
greater than 90%. The institutional review board at the Harvard T.H. Chan School Public Health 
approved this study. As approved by the committee, return of the questionnaires was considered to 
imply informed consent.  A semiquantitative food frequency questionnaire (FFQ) was administered to 
obtain information on usual dietary intake over the previous year. The FFQ was first administered in 
1986 in the HPFS and was repeated almost every 4 years thereafter. The reproducibility and validity of 
the FFQ have been estabished291 295. For each food item, the questionnaire specified a common serving 
size and queried respondents on average intake during the previous year; responses in 9 categories 
ranged from almost never to 6 or more per day. Cases of lung cancer were self-reported by the 
participants or identified on their death certificates and were subsequently confirmed by medical 
records. 
1) European/Australian cohorts 
The Melbourne Collaborative Cohort Study (MCCS) 
The MCCS is a prospective cohort study of 41,514 participants (17,045 men and 24,469 women) aged 
27-88 years at recruitment296; 99.3% of whom were aged 40-69 years.  Recruitment occurred between 
1990 and 1994.  Southern European migrants to Australia (including 5,411 Italians and 4,525 Greeks) 
were over-sampled to extend the range of lifestyle exposures and to increase genetic variation. 
Subjects were recruited via Electoral Rolls (registration to vote is compulsory for adults in Australia), 
advertisements, and community announcements in local media.  Comprehensive lists of Italian and 
Greek surnames were used to target southern European migrants in phonebooks and electoral rolls.  
Passive follow-up of the cohort has been conducted by record linkage to Electoral Rolls, electronic 
phonebooks, the Victorian Cancer Registry and death records; as well as national cancer and death 
records to identify events outside of Victoria. 
At recruitment participant’s height and weight were measured, blood samples collected and 
questionnaires covering lifestyle (diet, smoking, physical activity and alcohol consumption), 
demographics and medical history completed. 
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Incident lung cancer cases under 80 years of age up to 31st December 2010 were identified through 
record linkage.  A total of 361 lung cancer cases and 361 controls matched for date of birth, gender, 
smoking status, and ethnicity were included for this analysis. 
The Malmö Diet and Cancer Study (MDCS) 
The Malmö Diet and Cancer Study (MDCS) is a population-based prospective cohort study that between 
1991 and 1996 recruited men and women aged 44 to 74 years of age living in Malmö, Sweden297. The 
main goal of the MDCS is to study the impact of diet on cancer incidence and mortality. It consists of a 
baseline examination including dietary assessment, a self-administered questionnaire, anthropometric 
measurements and collection of blood samples.  A total of 201 incident lung cancer cases and 201 
individually matched controls were available for this analysis. 
The Northern Sweden Health and Disease Study Cohort (NSHDS) 
The Northern Sweden Health and Disease Study (NSHDS) encompasses several prospective cohorts, the 
current study involving study participants from the Västerbotten Intervention Project (VIP), a sub-
cohort within NSHDS298. VIP is an ongoing prospective cohort and intervention study intended for 
health promotion of the general population of the Västerbotten County in northern Sweden. VIP was 
initiated in 1985 and all residents in the Västerbotten County were invited to participate by attending a 
health check-up at 40, 50 and 60 years of age. Participants were asked to complete a self-administered 
questionnaire including various demographic factors such as education, smoking habits, physical 
activity and diet. In addition, height and weight were measured and participants were asked to donate 
a fasting blood sample for future research. Incident lung cancer cases were identified through linkage 
with the regional cancer registry. A total of 245 incident lung cancer cases and 245 individually matched 
controls were included for this analysis. 
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) 
The ATBC Study was a randomized, double-blind, placebo-controlled, primary cancer prevention trial 
testing daily supplementation with α-tocopherol (50 mg/day) or β-carotene (20 mg/day), or both299. 
Between 1985 and 1988, the study enrolled and randomized 29,133 50-69 year old male cigarette 
smokers from southwestern Finland.  Study supplementation continued for 5-8 years (median 6.1 
years) until death or trial closure (April 30, 1993).   At baseline, participants completed questionnaires 
regarding general risk factors, medical history, smoking habits, and dietary intake.  Height, weight, 
heart rate, and blood pressure were measured by trained nurses and fasting serum samples were 
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collected and stored at –70 oC.  Lung cancer cases diagnosed during follow-up through 2009 were 
identified through linkage with the Finnish Cancer Registry, and 200 were individually matched to 200 
controls for this analysis. 
The Nord-Trøndelag Health Study (HUNT) 
The HUNT study is a longitudinal population based study having invited all persons aged 20-100 years 
living in the county of Nord-Trøndelag, Norway to three data collections, HUNT1 (1984-86), HUNT2 
(1995-97) and HUNT 3 (2006-08) (http://www.ntnu.edu/hunt).  Comprehensive data on life style, 
health status, symptoms, diseases and anthropometrics have been collected through questionnaires, 
interviews and clinical examinations, and in HUNT2 and HUNT3 biological material as blood and urine 
additionally were collected and stored. For this study, data have been linked to the Norwegian Cancer 
Registry and 238 incident lung cancer cases and 238 individually matched controls have been included. 
2) Asian cohorts 
The Shanghai Men’s Health Study (SMHS) and the Shanghai Women’s Health Study (SWHS) 
The SMHS and SWHS are population-based cohort studies conducted in eight communities of urban 
Shanghai. Their designs and methods have been described elsewhere300 301. 
Briefly, the SWHS recruited 74,941 women during 1997-2000 (response rate: 93%) and the SMHS 
recruited 61,480 men during 2002-2006 (response rate: 74%). Similar methods and questionnaires 
were used in both studies. At baseline in-person interviews, information on sociodemographic, diet, 
lifestyle, occupation and medical history was obtained; height, body weight, and waist circumference 
were measured. Blood samples were collected from 75% of the study participants in both studies, 
processed within 6 hours, and stored at -70? until analysis.  
The SMHS and SWHS have been followed up by annual record linkage with the population-based 
Shanghai Cancer Registry and Shanghai Vital Statistics Registry and in-person surveys every 2-3 years. 
Exposure information, including dietary intake, was updated in the in-person follow-up surveys.  All 
possible matches from the linkages are checked manually and verified by home visits. Medical charts 
were obtained from the initial diagnostic hospitals to verify cancer diagnosis.  Death certificate data 
from the Shanghai Vital Statistics Unit was used to identify the primary cause of death. 
The studies were approved by the Institutional Review boards of the Shanghai Cancer Institute and 
Vanderbilt University. Informed consent was obtained from all participants.        
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The Singapore Chinese Health Study (SCHS) 
The design of the SCHS study has been described193 302. Briefly, the cohort was drawn from permanent 
residents or citizens of Singapore who resided in government-built housing estates (86% of the 
Singapore population reside in such facilities). The eligible age range for cohort enrolment was 45-74 
years. We restricted study subjects to the two major dialect groups of Chinese in Singapore: the 
Hokkiens and the Cantonese, who originated from Fujian and Guangdong provinces in Southern China, 
respectively. Between April 1993 and December 1998, 63,257 subjects (approximately 85% of eligible 
subjects) were enrolled into the cohort study.  At recruitment, each study subject was interviewed in 
person by a trained interviewer using a structured questionnaire that emphasized current diet assessed 
via a validated, 165-item food frequency questionnaire. The questionnaire also requested information 
on demographics, lifetime use of tobacco, incense use, current physical activity, usual sleep duration, 
reproductive history (women only), occupational exposure, medical history, and family history of 
cancer.   
Beginning in April 1994, a random 3% sample of cohort participants were asked to provide blood or 
buccal cell (if request for blood sample was denied), and spot urine samples. Eligibility for this 
biospecimen subcohort was extended to all surviving cohort participants starting in January 2000. By 
April 2005, all surviving cohort subjects had been contacted for biospecimen donation. Approximately 
60% of eligible cohort participants donated biospecimens.  
The cohort has been passively followed for death and cancer occurrence through regular record linkage 
with the population-based Singapore Cancer Registry and the Singapore Registry of Births and Deaths. 
Migration out of Singapore, especially among housing estate residents, is negligible.  As of latest 
update, only 55 individuals from this cohort were known to be lost to follow-up due to migration and 
other reason.   
A nested case-control study of incident lung cancer cases within the Singapore Chinese Health Study 
was used to examine the association between serum levels of vitamin B6 and other compounds in the 
one-carbon metabolism pathway and risk of lung cancer. Briefly, 422 lung cancer cases were identified 
among cohort participants with available prediagnostic plasma samples as of 12/31/2011.  For each 
case, one control subject was randomly selected from all eligible cohort members who were alive and 
free of cancer on the date of cancer diagnosis of the index case.  The control subject was individually 
matched to the index case by gender, dialect group (Hokkien, Cantonese), age at enrolment (±3 years), 
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date of baseline interview (±2 year), date of biospecimen collection (±6 months), and smoking status 
(current, former, and never smokers).  For current smokers, cases and controls were further matched 
by number of cigarettes per day (<15, ≥15 cigarettes/day). For former smokers, cases and controls were 
further matched by years since quitting smoking (<10, ≥10 years). One plasma aliquot per subject was 
retrieved from the biorepository and all plasma samples were sent to the laboratory (B-vital) for 
measurements. 
The Shanghai Cohort Study (SCS) 
The SCS study is a residential cohort of 18,244 men in Shanghai, China, assembled during 1986-89 when 
subjects were between the ages of 45 and 64 years. Approximately 80% of eligible men participated in 
the study. At the time of recruitment, each cohort subject was interviewed in-person by a trained nurse 
interviewer using a structured questionnaire that included background information, history of tobacco 
and alcohol use, current diet, and medical history303 304. 
At the completion of the interview, the nurse collected a 10 ml blood and a single void urine specimen 
from the study participant.  Blood and urine samples were kept in insulated boxes with ice (0-2oC).  The 
serum was separated from blood specimen within 3-4 hours after collection. Two sets of serum (2 ml 
and 1 ml, respectively) and two sets of urine samples (10 ml each) per subject have been stored at -
80oC. 
The cohort has been followed for the occurrence of cancer and death through routine ascertainment of 
new cases from the population-based Shanghai Cancer Registry and Shanghai Vital Statistics Units. To 
maximize the cancer findings and minimize the loss of follow-up, we have recontacted each surviving 
cohort member annually. Retired nurses visit the last known address of each living cohort member and 
record details of the interim health history of the cohort member. As of December 31, 2014, 
cumulatively 612 (3.4%) original subjects were lost to follow-up (i.e., persons we have no record of 
death and we have been unable to locate through our annual follow-up recontacts), and 574 (3.1%) 
refused to our continued follow-up interview (their cancer and vital status has been continually 
updated through record linkage analyses) after 26 years of follow-up since the beginning of the study. 
A nested case-control study of incident lung cancer cases within the Shanghai Cohort Study was used to 
examine the association between serum levels of vitamin B6 and other compounds in the one-carbon 
metabolism pathway and risk of lung cancer. Briefly, 516 lung cancer cases were identified among 
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cohort participants with available serum samples as of 12/31/2006. For each case, we randomly 
selected one control subject from all cohort members who were free of cancer and alive at the time of 
cancer diagnosis of the index case.  Controls were matched to the index case by age at enrolment (±2 
years), date of biospecimen collection (±1 month) and neighbourhood of residence at recruitment, and 
smoking status (current, former and never smokers) as established previously for other studies. For 
former smokers, cases and controls were further matched by years since quitting smoking (<10 vs ≥10 
years).  One serum vial per subject was retrieved from biorepository and all serum samples were sent 
to the laboratory (B-vital) for measurements.    
Biochemical analyses 
Serum or plasma samples from all study participants were sent on dry ice to the Bevital A/S laboratory 
(http://www.bevital.no) in Bergen, Norway, were they were kept below −80°C until analysis. 
Concentrations of vitamin B6, methionine and cotinine were determined by mass spectrometry based 
methods (LC-MS/MS, GC-MS/MS),239 240, and microbiological methods were used to determine 
concentrations of folate (Lactobacillus casei).241 Samples were analyzed in batches of 86 samples, and 
quality control procedures included 6 calibration samples, 2 control samples, and 1 blank sample in 
each batch. The coefficients of variation (CVs) within and between batches were, respectively, 3% and 
7% for vitamin B6, 4% and 5% for folate, and 1% and 3% for methionine. All lung cancer cases and their 
individually matched controls were analyzed together within the same batches in random order. The 
laboratory staff was blinded to the case-control status of the blood samples.  
Statistical analyses 
We fitted hierarchical linear models to the biomarker concentrations to evaluate between-cohort 
variability in mean concentrations, and the extent to which this variability could be accounted for by 
individual level covariates such as age, sex, body mass index, and smoking status. To account for the 
nested nature of the data (with participants nested within cohorts) and to allow model parameters to 
vary across cohorts, we used a hierarchical linear regression model to regress standardized, log 
transformed biomarker concentrations on these covariates. In particular, let ? denote the outcome 
variable (i.e., log transformed concentrations), and ? denote a matrix of ? covariates. We model the 
outcome of participant ? from cohort ? as 
??? ? ????????? ? ?????? ???? 
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Each of the ? components of the cohort-specific vector of regression coefficients ??? are modeled with 
independent normal distributions, as are the cohort-specific intercepts ??: 
??? ? ?????????? ???????? ? ????????? ???? 
The overall intercept ? and mean regression coefficients ?? were given diffuse ????????? ???? prior 
distributions, and the hierarchical standard deviation parameters ?? and ? were given weakly 
informative ??????????????? hyperprior distributions. The residual standard deviation ? was also given 
a ??????????????? prior distribution. We conducted sensitivity analyses in which we specified different 
scales for the Half-Cauchy hyperpriors, and found that the posterior distributions of ?? and ??? were 
insensitive to the specified scale of the hyperpriors. 
Risk analysis involved calculating quartiles of circulating concentrations for each biomarker based on 
the distribution among controls, both overall and by region (United States [US], Europe and Australia 
combined [EU/AU], and Asia). Relative risks of lung cancer were estimated by calculating odds ratios 
(OR) and 95% confidence intervals (CI) using conditional logistic regression (conditioning on matched 
case-control sets) with the first quartile as the referent. Additional covariates were included to account 
for confounding by risk factors, including indicators of educational attainment (in six categories) and 
tobacco exposure (in addition to matching to smoking status in 5 categories: cotinine concentrations 
[defined using quartiles of the distribution among participants reporting to be current smokers]). 
Including additional covariates of body mass index (BMI) and alcohol intake did not appreciably alter 
the results and were not included in the final models. As a sensitivity analysis, we fitted models that 
were additionally adjusted for smoking duration or pack-years of smoking among ever smokers, 90% of 
which had such information available. All risk analyses were conducted overall and by stratifying for 
never, former and current smokers, as well as by region (US, EU/AU, Asia).  
As an indication of the overall statistical strength of association between each biomarker and risk, we 
calculated a p-value for trend by including the base-2 logarithm (log2) of the biomarker concentration 
as a continuous variable in a separate conditional logistic regression model. The same approach was 
used in stratified risk analyses according to other pre-defined demographic characteristics and risk 
factors. OR estimates per log2 unit (log2 OR) may be interpreted as the relative risk associated with a 
doubling in the concentration of a circulating biomarker. We also performed risk analyses for log2OR on 
each biomarker separately for each individual cohort, as well for US cohorts by the period of blood 
sample collection (before and after 1996 when folate fortification of food items took effect) to evaluate 
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potential impact of folate fortification. X² tests were used to assess heterogeneity in log2 OR estimates 
in stratified analyses.  
Finally, in order to evaluate the specific hypothesis of whether deficiency in vitamin B6 or folate is 
particularly important in lung cancer etiology, we conducted analysis by categorizing subjects into 
deficient, or normal category based on clinically defined cut-off values. For vitamin B6, <20 nmol/L was 
considered deficient whereas ≥20nmol/L was considered normal 305. For folate deficiency, subjects 
were classified in three categories; <7 nmol/L as deficient, 7-12.9 nmol/L as moderately deficient, and ≥ 
13 nmol/L as normal 244 306.  
All statistical analyses were conducted using SAS 9.2 (Cary, North Carolina) 245, R version 3.1.3 247 or 
Stan version 2.9.0 248.  
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Appendix 3- Supplementary table 1 for Article 1 
Linear regression for plasma vitamin B2, B6, Folate, B12, Homocysteine and Methionine in relation to 
lifestyle factors, to nutrients and to food groups as assessed by food frequency questionnaires. 
Variable n 
ratio concentration a 
(95% CI) P n 
ratio concentration a 
(95% CI) P n 
ratio concentration a 
(95% CI) P 
    Serum riboflavin      Serum  vitamin B6   Serum folate 
Never smokers 539 1.00 [reference]   539 1.00 [reference]   539 1.00 [reference]   
Former smokers 489 0.96 (0.89 - 1.04) 0.39 489 0.94 (0.87 - 1.01) 0.12 489 0.95 (0.89 - 1.03) 0.25 
Current smokers 456 0.83 (0.77 - 0.90) 1x10-5 456 0.86 (0.80 - 0.93) 3x10-4 456 0.87 (0.81 - 0.94) 4x10-4 
log2-cotinineb 456 0.93 (0.90 - 0.96) 2x10-7 456 0.93 (0.91 - 0.96) 1x10-5 456 0.94 (0.91 - 0.96) 1x10-5 
Alcohol intake at recruitmentc 995 0.96 (0.93 - 1.00) 0.001 995 1.05 (1.02 - 1.08) 7x10-4 995 0.99 (0.96 - 1.03) 0.31 
Following variables adjusted for cotinine (in quartiles) and alcohol at recruitment, among all controls  
Vitamin B2 (nutrient) 995 1.22 (1.12 - 1.32) 2x10-7 995 1.01 (0.94 - 1.09) 0.62 995 1.07 (1.00 - 1.16) 0.06 
Vitamin B6 (nutrient) 995 1.11 (1.00 - 1.22) 0.04 995 1.10 (1.00 - 1.20) 0.04 995 1.10 (1.00 - 1.20) 0.04 
Folate (nutrient) 995 1.1 (1.01 - 1.21) 0.01 995 1.13 (1.04 - 1.23) 0.004 995 1.26 (1.17 - 1.37) 2x10-8 
Vitamin B12 (nutrient) 995 1.06 (1.00 - 1.12) 0.01 995 0.98 (0.94 - 1.03) 0.57 995 1.00 (0.95 - 1.05) 0.85 
Vegetables 995 1.01 (0.97 - 1.06) 0.87 995 1.06 (1.02 - 1.10) 0.006 995 1.10 (1.06 - 1.15) 3x10-5 
Leafy vegetables 959 1.02 (0.99 - 1.04) 0.08 959 1.03 (1.00 - 1.05) 0.02 959 1.05 (1.02 - 1.07) 2x10-5 
Fruiting vegetables 992 1.03 (1.00 - 1.06) 0.22 992 1.05 (1.02 - 1.08) 0.003 992 1.05 (1.02 - 1.08) 4x10-4 
Root vegetables 950 0.98 (0.96 - 1.01) 0.30 950 1.02 (1.00 - 1.05) 0.18 950 1.02 (1.00 - 1.05) 0.42 
Dairy products 992 1.08 (1.05 - 1.12) 5x10-7 992 1.00 (0.97 - 1.03) 0.57 992 0.99 (0.96 - 1.02) 0.54 
Meat products 995 1.00 (0.97 - 1.03) 0.75 995 0.98 (0.95 - 1.01) 0.14 995 0.93 (0.91 - 0.96) 1x10-5 
Serum  vitamin B12 Serum  homocysteine Serum  methionine 
Never smokers 539 1.00 [reference]   539 1.00 [reference]   539 1.00 [reference]   
Former smokers 489 1.06 (1.01 - 1.11) 0.02 489 1.02 (0.98 - 1.07) 0.33 489 0.98 (0.95 - 1.01) 0.21 
Current smokers 456 1.00 (0.95 - 1.05) 0.85 456 1.08 (1.04 - 1.13) 0.001 456 0.95 (0.92 - 0.98) 0.002 
log2-cotinineb 456 0.99 (0.97 - 1.00) 0.12 456 1.03 (1.01 - 1.05) 0.001 456 0.98 (0.96 - 0.99) 9x10-5 
Alcohol intake at recruitmentc 995 1.01 (0.99 - 1.03) 0.72 995 1.03 (1.01 - 1.05) 0.003 995 1.00 (0.99 - 1.02) 0.09 
Following variables adjusted for cotinine (in quartiles) and alcohol at recruitment, among all controls 
Vitamin B2 (nutrient) 995 1.09 (1.04 - 1.14) 2x10-4 995 0.88 (0.85 - 0.92) 3x10-10 995 1.04 (1.00 - 1.07) 0.02 
Vitamin B6 (nutrient) 995 1.05 (0.99 - 1.11) 0.06 995 0.88 (0.84 - 0.93) 2x10-7 995 1.05 (1.01 - 1.10) 0.003 
Folate (nutrient) 995 1.02 (0.97 - 1.08) 0.21 995 0.89 (0.86 - 0.93) 4x10-8 995 1.04 (1.01 - 1.08) 0.01 
Vitamin B12 (nutrient) 995 1.08 (1.04 - 1.11) 2x10-7 995 0.92 (0.90 - 0.95) 1x10-8 995 1.02 (1.00 - 1.04) 0.04 
Vegetables 995 1.02 (0.99 - 1.05) 0.13 995 0.96 (0.94 - 0.98) 2x10-4 995 1.01 (1.00 - 1.03) 0.09 
Leafy vegetables 959 1.01 (1.00 - 1.03) 0.09 959 0.99 (0.98 - 1.00) 0.11 959 1.00 (0.99 - 1.01) 0.72 
Fruiting vegetables 992 0.99 (0.97 - 1.01) 0.23 992 0.98 (0.97 - 1.00) 0.02 992 1.00 (0.99 - 1.02) 0.4 
Root vegetables 950 1.01 (1.00 - 1.03) 0.06 950 0.99 (0.98 - 1.00) 0.40 950 1.00 (0.99 - 1.01) 0.92 
Dairy products 992 1.04 (1.02 - 1.06) 8x10-5 992 0.97 (0.96 - 0.99) 9x10-4 992 1.01 (0.99 - 1.02) 0.16 
Meat products 995 1.03 (1.01 - 1.05) 0.002 995 0.96 (0.94 - 0.97) 1x10-6 995 1.01 (1.00 - 1.02) 0.07 
a Ratios of plasma levels were calculated as 2 raised to the power of the beta estimates from linear regression models with log2- plasma levels as response. The linear 
regression models were adjusted for case-control status, age, sex, country and as indicated adjusted for cotinine (in quartiles) and alcohol at recruitment. The base 2 
logarithm of each nutrient or food group was included as covariate in the linear regression models. The level ratio can thus be interpreted as the average relative 
change in serum levels that would be expected for a doubling in dietary intake. 
b Among current smokers 
c coded 0/1/2/3/4/5/6/ ~ alcohol[g/day]=0 / 0.1-6 / 6.1-12 / 12.1-24 / 24.1-60 / 60.1-96 in men or >60 in women / >90 in men. Adjusted for case-control status, age, 
sex, country and cotinine (in quartiles) among all controls. 
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Appendix 4- Supplementary table 2 for Article 1 
  Spearman correlation coefficient between plasma vitamin B2, B6, folate, B12, 
homocysteine and methionine  
Overall  
  Pyridoxal 5'-phosphate Folate Cobalamin Homocysteine Methionine 
Riboflavin (Vitamin B2) 0.25** 0.35** 0.09* -0.12** 0.005 
Pyridoxal 5'-phosphate (Vitamin B6)   0.34** 0.14** -0.14** 0.11** 
Folate (vitamin B9)     0.11** -0.32** -0.04* 
Cobalamin (Vitamin B12)       -0.29** 0.05 
Homocysteine         -0.04 
Matched controls 
  Pyridoxal 5'-phosphate Folate Cobalamin Homocysteine Methionine 
Riboflavin (Vitamin B2) 0.21** 0.30** 0.08 -0.03 -0.02 
Pyridoxal 5'-phosphate (Vitamin B6)   0.30** 0.13* -0.09** 0.18** 
Folate (vitamin B9)     0.15** -0.22** -0.01 
Cobalamin (Vitamin B12)       -0.25** 0.10* 
Homocysteine         -0.09* 
Cases 
  Pyridoxal 5'-phosphate Folate Cobalamin Homocysteine Methionine 
Riboflavin (Vitamin B2) 0.29** 0.39** 0.10* -0.19** 0.03 
Pyridoxal 5'-phosphate (Vitamin B6)   0.38** 0.14* -0.18** 0.04 
Folate (vitamin B9)     0.08* -0.37** -0.10* 
Cobalamin (Vitamin B12)       -0.32** 0.01 
Homocysteine         0.00 
* indicates 0.001≤p<0.05 and ** indicates p<0.001  
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Hazard ratios and 95% Confidence Intervals of all-cause mortality among   Head and Neck Cancer 
(HNC) and Esophagus Squamous Cell Carcinoma (ESCC) cases for plasma levels of Vitamins B2, B6, 
Folate, B12, Homocysteine and Methionine 
Quartile (Range) Decesaedb Aliveb 
Head and neck cancera                       Esophagus Squamous Cell Carcinoma  
Minimally adjustedc Adjusted for risk factord   Minimally adjusted
e Adjusted for risk factorf 
Riboflavin (Vitamin B2), nmol/Lg           
 1 (2.5 - 9.4)  75 (27.1%) 85 (31.3%) 1[Reference] 1[Reference]   1[Reference] 1[Reference] 
 2 (9.5 - 13.1)   54 (19.5%) 47 (17.3%) 1.26 (0.78 - 2.03) 1.32 (0.81 - 2.16)   0.76 (0.28 - 2.09) 0.59 (0.18 - 1.97) 
 3 (13.2 - 21.3)  81 (29.2%) 76 (27.9%) 1.07 (0.69 - 1.65) 1.13 (0.72 - 1.78)   0.83 (0.32 - 2.12) 1.07 (0.34 - 3.32) 
 4 (21.4 - 199) 67 (24.2%) 64 (23.5%) 1.05 (0.62 - 1.77) 1.30 (0.74 - 2.28)   0.85 (0.33 - 2.18) 1.03 (0.33 - 3.25) 
P for trendh     0.76 0.29   0.92 0.55 
Pyridoxal 5'-phosphate (Vitamin B6), nmol/Lg     
 1 (7.2 - 25.6)   80 (28.9%) 85 (31.3%) 1[Reference] 1[Reference] 1[Reference] 1[Reference] 
 2 (25.7 - 34.5)   59 (21.3%) 66 (24.3%) 0.80 (0.50 - 1.27) 0.81 (0.49 - 1.32) 2.02 (0.76 - 5.36) 3.65 (1.13 - 11.81) 
 3 (34.6 -  47.6)   64 (23.1%) 61 (22.4%) 0.89 (0.56 - 1.40) 0.91 (0.56 - 1.48) 1.78 (0.67 - 4.71) 3.26 (1.02 - 10.46) 
 4 (47.7 - 272)  74 (26.7%) 60 (22.1%) 0.96 (0.60 - 1.53) 0.96 (0.59 - 1.56) 1.73 (0.71 - 4.19) 2.66 (0.96 - 7.39) 
P for trendh     0.87 0.87   0.51 0.26 
Serum folate (vitamin B9), nmol/Lg           
 1 (0.3 - 9.1)   73 (26.4%) 104 (38.2%) 1[Reference] 1[Reference]   1[Reference] 1[Reference] 
 2 (9.2 - 12.8)   64 (23.1%) 52 (19.1%) 1.37 (0.85 - 2.21) 1.40 (0.86 - 2.27)   1.16 (0.48 - 2.81) 1.83 (0.68 - 4.89) 
 3 (12.9 -  18.1)   71 (25.6%) 53 (19.5%) 1.43 (0.90 - 2.26) 1.40 (0.87 - 2.25)   0.77 (0.30 - 2.01) 1.20 (0.41 - 3.51) 
 4 (18.2 - 109)   69 (24.9%) 63 (23.2%) 0.98 (0.58 - 1.66) 1.01 (0.58 - 1.77)   1.06 (0.42 - 2.69) 1.11 (0.44 - 2.83) 
P for trendh     0.97 0.98   0.78 0.91 
Cobalamin (Vitamin B12), pmol/Lg           
 1 (75.1 - 265)   84 (30.3%) 70 (25.7%) 1[Reference] 1[Reference] 1[Reference] 1[Reference] 
 2 (266 - 328)  65 (23.5%) 71 (26.1%) 0.87 (0.56 - 1.34) 0.90 (0.57 - 1.41) 1.24 (0.51 - 3.01) 0.91 (0.33 - 2.52) 
 3 (329 -  391)   49 (17.7%) 53 (19.5%) 0.74 (0.45 - 1.21) 0.73 (0.44 - 1.21) 0.96 (0.39 - 2.39) 0.66 (0.23 - 1.86) 
 4 (392 - 2737) 79 (28.5%) 78 (28.7%) 0.60 (0.38 - 0.96) 0.55 (0.34 - 0.90) 1.74 (0.78 - 3.87) 1.18 (0.45 - 3.08) 
P for trendh     0.06 0.06   0.17 0.49 
Homocysteine, μmol/Lg             
 1 (4.9 - 8.3)   53 (19.1%) 66 (24.3%) 1[Reference] 1[Reference]   1[Reference] 1[Reference] 
 2 (8.4- 10.1)   62 (22.4%) 68 (25.0%) 1.00 (0.59 - 1.70) 1.01 (0.59 - 1.74)   0.93 (0.38 - 2.25) 0.62 (0.23 - 1.67) 
 3 (10.2 -  12.4)  58 (20.9%) 46 (16.9%) 1.39 (0.82 - 2.34) 1.36 (0.80 - 2.32)   1.27 (0.49 - 3.28) 0.98 (0.34 - 2.81) 
 4 (12.5 - 64.9) 104 (37.5%) 92 (33.8%) 1.53 (0.94 - 2.50) 1.42 (0.85 - 2.37)   1.19 (0.52 - 2.74) 1.03 (0.40 - 2.63) 
P for trendh     0.44 0.62   0.39 0.25 
Methionine, μmol/Lg       
 1 (12.6 - 21.8) 83 (30.0%) 72 (26.5%) 1[Reference] 1[Reference] 1[Reference] 1[Reference] 
 2 (21.9 - 25.1) 61 (22.0%) 58 (21.3%) 0.84 (0.54 - 1.32) 0.85 (0.54 - 1.35) 0.80 (0.31 - 2.07) 0.75 (0.28 - 2.06) 
 3 (25.2 -  29.3)  67 (24.2%) 74 (27.2%) 0.64 (0.39 - 1.03) 0.66 (0.41 - 1.09) 0.93 (0.39 - 2.22) 1.12 (0.40 - 3.14) 
 4 (29.4 - 62.9)   66 (23.8%) 68 (25.0%) 0.69 (0.44 - 1.11) 0.73 (0.45 - 1.17) 1.89 (0.88 - 4.04) 3.22 (1.31 - 7.94) 
P for trendh     0.01 0.02   0.56 0.15 
a Adenocarcinoma excluded 
b Vital status among cancer cases of the head and neck and esophagus at the last follow-up. 
cAssessed by analysing HNC cases by Cox-proportional hazards regression, adjusting for country, sex, and age at diagnosis. 
dAssessed by analysing HNC cases by Cox-proportional hazards regression, adjusting for country, sex, and age at diagnosis, and further by educational attainment (5 groups), 
smoking status (never/former/current/missing), plasma cotinine (quartiles defined among current smokers) and alcohol intake at recruitment (g/day). 
eAssessed by analysing ESCC cases by Cox-proportional hazards regression, adjusting for country, sex, and age at diagnosis. 
fAssessed by analysing ESCC cases by Cox-proportional hazards regression, adjusting for country, sex, and age at diagnosis, and further by educational attainment (5 groups), 
smoking status (never/former/current/missing), plasma cotinine (quartiles defined among current smokers) and alcohol intake at recruitment (g/day). 
g Quartile cut-off points were determined based on the plasma level distribution of each biomarker among 516 individually matched controls of the head and neck and esophagus. 
hP for trend assessed by the base 2 logarithm of the serum levels 
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Appendix 6- Supplementary table 4 for Article 1 
Odds ratios of Head and Neck Cancer (HNC) and Esophagus Squamous Cell Carcinoma (ESCC) for plasma 
levels of Vitamins B2, B6, Folate, B12, homocysteine and methionine excluding cases that were diagnosed with 
HNC and ESCC cancer less than a year after blood draw. 
 Odds Ratio (95% Confidence Interval) 
Head and neck cancera  Esophagus Squamous Cell Carcinoma 
Quartile (Range) Caseb Controlb 
Matched 
controls 
unadjustedc       
(n=323/323)c 
Matched 
controls 
adjustedd          
(n=323/323)d 
All controls 
combined 
adjustede          
(n = 323/923)e 
  
Matched 
controls 
unadjustedf      
(n=68/68)f 
Matched controls 
adjustedd       
(n=68/68)d 
All controls 
combined 
adjustedg          
n = (68/923)g 
Riboflavin (Vitamin B2), nmol/Lh               
 1 (2.5 - 9.4)  140 (29.2%) 122 (25.5%) 1[Reference] 1[Reference] 1[Reference]   1[Reference] 1[Reference] 1[Reference] 
 2 (9.5 - 13.1)   90 (18.8%) 115 (24.0%) 0.66 (0.42 - 1.03) 0.83 (0.48 - 1.43) 0.81 (0.54 - 1.21)   0.51 (0.17 - 1.54) 0.31 (0.03 - 2.76) 0.51 (0.21 - 1.25) 
 3 (13.2 - 21.3)  135 (28.2%) 119 (24.8%) 1.07 (0.69 - 1.66) 1.50 (0.88 - 2.55) 1.17 (0.79 - 1.73)   0.68 (0.25 - 1.88) 0.42 (0.05 - 3.41) 0.96 (0.44 - 2.06) 
 4 (21.4 - 199) 114 (23.8%) 123 (25.7%) 0.67 (0.42 - 1.07) 1.20 (0.67 - 2.15) 1.22 (0.78 - 1.89)   0.73 (0.26 - 2.04) 1.14 (0.19 - 6.73) 1.17 (0.51 - 2.69) 
P for trendi     0.21 0.22 0.29   0.43 0.69 0.46 
Pyridoxal 5'-phosphate (Vitamin B6), nmol/Lh             
 1 (7.2 - 25.6)   150 (31.3%) 122 (25.5%) 1[Reference] 1[Reference] 1[Reference] 1[Reference] 1[Reference] 1[Reference] 
 2 (25.7 - 34.5)   106 (22.1%) 115 (24.0%) 0.72 (0.46 - 1.12) 0.85 (0.5 - 1.44) 0.97 (0.65 - 1.44) 0.86 (0.32 - 2.31) 1.51 (0.34 - 6.64) 0.98 (0.42 - 2.28) 
 3 (34.6 -  47.6)   104 (21.7%) 119 (24.8%) 0.68 (0.44 - 1.06) 0.99 (0.57 - 1.7) 1.10 (0.73 - 1.66) 0.92 (0.32 - 2.60) 0.93 (0.17 - 5.11) 1.28 (0.55 - 2.98) 
 4 (47.7 - 272)  119 (24.8%) 123 (25.7%) 0.75 (0.48 - 1.16) 0.98 (0.57 - 1.7) 1.01 (0.67 - 1.53) 1.17 (0.46 - 2.94) 1.96 (0.40 - 9.48) 2.36 (1.08 - 5.18) 
P for trendi     0.23 0.83 0.68   0.86 0.72 0.06 
Serum folate (vitamin B9), nmol/Lh               
 1 (0.3 - 9.1)   152 (31.7%) 117 (24.4%) 1[Reference] 1[Reference] 1[Reference]   1[Reference] 1[Reference] 1[Reference] 
 2 (9.2 - 12.8)   101 (21.1%) 121 (25.3%) 0.50 (0.32 - 0.81) 0.63 (0.35 - 1.13) 0.81 (0.54 - 1.21)   0.89 (0.31 - 2.54) 5.09 (0.72 - 35.75) 1.05 (0.49 - 2.28) 
 3 (12.9 -  18.1)   106 (22.1%) 118 (24.6%) 0.58 (0.36 - 0.96) 0.73 (0.40 - 1.33) 1.09 (0.73 - 1.65)   0.61 (0.20 - 1.84) 1.92 (0.30 - 12.34) 0.94 (0.40 - 2.20) 
 4 (18.2 - 109)   120 (25.1%) 123 (25.7%) 0.47 (0.28 - 0.79) 0.62 (0.33 - 1.16) 0.93 (0.61 - 1.42)   0.96 (0.30 - 3.09) 6.71 (0.63 - 71.05) 0.90 (0.40 - 2.01) 
P for trendi     2x10-4 0.009 0.32   0.66 0.27 0.97 
Cobalamin (Vitamin B12), pmol/Lh 
 1 (75.1 - 265)   139 (29.0%) 119 (24.8%) 1[Reference] 1[Reference] 1[Reference] 1[Reference] 1[Reference] 1[Reference] 
 2 (266 - 328)  121 (25.3%) 120 (25.1%) 0.79 (0.51 - 1.23) 1.01 (0.59 - 1.72) 0.83 (0.56 - 1.23) 1.20 (0.39 - 3.74) 1.17 (0.23 - 5.90) 1.08 (0.49 - 2.36) 
 3 (329 -  391)   86 (18.0%) 120 (25.1%) 0.56 (0.34 - 0.91) 0.59 (0.32 - 1.07) 0.64 (0.42 - 0.98) 0.80 (0.26 - 2.42) 1.41 (0.31 - 6.32) 0.92 (0.41 - 2.07) 
 4 (392 - 2737) 133 (27.8%) 120 (25.1%) 0.86 (0.53 - 1.39) 1.06 (0.59 - 1.90) 0.89 (0.60 - 1.31) 1.16 (0.36 - 3.75) 1.02 (0.21 - 4.94) 1.05 (0.49 - 2.27) 
P for trendi     0.89 0.78 0.70   0.88 0.73 0.86 
Homocysteine, μmol/Lh               
 1 (4.9 - 8.3)   101 (21.1%) 122 (25.5%) 1[Reference] 1[Reference] 1[Reference]   1[Reference] 1[Reference] 1[Reference] 
 2 (8.4- 10.1)   114 (23.8%) 122 (25.5%) 1.40 (0.86 - 2.25) 1.47 (0.83 - 2.60) 1.33 (0.88 - 2.03)   0.9 (0.31 - 2.62) 0.62 (0.12 - 3.13) 1.10 (0.48 - 2.54) 
 3 (10.2 -  12.4)  88 (18.4%) 117 (24.4%) 1.15 (0.70 - 1.89) 1.06 (0.59 - 1.94) 0.91 (0.58 - 1.44)   1.23 (0.42 - 3.58) 1.05 (0.23 - 4.79) 0.84 (0.34 - 2.05) 
 4 (12.5 - 64.9) 176 (36.7%) 118 (24.6%) 3.21 (1.84 - 5.62) 2.61 (1.32 - 5.17) 1.89 (1.22 - 2.91)   1.72 (0.64 - 4.64) 0.99 (0.23 - 4.24) 1.85 (0.80 - 4.29) 
P for trendi     7x10-5 0.007 0.003   0.06 0.53 0.07 
Methionine, μmol/Lh 
 1 (12.6 - 21.8) 138 (28.8%) 121 (25.3%) 1[Reference] 1[Reference] 1[Reference] 1[Reference] 1[Reference] 1[Reference] 
 2 (21.9 - 25.1) 103 (21.5%) 118 (24.6%) 0.74 (0.50 - 1.12) 0.96 (0.59 - 1.56) 0.86 (0.58 - 1.29) 0.87 (0.35 - 2.19) 4.18 (0.48 - 36.12) 0.69 (0.32 - 1.50) 
 3 (25.2 -  29.3)  118 (24.6%) 120 (25.1%) 0.86 (0.55 - 1.34) 1.21 (0.7 - 2.11) 0.92 (0.61 - 1.38) 0.57 (0.20 - 1.59) 0.78 (0.13 - 4.84) 0.87 (0.40 - 1.92) 
 4 (29.4 - 62.9)   120 (25.1%) 120 (25.1%) 0.91 (0.56 - 1.46) 1.4 (0.77 - 2.54) 1.06 (0.70 - 1.61) 0.60 (0.19 - 1.85) 1.50 (0.18 - 12.27) 1.08 (0.49 - 2.38) 
P for trendi     0.42 0.36 0.94   0.18 0.59 0.90 
a Adenocarcinoma excluded 
b Numbers include all cancer cases of the head and neck and esophagus, and individually matched control for whom laboratory measurements were available for complete case sets. 
Uninformative case-sets were excluded. 
c Assessed by analysing HNC  cases and their individually matched controls by conditional logistic regression, conditioning on individual case set.  
d Further adjusted for educational attainment (in 5 groups), smoking status (never/former/current/missing), cotinine (quartiles defined among current smokers) and alcohol intake at 
recruitment(g/day) 
e Assessed by analysing HNC  cases and all controls combined by unconditional logistic regression, adjusting for country, sex, age at recruitment (in 5 year groups), educational attainment (in 5 
groups), smoking status (never/former/current/missing), cotinine (quartiles defined among current smokers) and alcohol intake at recruitment (g/day). 
f Assessed by analysing ESCC cases and their individually matched controls by conditional logistic regression, conditioning on individual case set.  
g Assessed by analysing ESCC cases and all controls combined by unconditional logistic regression, adjusting for country, sex, age at recruitment (in 5 year groups), educational attainment (in 
5 groups), smoking status (never/former/current/missing), cotinine (quartiles defined among current smokers) and alcohol intake at recruitment (g/day). 
h Quartile cut-off points were determined based on the plasma level distribution of each biomarker among the 516 individually matched controls of the head and neck and esophagus . 
i P for trend assessed by the base 2 logarithm of the serum levels 
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Appendix 7- Supplementary table 5 for Article 1 
Odds ratios of Head and Neck Cancer (HNC) and Esophagus Squamous Cell Carcinoma (ESCC) for 
dietary intake of B-vitamins and plasma levels of vitamin B2, B6, Folate and B12.  
 Odds Ratio (95% Confidence Interval) 
   Head and neck cancer
a             
Esophagus Squamous               
Cell Carcinomaa  
Quartile 
(Range) Case
b Controlb Overall - by dietary intakec 
Overall - by 
serum levelfrom 
table 2  
  Overall - by dietary intaked 
Overall - by serum 
levelfrom table 2  
Riboflavin (Vitamin B2), mg/dayd           
 1 (0.52 - 1.32)  145 (28.2%) 129 (24.7%) 1[Reference] 1[Reference]   1[Reference] 1[Reference] 
 2 (1.33 - 1.70)   125 (24.3%) 130 (24.9%) 0.95 (0.59 - 1.53) 0.75 (0.45 - 1.27)   0.14 (0.03 - 0.71) 0.17 (0.02 - 1.26) 
 3 (1.71 - 2.23)  116 (22.6%) 131 (25.1%) 0.82 (0.50 - 1.35) 1.33 (0.80 - 2.20)   1.06 (0.25 - 4.42) 0.57 (0.09 - 3.56) 
 4 (2.24 - 4.35) 128 (24.9%) 132 (25.3%) 0.84 (0.48 - 1.46) 1.19 (0.68 - 2.08)   2.29 (0.38 - 13.92) 0.94 (0.18 - 4.92) 
P for trende     0.28 0.22   0.60 0.84 
Pyridoxal 5'-phosphate (Vitamin B6), mg/dayd 
 1 (0.57 - 1.51)   160 (31.1%) 129 (24.7%) 1[Reference] 1[Reference] 1[Reference] 1[Reference] 
 2 (1.52 - 1.89)   96 (18.7%) 130 (24.9%) 0.53 (0.31 - 0.90) 0.75 (0.45 - 1.26) 0.41 (0.11 - 1.56) 1.96 (0.51 - 7.56) 
 3 (1.90 - 2.36)   127 (24.7%) 131 (25.1%) 0.67 (0.38 - 1.15) 0.96 (0.57 - 1.63) 1.20 (0.20 - 7.22) 1.41 (0.28 - 7.18) 
 4 (2.37 - 4.43)  131 (25.5%) 132 (25.3%) 0.53 (0.29 - 0.97) 1.01 (0.59 - 1.71) 3.25 (0.48 - 22.11) 1.82 (0.45 - 7.42) 
P for trende     0.08 0.48   0.29 0.82 
Serum folate (vitamin B9),  μg/dayd         
 1 (87 - 237)   174 (33.9%) 129 (24.7%) 1[Reference] 1[Reference]   1[Reference] 1[Reference] 
 2 (238 - 291)   100 (19.5%) 130 (24.9%) 0.68 (0.42 - 1.12) 0.62 (0.36 - 1.08)   0.64 (0.13 - 3.21) 7.78 (1.24 - 49.05) 
 3 (292 - 367)   113 (22%) 131 (25.1%) 0.62 (0.37 - 1.04) 0.77 (0.44 - 1.36)   0.63 (0.15 - 2.61) 4.08 (0.74 - 22.60) 
 4 (368 - 1057)   127 (24.7%) 132 (25.3%) 0.81 (0.46 - 1.41) 0.62 (0.34 - 1.13)   1.63 (0.24 - 11.01) 12.45 (1.14 - 135.5) 
P for trende     0.13 0.02   0.62 0.14 
Cobalamin (Vitamin B12),μg/dayd           
 1 (0.21 - 4.04)   125 (24.3%) 129 (24.7%) 1[Reference] 1[Reference] 1[Reference] 1[Reference] 
 2 (4.05 - 5.75)  123 (23.9%) 130 (24.9%) 1.05 (0.61 - 1.81) 1.01 (0.61 - 1.68) 1.52 (0.42 - 5.52) 1.49 (0.33 - 6.73) 
 3 (5.76 -  7.76)   120 (23.3%) 131 (25.1%) 0.90 (0.52 - 1.56) 0.59 (0.33 - 1.05) 1.17 (0.27 - 5.03) 1.07 (0.27 - 4.32) 
 4 (7.77 - 28.85) 146 (28.4%) 132 (25.3%) 0.90 (0.51 - 1.58) 1.20 (0.68 - 2.10) 1.00 (0.28 - 3.61) 0.94 (0.21 - 4.25) 
P for trende     0.81 0.64   0.82 0.78 
a Adenocarcinoma excluded 
b Numbers include all cancer cases of the head and  neck and esophagus, and individually matched control for whom food frequency questionnaire 
measurements were available for complete case sets. Uninformative case-sets were excluded. 
c Assessed by analysing HNC cancer cases and their individually matched controls by conditional logistic regression, conditioning on individual case set and 
adjusting by educational attainment (in 5 groups), smoking status (never/former/current/missing), cotinine (quartiles defined among current smokers) and 
alcohol intake at recruitment. 
c Assessed by analysing ESCC cancer cases and their individually matched controls by conditional logistic regression, conditioning on individual case set and 
adjusting by educational attainment (in 5 groups), smoking status (never/former/current/missing), cotinine (quartiles defined among current smokers) and 
alcohol intake at recruitment. 
d Quartile cut-off points were determined based on the dietary intake distribution of each nutrient among the 516 individually matched controls of the head and 
neck and esophagus. 
e P for trend assessed by the base 2 logarithm of the serum levels 
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Appendix 8- Supplementary figure 1 for Article 1 
Forest plot showing Stratified OR of cancer of the head and neck and esophagus for log2- of plasma 
homocysteine. 
 
a Head and neck and esophagus cancer cases (adenocarcinoma excluded) and controls included in each stratified analysis (control group 2 were 
included).  
b ORs were assessed by unconditional logistic regression by including the base 2 logarithm of plasma biomarker levels (ORs indicate relative 
risks of a doubling in plasma levels), and where relevant adjusted for age, sex, and country; the black dots indicate the ORs and the horizontal 
lines indicate the 95% confidence intervals. 
c P heterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being the identical. 
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Appendix 9- Supplementary figure 2 for Article 1 
Forest plot showing Stratified OR of cancer of the head and neck and esophagus for log2- of plasma 
homocysteine vitamin B2. 
 
a Head and neck and esophagus cancer cases (adenocarcinoma excluded) and controls included in each stratified analysis (control group 2 were 
included).  
b ORs were assessed by unconditional logistic regression by including the base 2 logarithm of plasma biomarker levels (ORs indicate relative 
risks of a doubling in plasma levels), and where relevant adjusted for age, sex, and country; the black dots indicate the ORs and the horizontal 
lines indicate the 95% confidence intervals. 
c P heterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being the identical. 
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Appendix 10- Supplementary figure 3 for Article 1 
Forest plot showing Stratified OR of cancer of the head and neck and esophagus for log2- of plasma 
homocysteine vitamin B6. 
 
a Head and neck and esophagus cancer cases (adenocarcinoma excluded) and controls included in each stratified analysis (control group 2 were 
included).  
b ORs were assessed by unconditional logistic regression by including the base 2 logarithm of plasma biomarker levels (ORs indicate relative 
risks of a doubling in plasma levels), and where relevant adjusted for age, sex, and country; the black dots indicate the ORs and the horizontal 
lines indicate the 95% confidence intervals. 
c P heterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being the identical. 
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Appendix 11- Supplementary figure 4 for Article 1 
Forest plot showing Stratified OR of cancer of the head and neck and esophagus for log2- of plasma folate. 
 
a Head and neck and esophagus cancer cases (adenocarcinoma excluded) and controls included in each stratified analysis (control group 2 were 
included).  
b ORs were assessed by unconditional logistic regression by including the base 2 logarithm of plasma biomarker levels (ORs indicate relative 
risks of a doubling in plasma levels), and where relevant adjusted for age, sex, and country; the black dots indicate the ORs and the horizontal 
lines indicate the 95% confidence intervals. 
c P heterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being the identical. 
  
France
Italy
Spain
United Kingdom
The Netherlands
Greece
Germany
Sweden and Norway
Esophagus squamous cell carcinoma
Hypopharynx and Larynx
Gum and Oral cavity
Oropharynx
Never smokers
Former smokers
By time since quitting smoking (years)
< 10
>= 10
Current smokers
38-49.9 years
50-59.9 years
60-69.9 years
70-85.3 years
Primary school
Higher than primary school
Men
Women
=0 g/day
0.1-6 g/day
6.1-12 g/day
12.1-24 g/day
24.1-60 g/day
60.1-96 g/day
Overall log2 - Folate (Vitamin B9)
By Country (p-heterogeneity= 0.01)c
By site (p-heterogeneity= 0.45)c
By smoking status (p-heterogeneity= 0.46)c
By age at diagnosis (p-heterogeneity= 0.86)c
By educational attainment (p-heterogeneity= 0.96)c
By gender (p-heterogeneity= 0.590)c
By alcohol intake at recruitment (p-heterogeneity= 0.21)c
443
7
63
90
79
63
20
93
28
73
145
110
67
95
110
45
59
233
36
143
195
68
197
230
295
148
78
107
40
65
96
42
994
20
158
152
195
123
39
228
79
995
995
995
995
436
341
91
242
200
82
277
457
174
393
567
609
385
117
343
134
182
174
34
0.95
2-14
0.72
0.42
1.05
1.46
0.70
1.10
1.55
1.02
1.01
0.78
1.05
0.95
1.07
1.36
0.92
0.82
1.10
0.86
0.91
1.09
0.91
0.95
0.91
0.99
1.04
1.15
1.22
0.77
0.72
1.01
0.81-1.10
0.0- 4 23
0.44-1.19
0.26-0.66
0.76-1.47
0.89-2.41
0.21-2.37
0.78-1.55
0.72-3.31
0.75-1.38
0.79-1.30
0.60-1.00
0.77-1.44
0.72-1.26
0.81-1.41
0.83-2.24
0.63-1.36
0.63-1.05
0.58-2.08
0.65-1.15
0.72-1.16
0.76-1.58
0.72-1.14
0.76-1.18
0.75-1.11
0.77-1.27
0.69-1.57
0.85-1.56
0.73-2.04
0.48-1.24
0.47-1.10
0.50-2.03
study group Casesa Controlsa ORb 95%CI
0.5 1.0 2.0
Ptrend: 0.48
Odds ratio (95% confidence interval)
1-35 months
36-75 months
76-107 months
108-151 months
By time from blood draw to diagnosis (p-heterogeneity= 0.60)c
111
115
104
108
227
251
239
267
1.11
0.81
1.03
0.99
0.79-1.55
0.58-1.12
0.74-1.44
0.73-1.34
OCM and smoking-related cancers - Appendices 
202 
 
Appendix 12- Supplementary figure 5 for Article 1 
Forest plot showing stratified OR of cancer of the head and neck and esophagus for log2- of plasma 
vitamin B12. 
 
a Head and neck and esophagus cancer cases (adenocarcinoma excluded) and controls included in each stratified analysis (control group 2 were 
included).  
b ORs were assessed by unconditional logistic regression by including the base 2 logarithm of plasma biomarker levels (ORs indicate relative 
risks of a doubling in plasma levels), and where relevant adjusted for age, sex, and country; the black dots indicate the ORs and the horizontal 
lines indicate the 95% confidence intervals. 
c P heterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being the identical. 
 
 
France
Italy
Spain
United Kingdom
The Netherlands
Greece
Germany
Sweden and Norway
Esophagus squamous cell carcinoma
Hypopharynx and Larynx
Gum and Oral cavity
Oropharynx
Never smokers
Former smokers
By time since quitting smoking (years)
< 10
>= 10
Current smokers
38-49.9 years
50-59.9 years
60-69.9 years
70-85.3 years
Primary school
Higher than primary school
Men
Women
=0 g/day
0.1-6 g/day
6.1-12 g/day
12.1-24 g/day
24.1-60 g/day
60.1-96 g/day
Overall log2 - Vitamin B12 (Cobalamin )
By Country (p-heterogeneity= 0.34)c
By site (p-heterogeneity= 0.99)c
By smoking status (p-heterogeneity= 0.74)c
By age at diagnosis (p-heterogeneity= 0.66)c
By educational attainment (p-heterogeneity= 0.65)c
By gender (p-heterogeneity= 0.09)c
By alcohol intake at recruitment (p-heterogeneity= 0.02)c
443
7
63
90
79
63
20
93
28
73
145
110
67
95
110
45
59
233
36
143
195
68
197
230
295
148
78
107
40
65
96
42
995
20
158
152
195
123
39
228
79
995
995
995
995
436
342
91
242
200
82
298
458
174
393
568
609
386
117
343
134
182
175
34
0.97
0.26
1.46
0.87
0.90
1.74
0.36
1.22
0.33
0.93
0.96
0.91
0.96
0.88
0.97
0.59
1.26
0.99
1.79
0.83
1.04
0.83
1.03
1.00
0.82
1.24
1.84
1.00
2.03
0.53
0.48
2.18
0.768-1.22
0.010-6.82
0.668-3.20
0.511-1.49
0.540-1.50
0.725-4.18
0.078-1.61
0.719-2.07
0.071-1.52
0.571-1.51
0.660-1.39
0.607-1.37
0.582-1.57
0.559-1.40
0.654-1.43
0.294-1.20
0.743-2.15
0.661-1.48
0.644-5.00
0.541-1.27
0.725-1.50
0.481-1.42
0.719-1.47
0.731-1.38
0.602-1.10
0.851-1.80
0.892-3.80
0.618-1.62
0.912-4.50
0.248-1.15
0.272-0.83
0.481-9.84
study group Casesa Controlsa ORb 95%CI
0.2 0.5 1.0 2.0 5.0
Ptrend: 0.77
Odds ratio (95% confidence interval)
1-35 months
36-75 months
76-107 months
108-151' months
By time from blood draw to diagnosis (p-heterogeneity= 0.46)
111
115
104
108
227
251
239
267
0.99
0.85
1.39
0.79
0.614-1.61
0.557-1.29
0.801-2.40
0.467-1.33
Anouar Fanidi, 2016 
203 
 
Appendix 13- Supplementary figure 6 for Article 1 
Forest plot showing stratified OR of cancer of the head and neck and esophagus for log2- of plasma 
methionine. 
 
a Head and neck and esophagus cancer cases (adenocarcinoma excluded) and controls included in each stratified analysis (control group 2 were 
included).  
b ORs were assessed by unconditional logistic regression by including the base 2 logarithm of plasma biomarker levels (ORs indicate relative 
risks of a doubling in plasma levels), and where relevant adjusted for age, sex, and country; the black dots indicate the ORs and the horizontal  
lines indicate the 95% confidence intervals. 
c P heterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being the identical. 
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Appendix 14- Supplementary methods for Article 1 
Study cohort – The European Prospective Investigation into Cancer and Nutrition (EPIC) 
521,330 individuals were recruited to the cohort between 1992 and 2000 from 10 European countries, of 
whom 385,747 donated a blood sample. Blood fractions were aliquoted into 0.5 mL straws, which were heat-
sealed and stored in liquid nitrogen tanks at -196°C, except in Umeå, Sweden, where samples were stored in 
1.8 mL plastic tubes in -80°C freezers. Participants completed self-administered questionnaires on lifestyle 
factors and diet. All participants gave written informed consent. The study was approved by the Ethics 
Committee at the International Agency for Research on Cancer (IARC), Lyon, France, as well as by the local 
ethics committees of the study centers. 
Follow-up for cancer incidence and mortality data 
The ascertainment of cases within EPIC reflects the predominant pattern of diagnosis in the general 
population. Incident cancer cases were identified at regular intervals through population-based cancer 
registries (Denmark, Italy except Naples, the Netherlands, Norway, Spain, Sweden and United Kingdom) or by 
active follow-up (France, Germany, Greece and Naples), which involved a combination of methods, including 
review of health insurance records, cancer and pathology registries, as well as direct contact with 
participants and their next-of-kin.  
Mortality data, including vital status, cause of death, and date of death, were obtained from mortality 
registries at the regional or national level. Subjects were followed up from study entry until cancer diagnosis 
(except non-melanoma skin cancer), death, emigration, or the end of the follow-up period for the relevant 
study center. End of follow-up was defined as the latest date of complete follow-up for both cancer 
incidence and vital status and varied between study centers from December 2004 to June 2010. Vital status 
at follow-up is over 98% complete.  
Validation study – The Melbourne Collaborative Cohort Study (MCCS) 
The MCCS is a prospective cohort study of 41,514 women and men aged 40 to 79 years at the time of 
recruitment which took place between 1990 and 1994 in Melbourne, Australia. Following blood draw, 
plasma fractions were stored in liquid nitrogen tanks at -196°C. Incident cancer diagnoses were identified via 
routine linkage to the Victorian Cancer Registry (VCR). There is a statutory requirement that all cancers 
diagnosed in the state of Victoria (the state in which Melbourne is situated), excluding non-melanoma skin 
cancer be reported to the VCR. Vital status and cause of death information were obtained via linkage to the 
National Death Index of Australia.  
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Biochemical analyses 
Plasma samples were sent on dry ice to the Bevital A/S laboratory (http://www.bevital.no) in Bergen, 
Norway. The study included measurements of plasma concentrations of vitamin B2 (riboflavin), vitamin B6 
(measured as pyridoxal 5’-phosphate, its active form), folate (vitamin B9), vitamin B12 (cobalamin), total 
homocysteine, and methionine. We also measured cotinine as an indicator of recent smoking behavior. 
Concentrations of B2, B6, homocysteine, methionine, and cotinine were determined by mass spectrometry 
based methods (liquid chromatography coupled to tandem mass spectrometry; gas chromatography coupled 
to tandem mass spectrometry),307-309 and microbiological methods were used to determine concentrations of 
folate (Lactobacillus casei)310 and B12 (Lactobacillus leichmannii)._ENREF_285 
Samples were analyzed in batches of 86 and quality control included 6 calibration samples, 2 control 
samples, and 1 blank sample in each batch. The coefficients of variations (CVs) within and between batches 
were, respectively, 6 and 11% for vitamin B2, 3% and 6% for vitamin B6, 4% and 5% for folate and vitamin 
B12, 1% and 3% for methionine, and 1% and 2% for homocysteine. All plasma samples were kept at −80°C 
and all RCC cases and their individual matched controls were analyzed together within the same batches in 
random order, as were samples from control group 2. The laboratory staff was blinded to the case-control 
status of the blood samples. 
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Appendix 15- Supplementary table 1 for Article 2 
Partial correlation coefficients between circulating concentrations of vitamins B2, 
B6, folate, B12, homocysteine and methionine, and dietary intake, alcohol intake, 
circulating cotinine, BMI, and waist-to-hip ratio 
  Circulating metabolites 
  Vitamin B6 Vitamin B2 Folate Vitamin B12 Homocysteine Methionine 
Total vegetable intake 0.07 -0.03 0.05 -0.03 -0.01 0.10 
Total fruit, nut, and seed intake 0.17 0.09 0.15 -0.01 -0.08 0.03 
Total dairy product intake 0.07 0.19 0.01 0.03 -0.10 0.10 
Total meat and meat product intake -0.06 -0.06 -0.02 -0.02 -0.07 -0.09 
Circulating cotinine -0.25 -0.15 -0.16 -0.03 0.16 -0.12 
Alcohol intake at recruitment 0.13 -0.04 0.03 -0.04 0.05 0.00 
Body Mass Index -0.13 0.00 -0.13 -0.06 0.05 -0.05 
Waist-to-hip ratio -0.13 0.05 -0.06 -0.07 0.00 -0.03 
a) Calculated as the correlation between the given variables among the 556 matched controls 
(control group 1) after conditioning on country, age at baseline, and sex 
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Appendix 16- Supplementary table 2 for Article 2 
Odds ratios of RCC for plasma concentrations of vitamins B2, B6, folate, B12, and homocycteine and 
methionine, by comparing RCC cases to control group 2 only, i) with and ii) without adjustment for 
risk factors, by iii) comparing cases to matched controls in a conditional analysis where missing 
covariate data were excluded in a sensitivity analysis, and by iv) comparing cases with all controls, 
adjusting for risk factors.  
  Odds Ratio (95% Confidence Interval)  
  i) Cases compared to control group 2, minimally adjusteda 
ii) Cases compared to control 
group 2, adjusted for all risk 
factorb 
iii) Cases compared to 
matched controls, adjusted 
for all risk factors (all missing 
data excluded)c 
iv) Cases compared to all 
controls, adjusted for all 
risk factorsd 
Quartile (Range) (n = 444/553)a (n = 444/553)b (n = 383/383)c (n = 556/1109)d 
Vitamin B2 (Riboflavin) [nmol/L]e   
1 (2.57-9.83) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2 (9.84-14.3) 0.72 (0.50-1.02) 0.76 (0.53 - 1.11) 0.78 (0.51 - 1.19) 0.74 (0.55 - 1.00) 
3 (14.4-22.2) 0.81 (0.55-1.19) 0.84 (0.56 - 1.25) 0.71 (0.46 - 1.09) 0.82 (0.60 - 1.12) 
4 (22.2-416) 0.78 (0.53-1.15) 0.87 (0.58 - 1.31) 0.79 (0.51 - 1.24) 0.78 (0.56 - 1.07) 
P for trendf 0.47 0.96 0.19 0.31 
Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]e 
1 (5.95-25.4) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2 (25.4-35.9) 0.64 (0.46-0.91) 0.69 (0.47 - 0.99) 0.67 (0.44 - 1.02) 0.65 (0.49 - 0.88) 
3 (35.9-51.9) 0.60 (0.42-0.86) 0.63 (0.43 - 0.93) 0.58 (0.37 - 0.90) 0.62 (0.46 - 0.84) 
4 (51.9-436) 0.52 (0.34-0.77) 0.55 (0.35 - 0.84) 0.34 (0.21 - 0.57) 0.49 (0.35 - 0.68) 
P for trendf 0.002 0.008 <0.001 <0.001 
Vitamin B9 (Folate) [nmol/L]e   
1 (0.20-8.40) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2 (8.41-11.8) 0.72 (0.48-1.08) 0.67 (0.44 - 1.03) 0.93 (0.58 - 1.49) 0.86 (0.62 - 1.17) 
3 (11.9-17.3) 0.52 (0.35-0.77) 0.52 (0.34 - 0.79) 0.95 (0.58 - 1.55) 0.73 (0.53 - 1.00) 
4 (17.3-109) 0.55 (0.37-0.83) 0.54 (0.35 - 0.84) 0.79 (0.47 - 1.31) 0.72 (0.51 - 1.00) 
P for trendf 0.01 0.02 0.07 0.03 
Vitamin B12 (Cobalamin) [pmol/L]e 
1 (75.2-281) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2 (281-343) 0.89 (0.63-1.26) 0.95 (0.66 - 1.37) 0.94 (0.60 - 1.45) 0.94 (0.70 - 1.27) 
3 (344-419) 0.93 (0.64-1.35) 1.03 (0.70 - 1.52) 1.06 (0.68 - 1.64) 0.93 (0.68 - 1.27) 
4 (419-5000) 0.99 (0.68-1.44) 1.07 (0.72 - 1.61) 0.76 (0.48 - 1.19) 0.83 (0.60 - 1.13) 
P for trendf 0.5 0.21 0.47 0.61 
Methionine [μmol/L]e   
1 (2.1-21.48) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2 (21.5-25) 0.84 (0.59-1.21) 0.82 (0.56 - 1.21) 1.13 (0.74 - 1.71) 0.95 (0.70 - 1.28) 
3 (25.0-28.9) 0.71 (0.47-1.05) 0.64 (0.42 - 0.98) 0.75 (0.47 - 1.19) 0.71 (0.51 - 0.98) 
4 (29.0-71.4) 0.72 (0.49-1.06) 0.74 (0.49 - 1.11) 0.66 (0.40 - 1.07) 0.78 (0.56 - 1.08) 
P for trendf 0.02 0.06 0.07 0.03 
Homocysteine [μmol/L]e 
1 (3.68-8.03) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2 (8.04-9.87) 0.79 (0.55-1.15) 0.73 (0.50 - 1.08) 1.13 (0.74 - 1.72) 0.88 (0.65 - 1.20) 
3 (9.88-11.9) 0.74 (0.49-1.13) 0.67 (0.43 - 1.04) 0.93 (0.59 - 1.48) 0.74 (0.53 - 1.04) 
4 (12.0-64.9) 0.91 (0.61-1.37) 0.84 (0.54 - 1.30) 0.84 (0.51 - 1.39) 0.88 (0.63 - 1.24) 
P for trendf 0.70 0.89 0.44 0.76 
a) Assessed by analyzing RCC cases and additional unmatched controls by unconditional logistic regression, adjusting for country, sex, and age at recruitment 
(in 5 year groups). Danish subjects did not contribute to this analysis. 
b) Assessed by analyzing RCC cases and additional unmatched controls by unconditional logistic regression after multiple imputation of missing covariate data, 
adjusting for country, sex, age at recruitment (in 5 year groups), waist-to-hip ratio (quartiles defined among matched controls), hypertension (yes/no), educational 
attainment (4 categories), smoking status (never/former/current), plasma cotinine (quartiles defined by the distribution for current smokers), alcohol intake at 
recruitment (g/day) and  alcohol intake (ever/never) . Danish subjects did not contribute to this analysis. 
c) Sensitivity analysis in which participants with missing covariate data were excluded. Assessed by analyzing RCC cases and their individually matched controls 
by conditional logistic regression, conditioning on individual case set, and adjusting for waist-to-hip ratio (quartiles defined among matched controls), 
hypertension (yes/no), educational attainment (4 categories), smoking status (never/former/current), plasma cotinine (quartiles defined by the distribution for 
current smokers), alcohol intake at recruitment (g/day) and alcohol intake (ever/never). Case-control numbers only include those case-sets where both the case 
and matched control had complete plasma measurements and covariate information.  
d) Assessed by analysing RCC cases and all controls combined by unconditional logistic regression after multiple imputation of missing covariate data, adjusting for country, sex, 
age at recruitment (in 5 year groups), waist-to-hip ratio (quartiles defined among matched controls), hypertension (yes/no), educational attainment (4 categories), smoking 
status (never/former/current), plasma cotinine (quartiles defined by the distribution for current smokers), alcohol intake at recruitment (g/day) and alcohol intake (ever/never). 
e) Quartile cut-off points were determined based on the plasma level distribution of each biomarker for 556 individually matched controls. 
f) P for trend assessed by the base 2 logarithm of plasma concentrations. 
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Appendix 17- Supplementary table 3 for Article 2 
Hazard ratios of all-cause mortality for RCC cases for quartiles of plasma vitamins B2, B6, folate, 
B12, and homocysteine and methionine: Sensitivity analysis excluding missing data 
    Hazard ratio (95% CI) 
Quartile (Range) Deceasedb Aliveb Person years Sensitivity analysis (missing covariate data excluded) Adjusted for risk factors
a 
Vitamin B2 (Riboflavin) [nmol/L]c 
1 (2.57-9.83) 50 (24%) 111 (32%) 744.1 1.00 (reference) 
2 (9.84-14.34) 52 (25%) 75 (22%) 602.8 1.35 (0.83 - 2.20) 
3 (14.35-22.16) 48 (23%) 85 (25%) 528.9 1.34 (0.83 - 2.19) 
4 (22.19-416.79) 55 (27%) 73 (21%) 501.4 1.65 (1.00 - 2.74) 
P for trendd 0.18 
Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]c 
1 (5.95-25.37) 90 (44%) 116 (34%) 890.4 1.00 (reference) 
2 (25.43-35.9) 51 (25%) 83 (24%) 576.5 0.85 (0.56 - 1.30) 
3 (35.92-51.88) 37 (18%) 84 (24%) 530.8 0.74 (0.46 - 1.19) 
4 (51.92-436.13) 27 (13%) 61 (18%) 379.5 0.54 (0.30 - 0.97) 
P for trendd 0.01 
Vitamin B9 (Folate) [nmol/L]c 
1 (0.2-8.4) 54 (26%) 97 (28%) 697.0 1.00 (reference) 
2 (8.41-11.84) 63 (31%) 74 (22%) 501.5 1.72 (1.07 - 2.76) 
3 (11.86-17.25) 46 (22%) 85 (25%) 594.9 1.06 (0.64 - 1.76) 
4 (17.27-109.35) 42 (20%) 87 (25%) 580.5 0.93 (0.54 - 1.59) 
P for trendd 0.53 
Vitamin B12 (Cobalamin) [pmol/L]c 
1 (75.16-281.28) 61 (30%) 90 (26%) 638.9 1.00 (reference) 
2 (281.37-343.39) 57 (28%) 90 (26%) 600.5 0.70 (0.44 - 1.11) 
3 (343.51-419) 46 (22%) 88 (26%) 595.5 0.64 (0.40 - 1.04) 
4 (419.35-5000) 41 (20%) 75 (22%) 539.1 0.77 (0.47 - 1.27) 
P for trendd 0.26 
Methionine [μmol/L]c 
1 (2.1-21.48) 63 (31%) 82 (24%) 657.7 1.00 (reference) 
2 (21.5-25) 49 (24%) 115 (33%) 765.7 0.85 (0.54 - 1.35) 
3 (25.01-28.94) 43 (21%) 71 (21%) 455.3 1.06 (0.64 - 1.73) 
4 (28.95-71.4) 50 (24%) 76 (22%) 498.4 1.06 (0.66 - 1.70) 
P for trendd 0.6 
Homocysteine [μmol/L]c 
1 (3.68-8.03) 36 (18%) 103 (30%) 658.3 1.00 (reference) 
2 (8.04-9.87) 58 (28%) 96 (28%) 677.6 1.95 (1.17 - 3.27) 
3 (9.88-11.94) 46 (22%) 68 (20%) 492.5 2.08 (1.23 - 3.53) 
4 (11.95-64.88) 65 (32%) 77 (22%) 548.8 1.67 (0.96 - 2.90) 
P for trendd 0.17 
a) Sensitivity analysis in which participants with missing covariate data were excluded. Assessed by analyzing RCC cases by Cox-
proportional hazards regression, adjusting for country, sex, and age at diagnosis, and further by hypertension (yes/no), waist-to-hip ratio 
(quartiles), educational attainment (4 categories), smoking status (never/former/current), plasma cotinine (quartiles defined by the 
distribution for current smokers), alcohol intake at recruitment (g/day), and body mass index (three categories were defined: <25 kg/m2; 
25-30 kg/m2, >30 kg/m2, in order to have a reasonable distribution of body mass index in each group).  
b) Vital status for RCC case at the last follow-up. 
c) Quartile cut-off points were determined based on the plasma level distribution of each biomarker for 556 individually matched controls. 
d) P for trend assessed by the base 2 logarithm of plasma concentrations. 
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Appendix 18- Supplementary table 4 for Article 2 
Distribution of Pyridoxal 5'-phosphate demographic, baseline, and tumour characteristics 
Pyridoxal 5'-phosphate [nmol/L]  
  RCC cases (n = 556) Matched controls (n = 556) 
  No. of cases 
Median                     
(5th to 95th percentile) 
No. of 
controls 
Median                     
(5th to 95th percentile) 
Gender         
Men 310 31.9 (13.1-83.1) 310 38.7 (16.6-110) 
Women 246 28.8 (12.1-116.6) 246 32.4 (13.6-122.1) 
Participating countries         
France 13 32.2 (11.2-314.8) 13 31.4 (23.2-128.3) 
Italy 88 25.1 (11.9-58.2) 88 31.7 (12.4-69.8) 
Spain 52 29.5 (17.3-53.3) 52 37.4 (19.2-71.4) 
United Kingdom 67 35.5 (11.9-123.7) 67 38.6 (16.8-203.9) 
The Netherlands 46 28.0 (14.2-77.4) 46 26.5 (14.2-91.3) 
Greece 17 23.1 (9.0-64.9) 17 28.5 (13.3-245) 
Germany 125 34.0 (15.0-104) 125 35.6 (13.9-78.7) 
Sweden 32 30.9 (15.4-148.1) 32 43.2 (19.5-270.1) 
Denmark 112 30.6 (13-101.1) 112 46.6 (17.6-194.6) 
Norway 4 27.1 (9.9-39.2) 4 36.4 (19.8-51.6) 
Smoking status         
Never smokers 225 31.9 (13.9-104) 244 36.0 (16.2-98.0) 
Former smokers 160 33.7 (14.2-84.9) 180 37.7 (16.1-95.7) 
Current smokers 166 26.2 (11.7-65.1) 129 33.8 (13.7-150.1) 
Educational attainment         
Primary school 229 27.3 (13.2-66.9) 206 33.8 (13.6-127) 
Technical/professional school 124 31.7 (11.9-86.8) 136 37.9 (14-122.1) 
Secondary school 77 30.8 (12.1-66.4) 66 31.6 (16.7-89.2) 
Higher education 110 35.7 (16.2-117) 134 39.0 (17.0-110) 
Body mass index         
<18.5 2 25.9 (7.3-44.5) 2 34.9 (18.1-51.7) 
18.5-25 179 31.9 (13-148.1) 221 36.0 (16.4-128.3) 
25-30 247 32.8 (13.6-81.3) 241 37.0 (16.4-101.5) 
30-35 99 27.5 (11.1-80.6) 69 36.4 (16.6-176.1) 
≥35 29 26.0 (13.2-45.3) 23 20.4 (9.5-52.7) 
Waist to hip ratio         
0.56-0.79 92 32.5 (11.9-89) 113 34.4 (16.2-127) 
0.80-0.89 129 31.5 (13.7-116.6) 145 33.1 (13.3-121.9) 
0.90-0.94 103 32.7 (13.9-66.2) 114 38.4 (16.6-145.8) 
0.95-1.30 196 28.4 (12.9-86.8) 148 38.3 (15.7-101.1) 
Hypertension         
No 276 29.8 (13.6-91.6) 325 37.8 (14.2-128.3) 
Yes 192 31.0 (12.9-86.8) 140 33.0 (14.1-89.3) 
Alcohol intake         
Never drinkers 37 28.4 (10.3-172.5) 22 33.5 (18.9-72.5) 
Ever drinkers 509 30.8 (13.6-86.8) 530 36.7 (14.6-121.9) 
Alcohol intake at recruitment         
<5 g/day 248 27.9 (11.9-102.6) 221 31.7 (13.5-108.5) 
5-20 g/day 156 30.0 (13.0-83.1) 173 37.9 (16.8-121.9) 
≥20 g/day 152 34 (14.2-86.8) 162 41.3 (17.5-108.9) 
Stage of the tumour         
 Localised 161 30.4 (13.9-102.6)     
 Metastatic 45 30.5 (14.7-66.2)     
 Metastatic regional 18 33.2 (12.9-183.9)     
 Metastatic distant 27 27.9 (13.2-81.3)     
Unknown 305 30.7 (13.0-83.5)     
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Appendix 19- Supplementary table 5 for Article 2 
Distribution of staging by selected variables 
  Stage Available 
  Yes (n=251) No (n=305) 
Gender     
Men 153 (61%) 157 (51.5%) 
Women 98 (39%) 148 (48.5%) 
Participating countries 
France 1 (0.4%) 12 (3.9%) 
Italy 33 (13.1%) 55 (18%) 
Spain 37 (14.7%) 15 (4.9%) 
United Kingdom 21 (8.4%) 46 (15.1%) 
The Netherlands 0 (0%) 46 (15.1%) 
Greece 12 (4.8%) 5 (1.6%) 
Germany 95 (37.8%) 30 (9.8%) 
Sweden 0 (0%) 32 (10.5%) 
Denmark 49 (19.5%) 63 (20.7%) 
Norway 3 (1.2%) 1 (0.3%) 
Smoking status 
Never smokers 100 (39.8%) 125 (41%) 
Former smokers 68 (27.1%) 92 (30.2%) 
Current smokers 81 (32.3%) 85 (27.9%) 
Unknown 2 (0.8%) 3 (1%) 
Educational attainment 
Primary school 116 (46.2%) 113 (37%) 
Technical/professional school 61 (24.3%) 63 (20.7%) 
Secondary school 24 (9.6%) 53 (17.4%) 
Higher education 48 (19.1%) 62 (20.3%) 
Unknown 2 (0.8%) 14 (4.6%) 
Body mass index 
<18.5 1 (0.4%) 1 (0.3%) 
18.5-25 68 (27.1%) 111 (36.4%) 
25-30 117 (46.6%) 130 (42.6%) 
30-35 50 (19.9%) 49 (16.1%) 
≥35 15 (6%) 14 (4.6%) 
Waist to hip ratio 
0.56-0.79 32 (12.7%) 60 (19.7%) 
0.80-0.89 58 (23.1%) 71 (23.3%) 
0.90-0.94 56 (22.3%) 47 (15.4%) 
0.95-1.30 102 (40.6%) 94 (30.8%) 
Unknown 3 (1.2%) 33 (10.8%) 
Hypertension 
No 132 (52.6%) 144 (47.2%) 
Yes 94 (37.5%) 98 (32.1%) 
Unknown 25 (10%) 63 (20.7%) 
Alcohol intake 
Never drinkers 20 (8%) 17 (5.6%) 
Ever drinkers 230 (91.6%) 279 (91.5%) 
Unknown 1 (0.4%) 9 (3%) 
Alcohol intake at recruitment 
<5 g/day 101 (40.2%) 147 (48.2%) 
5-20 g/day 71 (28.3%) 85 (27.9%) 
≥20 g/day 79 (31.5%) 73 (23.9%) 
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Age at recruitment     
< 40 6 (2.4%) 7 (2.3%) 
40-45 19 (7.6%) 16 (5.2%) 
45-50 20 (8%) 27 (8.9%) 
50-55 53 (21.1%) 79 (25.9%) 
55-60 55 (21.9%) 66 (21.6%) 
65-70 81 (32.3%) 81 (26.6%) 
75-80 11 (4.4%) 21 (6.9%) 
> 80 6 (2.4%) 8 (2.6%) 
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Appendix 20- Supplementary figure 1 for Article 3 
Forest plot showing stratified ORs of lung cancer for log2- of circulating vitamin B6 overall. 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
b Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
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Appendix 21- Supplementary figure 2 for Article 3 
 
Forest plot showing stratified ORs of lung cancer for log2- of circulating vitamin B6 among never smokers. 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
b Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
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Appendix 22- Supplementary figure 3 for Article 3 
Forest plot showing stratified ORs of lung cancer for log2- of circulating vitamin B6 among former smokers. 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
b Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
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Appendix 23- Supplementary figure 4 for Article 3 
Forest plot showing stratified ORs of lung cancer for log2- of circulating vitamin B6 among current 
smokers. 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
b Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
 
 
 
 
 
Men
Women
United States
Europe/Australia
Asia
Large cell carcinoma
Small cell carcinoma
Squamous cell carcinoma
Adenocarcinoma
1-35 months
36-72 months
73-120 months
>120 months
Current smokers log2-Vitamin B6
By gender (p-heterogeneity= 0.11)b
By Continent (p-heterogeneity= 0.04)b
By histology (p-heterogeneity= 0.01)b
By time from blood draw to diagnosis (p-heterogeneity=0.07)b
2519
1718
801
824
698
997
75
330
531
683
479
567
633
840
2519
1718
801
824
698
997
2519
2519
2519
2519
2519
2519
2519
2519
0.92
0.88
0.97
0.97
0.95
0.81
1.19
1.12
0.82
0.92
0.79
0.92
0.93
1.00
0.87-0.98
0.82-0.96
0.88-1.07
0.89-1.06
0.85-1.07
0.72-0.91
0.78-1.82
0.96-1.30
0.72-0.95
0.82-1.03
0.69-0.91
0.81-1.04
0.82-1.05
0.90-1.12
study group Cases Controls ORa 95%CI
0.8 1.0 1.2 1.4 1.6
OCM and smoking-related cancers - Appendices 
216 
 
Appendix 24- Supplementary figure 5 for Article 3 
Forest plot showing stratified ORs of lung cancer for log2- of circulating folate overall. 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
b Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
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Appendix 25- Supplementary figure 6 for Article 3 
Forest plot showing stratified ORs of lung cancer for log2- of circulating folate among never smokers. 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
b Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
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Appendix 26- Supplementary figure 7 for Article 3 
Forest plot showing stratified ORs of lung cancer for log2- of circulating folate among former smokers. 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
b Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
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Appendix 27- Supplementary figure 8 for Article 3 
Forest plot showing stratified ORs of lung cancer for log2- of circulating folate among current smokers. 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
b Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
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Appendix 28- Supplementary figure 9 for Article 3 
Forest plot showing stratified ORs of lung cancer for log2 of circulating vitamin B6 by LC3 cohorts.   
 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
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Appendix 29- Supplementary figure 10 for Article 3 
Forest plot showing stratified ORs of lung cancer for log2 of circulating folate by LC3 cohorts.   
 
 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
 
 
WHI
SCCS
PLCO
NYUWHS
CPS
CLUE
MEC
WHS
NHS
HPFS
PHS
MCCS
MDCS
NSHDS
ATBC
HUNT
SCS
SCHS
SMHS
SWHS
Overall log2-Folate
US cohorts
EU/AU cohorts
Asian cohorts
5364
241
226
450
171
182
191
174
184
345
155
81
354
198
244
200
193
513
422
421
419
5364
241
226
450
171
182
191
174
184
345
155
81
354
198
244
200
193
513
422
421
419
0.94
1.17
1.08
0.95
0.86
1.10
0.96
0.84
1.02
1.00
1.12
0.66
0.87
0.90
0.78
1.10
0.98
0.85
0.86
0.81
1.07
0.90-0.97
0.91-1.50
0.84-1.38
0.81-1.12
0.67-1.12
0.86-1.41
0.79-1.16
0.65-1.10
0.83-1.26
0.86-1.16
0.90-1.40
0.43-0.99
0.73-1.04
0.70-1.16
0.61-0.99
0.81-1.49
0.72-1.33
0.72-1.02
0.73-1.02
0.66-0.98
0.89-1.28
study group Cases Controls ORa 95%CI
0.6 0.8 1.0 1.2
Odds ratio (95 CI%)
OCM and smoking-related cancers - Appendices 
222 
 
Appendix 30- Supplementary figure 11 for Article 3 
Forest plot showing stratified ORs of lung cancer for log2 of circulating methionine by LC3 cohorts. 
 
 
aORs were assessed by conditional logistic regression by including the base 2 logarithm of circulating concentrations (ORs indicate relative 
risks of a doubling in circulating concentrations), and where relevant adjusted for cotinine and education; the black squares and horizontal lines 
indicate the ORs and 95% CIs; the size of the black squares is proportional to the inverse variance of the logistic regression estimates.                        
Pheterogeneity indicates results of chi-square test assessing the null hypothesis of ORs being identical.   
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Appendix 34- Supplementary table 1 for Article 3 
 Odds ratios of lung cancer for circulating levels of vitamin B6, folate and methionine among ever smoking participants in US 
US cohorts 
    Model 1
a  Model 2
b  Model 3
c 
    Cases Controls OR (95%CI)   OR (95%CI)   OR (95%CI) 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
All ever       
smokers 
1  (5.08-29.89) 487 455 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (29.90-49.90) 386 387 0.96 (0.79 - 1.17)   0.98 (0.8 - 1.2)   0.96 (0.78 - 1.18) 
3  (49.91-90.05) 328 343 0.93 (0.76 - 1.14)   0.95 (0.76 - 1.17)   0.91 (0.74 - 1.13) 
4  > 90.05 322 338 0.92 (0.74 - 1.14)   0.97 (0.77 - 1.21)   0.97 (0.78 - 1.22) 
P for trende     0.32   0.61   0.57 
Folate (Vitamin B9) [nmol/L]d           
1  (1.70-17.45) 450 429 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (17.46-33.35) 369 388 0.93 (0.76 - 1.14)   0.96 (0.78 - 1.19)   0.95 (0.77 - 1.17) 
3  (33.36-59.10) 353 350 0.98 (0.78 - 1.22)   1.01 (0.8 - 1.27)   1 (0.8 - 1.26) 
4  > 59.10 351 356 0.98 (0.77 - 1.25)   1.03 (0.81 - 1.32)   1.03 (0.81 - 1.32) 
P for trende . . 0.75   0.96   0.97 
Methionine [μmol/L]d             
1  (11.83-22.77) 385 363 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.78-26.16) 375 367 0.94 (0.76 - 1.16)   0.95 (0.77 - 1.18)   0.95 (0.77 - 1.18) 
3  (26.17-30.47) 372 366 0.96 (0.77 - 1.18)   0.95 (0.76 - 1.19)   0.98 (0.79 - 1.23) 
4  > 30.47 391 427 0.85 (0.69 - 1.05)   0.85 (0.69 - 1.06)   0.85 (0.69 - 1.06) 
P for trende     0.12   0.09   0.14 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Former 
smokers 
1  (5.08-29.89) 164 158 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (29.90-49.90) 161 165 0.94 (0.69 - 1.28)   0.95 (0.68 - 1.31)   0.95 (0.68 - 1.32) 
3  (49.91-90.05) 178 181 0.95 (0.69 - 1.29)   0.94 (0.67 - 1.3)   0.9 (0.65 - 1.26) 
4  > 90.05 200 199 0.97 (0.71 - 1.32)   1.03 (0.73 - 1.43)   1.08 (0.77 - 1.51) 
P for trende     0.32   0.52   0.61 
Folate (Vitamin B9) [nmol/L]d           
1  (1.70-17.45) 110 100 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (17.46-33.35) 163 159 0.92 (0.63 - 1.32)   0.94 (0.64 - 1.38)   1.02 (0.7 - 1.51) 
3  (33.36-59.10) 196 210 0.84 (0.59 - 1.19)   0.87 (0.6 - 1.26)   0.94 (0.65 - 1.37) 
4  > 59.10 234 234 0.89 (0.62 - 1.28)   0.97 (0.66 - 1.43)   1.02 (0.7 - 1.5) 
P for trende     0.51   0.83   0.88 
Methionine [μmol/L]d             
1  (11.83-22.77) 150 132 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.78-26.16) 165 167 0.87 (0.63 - 1.2)   0.92 (0.65 - 1.3)   0.89 (0.63 - 1.27) 
3  (26.17-30.47) 184 189 0.85 (0.62 - 1.16)   0.85 (0.6 - 1.18)   0.93 (0.66 - 1.32) 
4  > 30.47 204 215 0.83 (0.61 - 1.13)   0.87 (0.62 - 1.21)   0.88 (0.63 - 1.24) 
P for trende     0.13   0.16   0.28 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Current 
smokers 
1  (5.08-29.89) 323 297 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (29.90-49.90) 225 222 0.98 (0.75 - 1.28)   1 (0.77 - 1.3)   0.98 (0.75 - 1.28) 
3  (49.91-90.05) 150 162 0.91 (0.69 - 1.21)   0.94 (0.7 - 1.24)   0.91 (0.69 - 1.21) 
4  > 90.05 122 139 0.85 (0.63 - 1.15)   0.87 (0.65 - 1.18)   0.86 (0.64 - 1.17) 
P for trende     0.52   0.68   0.57 
Folate (Vitamin B9) [nmol/L]d           
1  (1.70-17.45) 340 329 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (17.46-33.35) 206 229 0.91 (0.71 - 1.17)   0.93 (0.73 - 1.2)   0.91 (0.71 - 1.17) 
3  (33.36-59.10) 157 140 1.07 (0.79 - 1.44)   1.09 (0.8 - 1.47)   1.06 (0.78 - 1.44) 
4  > 59.10 117 122 1.06 (0.75 - 1.51)   1.06 (0.74 - 1.51)   1.06 (0.75 - 1.52) 
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P for trende . . 0.97   0.95   0.98 
Methionine [μmol/L]d             
1  (11.83-22.77) 235 231 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.78-26.16) 210 200 1.01 (0.77 - 1.33)   1 (0.76 - 1.32)   1.01 (0.76 - 1.33) 
3  (26.17-30.47) 188 177 1.03 (0.76 - 1.38)   1.03 (0.76 - 1.38)   1.03 (0.76 - 1.38) 
4  > 30.47 187 212 0.85 (0.63 - 1.14)   0.84 (0.62 - 1.12)   0.84 (0.62 - 1.12) 
P for trende     0.39   0.32   0.36 
  
 
 
 
Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d 
        
Smoking      
men 
1  (5.08-29.89) 221 192 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (29.90-49.90) 175 174 0.89 (0.66 - 1.2)   0.91 (0.67 - 1.24)   0.87 (0.64 - 1.18) 
3  (49.91-90.05) 150 156 0.83 (0.6 - 1.13)   0.82 (0.59 - 1.14)   0.74 (0.53 - 1.03) 
4  > 90.05 129 153 0.7 (0.5 - 0.98)   0.74 (0.53 - 1.06)   0.75 (0.52 - 1.06) 
P for trende     0.02   0.04   0.04 
Folate (Vitamin B9) [nmol/L]d           
1  (1.70-17.45) 185 164 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (17.46-33.35) 152 176 0.8 (0.57 - 1.11)   0.85 (0.6 - 1.18)   0.85 (0.6 - 1.19) 
3  (33.36-59.10) 172 166 0.91 (0.64 - 1.32)   0.98 (0.67 - 1.42)   0.98 (0.67 - 1.43) 
4  > 59.10 166 169 0.89 (0.6 - 1.32)   0.96 (0.64 - 1.45)   0.97 (0.64 - 1.47) 
P for trende     0.93   0.80   0.87 
Methionine [μmol/L]d             
1  (11.83-22.77) 161 147 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.78-26.16) 161 133 1.06 (0.76 - 1.49)   1.05 (0.75 - 1.49)   1.03 (0.73 - 1.47) 
3  (26.17-30.47) 162 155 0.96 (0.69 - 1.33)   0.94 (0.67 - 1.33)   0.99 (0.69 - 1.4) 
4  > 30.47 191 240 0.69 (0.5 - 0.94)   0.69 (0.49 - 0.95)   0.68 (0.49 - 0.95) 
P for trende     0.02   0.01   0.03 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Smoking 
women 
1  (5.08-29.89) 266 263 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (29.90-49.90) 211 213 1.02 (0.77 - 1.33)   1.03 (0.78 - 1.36)   1.03 (0.78 - 1.36) 
3  (49.91-90.05) 178 187 1 (0.76 - 1.32)   1.03 (0.78 - 1.37)   1.05 (0.79 - 1.4) 
4  > 90.05 193 185 1.12 (0.84 - 1.49)   1.15 (0.86 - 1.54)   1.16 (0.86 - 1.55) 
P for trende     0.52   0.34   0.35 
Folate (Vitamin B9) [nmol/L]d           
1  (1.70-17.45) 265 265 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (17.46-33.35) 217 212 1.05 (0.8 - 1.36)   1.07 (0.82 - 1.39)   1.04 (0.8 - 1.36) 
3  (33.36-59.10) 181 184 1.01 (0.76 - 1.34)   1.03 (0.77 - 1.37)   1.01 (0.76 - 1.34) 
4  > 59.10 185 187 1.05 (0.77 - 1.42)   1.08 (0.79 - 1.48)   1.07 (0.79 - 1.46) 
P for trende     0.77   0.92   0.91 
Methionine [μmol/L]d             
1  (11.83-22.77) 224 216 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.78-26.16) 214 234 0.86 (0.65 - 1.13)   0.88 (0.66 - 1.16)   0.89 (0.68 - 1.18) 
3  (26.17-30.47) 210 211 0.96 (0.73 - 1.28)   0.97 (0.72 - 1.3)   1 (0.75 - 1.33) 
4  > 30.47 200 187 1.06 (0.79 - 1.41)   1.07 (0.79 - 1.43)   1.07 (0.8 - 1.44) 
P for trend     0.85   0.86   0.81 
a) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles) and education (in 
7 categories). 
b) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles), education (in 7 
categories), and number of years of smoking (continuous). 
c) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles), education (in 7 
categories), and number of pack-years of smoking (continuous). 
d) Quartile cut-off points were determined based on the circulating level distribution of US matched controls. 
e) P for trend assessed by the base 2 logarithm of the circulating levels. 
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Appendix 35- Supplementary table 2 for Article 3 
Odds ratios of lung cancer for circulating levels of vitamin B6, folate and methionine among ever smoking participants in EU/AU  
European/Asian cohorts 
    Model 1
a  Model 2
b  Model 3
c 
    Cases Controls OR (95%CI)   OR (95%CI)   OR (95%CI) 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
All ever       
smokers 
1  (4.37-22.41) 334 245 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.42-30.90) 216 254 0.65 (0.5 - 0.83)   0.63 (0.49 - 0.82)   0.65 (0.5 - 0.84) 
3  (30.91-44.95) 186 217 0.65 (0.5 - 0.86)   0.65 (0.49 - 0.86)   0.66 (0.5 - 0.87) 
4  > 44.96 201 221 0.71 (0.54 - 0.93)   0.71 (0.54 - 0.94)   0.69 (0.52 - 0.91) 
P for trende     0.31   0.65   0.17 
Folate (Vitamin B9) [nmol/L]d           
1  (0.24-7.78) 279 230 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (7.79-10.77) 220 243 0.74 (0.56 - 0.97)   0.77 (0.58 - 1.01)   0.74 (0.56 - 0.97) 
3  (10.78-15.98) 230 231 0.84 (0.64 - 1.11)   0.83 (0.63 - 1.1)   0.86 (0.65 - 1.13) 
4  > 15.98 208 233 0.76 (0.57 - 1)   0.76 (0.57 - 1.02)   0.75 (0.56 - 1) 
P for trende     0.06   0.06   0.04 
Methionine [μmol/L]d             
1  (10.63-22.81) 221 235 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.82-26.29) 249 218 1.23 (0.94 - 1.6)   1.18 (0.89 - 1.55)   1.24 (0.95 - 1.63) 
3  (26.30-29.91) 235 241 0.97 (0.74 - 1.29)   1 (0.75 - 1.33)   0.99 (0.75 - 1.31) 
4  > 29.91 232 243 1.01 (0.77 - 1.33)   0.97 (0.73 - 1.3)   1.03 (0.78 - 1.37) 
P for trende     0.79   0.75   0.96 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Former 
smokers 
1  (4.37-22.41) 48 35 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.42-30.90) 62 55 0.8 (0.45 - 1.42)   0.88 (0.47 - 1.63)   0.83 (0.45 - 1.52) 
3  (30.91-44.95) 58 74 0.55 (0.31 - 0.98)   0.64 (0.34 - 1.2)   0.54 (0.29 - 1) 
4  > 44.96 77 81 0.66 (0.38 - 1.16)   0.67 (0.36 - 1.23)   0.61 (0.34 - 1.09) 
P for trende     0.72   0.51   0.28 
Folate (Vitamin B9) [nmol/L]d           
1  (0.24-7.78) 50 31 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (7.79-10.77) 53 60 0.52 (0.28 - 0.95)   0.53 (0.27 - 1.02)   0.55 (0.29 - 1.03) 
3  (10.78-15.98) 62 64 0.57 (0.32 - 1.02)   0.54 (0.29 - 1.02)   0.58 (0.31 - 1.06) 
4  > 15.98 80 90 0.51 (0.28 - 0.91)   0.48 (0.25 - 0.9)   0.5 (0.27 - 0.92) 
P for trende     0.03   0.02   0.01 
Methionine [μmol/L]d             
1  (10.63-22.81) 52 64 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.82-26.29) 56 51 1.33 (0.79 - 2.24)   1.35 (0.76 - 2.39)   1.31 (0.76 - 2.24) 
3  (26.30-29.91) 68 61 1.37 (0.82 - 2.29)   1.54 (0.88 - 2.69)   1.28 (0.75 - 2.19) 
4  > 29.91 69 69 1.23 (0.75 - 2.03)   1.05 (0.61 - 1.82)   1.21 (0.72 - 2.05) 
P for trende     0.82   0.91   0.93 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Current 
smokers 
1  (4.37-22.41) 286 210 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.42-30.90) 154 199 0.6 (0.45 - 0.8)   0.58 (0.43 - 0.77)   0.6 (0.45 - 0.8) 
3  (30.91-44.95) 128 143 0.7 (0.51 - 0.96)   0.68 (0.49 - 0.94)   0.7 (0.51 - 0.97) 
4  > 44.96 124 140 0.74 (0.54 - 1.02)   0.76 (0.55 - 1.05)   0.74 (0.54 - 1.02) 
P for trende     0.33   0.44   0.31 
Folate (Vitamin B9) [nmol/L]d           
1  (0.24-7.78) 229 199 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (7.79-10.77) 167 183 0.79 (0.59 - 1.08)   0.82 (0.6 - 1.11)   0.78 (0.58 - 1.07) 
3  (10.78-15.98) 168 167 0.91 (0.67 - 1.26)   0.91 (0.66 - 1.25)   0.92 (0.67 - 1.27) 
4  > 15.98 128 143 0.83 (0.59 - 1.16)   0.84 (0.6 - 1.18)   0.82 (0.59 - 1.15) 
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P for trende     0.39   0.43   0.36 
Methionine [μmol/L]d             
1  (10.63-22.81) 169 171 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.82-26.29) 193 167 1.17 (0.85 - 1.6)   1.13 (0.82 - 1.55)   1.19 (0.87 - 1.64) 
3  (26.30-29.91) 167 180 0.84 (0.61 - 1.17)   0.85 (0.61 - 1.19)   0.88 (0.63 - 1.23) 
4  > 29.91 163 174 0.92 (0.66 - 1.28)   0.92 (0.66 - 1.29)   0.95 (0.68 - 1.33) 
P for trende     0.60   0.66   0.81 
  
 
 
 
 
 
Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d 
        
Smoking      
men 
1  (4.37-22.41) 195 146 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.42-30.90) 140 162 0.67 (0.49 - 0.92)   0.68 (0.49 - 0.94)   0.7 (0.5 - 0.97) 
3  (30.91-44.95) 123 133 0.73 (0.51 - 1.03)   0.76 (0.53 - 1.09)   0.74 (0.51 - 1.06) 
4  > 44.96 117 134 0.72 (0.51 - 1.02)   0.74 (0.52 - 1.06)   0.71 (0.5 - 1.02) 
P for trende     0.29   0.37   0.21 
Folate (Vitamin B9) [nmol/L]d           
1  (0.24-7.78) 158 121 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (7.79-10.77) 135 145 0.71 (0.5 - 1.02)   0.72 (0.5 - 1.04)   0.71 (0.49 - 1.02) 
3  (10.78-15.98) 151 161 0.73 (0.51 - 1.04)   0.69 (0.48 - 1)   0.75 (0.52 - 1.08) 
4  > 15.98 131 148 0.67 (0.46 - 0.97)   0.66 (0.45 - 0.98)   0.65 (0.44 - 0.96) 
P for trende     0.03   0.02   0.01 
Methionine [μmol/L]d             
1  (10.63-22.81) 95 100 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.82-26.29) 144 126 1.23 (0.84 - 1.8)   1.22 (0.82 - 1.81)   1.29 (0.87 - 1.91) 
3  (26.30-29.91) 164 166 0.98 (0.67 - 1.44)   1.06 (0.71 - 1.58)   1.03 (0.7 - 1.52) 
4  > 29.91 172 183 0.99 (0.68 - 1.42)   1 (0.68 - 1.46)   1.03 (0.7 - 1.5) 
P for trende     0.53   0.65   0.73 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Smoking 
women 
1  (4.37-22.41) 139 99 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.42-30.90) 76 92 0.59 (0.39 - 0.9)   0.54 (0.35 - 0.83)   0.55 (0.35 - 0.84) 
3  (30.91-44.95) 63 84 0.54 (0.35 - 0.85)   0.5 (0.31 - 0.79)   0.54 (0.34 - 0.85) 
4  > 44.96 84 87 0.67 (0.43 - 1.04)   0.66 (0.42 - 1.03)   0.64 (0.41 - 0.99) 
P for trende     0.69   0.67   0.46 
Folate (Vitamin B9) [nmol/L]d           
1  (0.24-7.78) 121 109 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (7.79-10.77) 85 98 0.76 (0.5 - 1.16)   0.82 (0.53 - 1.25)   0.78 (0.51 - 1.19) 
3  (10.78-15.98) 79 70 1.06 (0.67 - 1.68)   1.12 (0.7 - 1.79)   1.06 (0.66 - 1.69) 
4  > 15.98 77 85 0.88 (0.57 - 1.37)   0.9 (0.57 - 1.4)   0.9 (0.57 - 1.4) 
P for trende     0.81   0.89   0.88 
Methionine [μmol/L]d             
1  (10.63-22.81) 126 135 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.82-26.29) 105 92 1.21 (0.82 - 1.78)   1.15 (0.77 - 1.71)   1.19 (0.8 - 1.76) 
3  (26.30-29.91) 71 75 0.95 (0.62 - 1.45)   0.93 (0.6 - 1.44)   0.94 (0.61 - 1.45) 
4  > 29.91 60 60 1.06 (0.67 - 1.67)   0.96 (0.61 - 1.54)   1.07 (0.67 - 1.7) 
P for trende     0.83   0.99   0.80 
a) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles) and education (in 
7 categories). 
b) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles), education (in 7 
categories), and number of years of smoking (continuous). 
c) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles), education (in 7 
categories), and number of pack-years of smoking (continuous). 
d) Quartile cut-off points were determined based on the circulating level distribution of EU/AU matched controls. 
e) P for trend assessed by the base 2 logarithm of the circulating levels. 
OCM and smoking-related cancers - Appendices 
230 
 
Appendix 36- Supplementary table 3 for Article 3 
Odds ratios of lung cancer for circulating levels of vitamin B6, folate and methionine among ever smoking participants in Asia 
Asian cohorts 
    Model 1
a  Model 2
b  Model 3
c 
    Cases Controls OR (95%CI)   OR (95%CI)   OR (95%CI) 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
All ever       
smokers 
1  (4.81-20.49) 490 391 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (20.50-30.82) 317 308 0.89 (0.71 - 1.13)   0.91 (0.72 - 1.15)   0.96 (0.76 - 1.22) 
3  (31.23-46.99) 205 259 0.68 (0.52 - 0.88)   0.72 (0.55 - 0.94)   0.73 (0.55 - 0.95) 
4  > 47.00 161 215 0.65 (0.49 - 0.87)   0.71 (0.54 - 0.95)   0.73 (0.54 - 0.97) 
P for trende     0.001   0.009   0.01 
Folate (Vitamin B9) [nmol/L]d           
1  (0.17-10.59) 418 348 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (10.60-15.00) 315 310 0.85 (0.68 - 1.07)   0.89 (0.71 - 1.13)   0.91 (0.72 - 1.15) 
3  (15.01-21.00) 222 274 0.73 (0.58 - 0.94)   0.77 (0.6 - 0.99)   0.81 (0.62 - 1.04) 
4  >21.01 218 241 0.83 (0.64 - 1.06)   0.89 (0.69 - 1.15)   0.89 (0.68 - 1.15) 
P for trende . . 0.05   0.26   0.22 
Methionine [μmol/L]d             
1  (12.32-23.17) 258 254 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (23.18-27.39) 282 267 1.12 (0.86 - 1.45)   1.22 (0.93 - 1.59)   1.19 (0.91 - 1.56) 
3  (27.39-32.22) 288 312 0.93 (0.71 - 1.2)   0.98 (0.75 - 1.29)   0.94 (0.72 - 1.23) 
4  >32.22 345 340 1.03 (0.8 - 1.31)   1.08 (0.83 - 1.39)   1.08 (0.83 - 1.39) 
P for trende     0.87   0.99   0.83 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Former 
smokers 
1  (4.81-20.49) 34 22 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (20.50-30.82) 40 38 0.67 (0.32 - 1.41)   0.71 (0.33 - 1.51)   0.82 (0.36 - 1.83) 
3  (31.23-46.99) 48 52 0.6 (0.3 - 1.17)   0.6 (0.3 - 1.2)   0.63 (0.31 - 1.31) 
4  > 47.00 54 64 0.55 (0.29 - 1.06)   0.64 (0.33 - 1.26)   0.66 (0.33 - 1.32) 
P for trende     0.29   0.58   0.65 
Folate (Vitamin B9) [nmol/L]d           
1  (0.17-10.59) 60 37 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (10.60-15.00) 32 48 0.42 (0.23 - 0.78)   0.47 (0.25 - 0.88)   0.47 (0.25 - 0.91) 
3  (15.01-21.00) 34 45 0.45 (0.24 - 0.86)   0.53 (0.27 - 1.02)   0.61 (0.31 - 1.2) 
4  >21.01 50 46 0.65 (0.36 - 1.19)   0.82 (0.43 - 1.55)   0.85 (0.45 - 1.62) 
P for trende     0.26   0.74   0.76 
Methionine [μmol/L]d             
1  (12.32-23.17) 62 48 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (23.18-27.39) 37 41 0.66 (0.36 - 1.22)   0.74 (0.4 - 1.4)   0.77 (0.4 - 1.47) 
3  (27.39-32.22) 43 45 0.69 (0.38 - 1.25)   0.74 (0.4 - 1.36)   0.71 (0.38 - 1.32) 
4  >32.22 34 42 0.59 (0.32 - 1.1)   0.61 (0.32 - 1.15)   0.56 (0.28 - 1.09) 
P for trende     0.17   0.17   0.17 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Current 
smokers 
1  (4.81-20.49) 456 369 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (20.50-30.82) 277 270 0.93 (0.73 - 1.18)   0.93 (0.73 - 1.19)   0.98 (0.76 - 1.26) 
3  (31.23-46.99) 157 207 0.68 (0.51 - 0.9)   0.74 (0.55 - 0.99)   0.73 (0.55 - 0.99) 
4  > 47.00 107 151 0.68 (0.49 - 0.94)   0.7 (0.5 - 0.98)   0.73 (0.52 - 1.02) 
P for trende     0.001   0.006   0.009 
Folate (Vitamin B9) [nmol/L]d           
1  (0.17-10.59) 358 311 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (10.60-15.00) 283 262 0.96 (0.75 - 1.23)   0.98 (0.76 - 1.26)   1 (0.78 - 1.29) 
3  (15.01-21.00) 188 229 0.8 (0.61 - 1.05)   0.82 (0.62 - 1.07)   0.84 (0.64 - 1.11) 
4  >21.01 168 195 0.84 (0.64 - 1.11)   0.85 (0.64 - 1.13)   0.86 (0.65 - 1.15) 
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P for trende     0.09   0.18   0.18 
Methionine [μmol/L]d             
1  (12.32-23.17) 196 206 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (23.18-27.39) 245 226 1.28 (0.96 - 1.72)   1.37 (1.02 - 1.86)   1.33 (0.98 - 1.8) 
3  (27.39-32.22) 245 267 1.02 (0.76 - 1.36)   1.07 (0.79 - 1.45)   1.02 (0.75 - 1.38) 
4  >32.22 311 298 1.16 (0.88 - 1.52)   1.21 (0.91 - 1.6)   1.22 (0.92 - 1.61) 
P for trende     0.71   0.58   0.44 
  
 
 
 
Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d 
        
Smoking      
men 
1  (4.81-20.49) 473 380 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (20.50-30.82) 293 292 0.89 (0.7 - 1.12)   0.89 (0.7 - 1.13)   0.96 (0.75 - 1.22) 
3  (31.23-46.99) 183 233 0.69 (0.53 - 0.9)   0.72 (0.55 - 0.95)   0.74 (0.56 - 0.98) 
4  > 47.00 151 195 0.69 (0.51 - 0.92)   0.75 (0.56 - 1.01)   0.77 (0.56 - 1.04) 
P for trende     0.003   0.02   0.04 
Folate (Vitamin B9) [nmol/L]d           
1  (0.17-10.59) 400 328 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (10.60-15.00) 296 292 0.84 (0.66 - 1.05)   0.88 (0.69 - 1.12)   0.89 (0.7 - 1.13) 
3  (15.01-21.00) 208 250 0.75 (0.58 - 0.96)   0.8 (0.62 - 1.04)   0.82 (0.63 - 1.07) 
4  >21.01 196 230 0.76 (0.59 - 0.98)   0.82 (0.63 - 1.07)   0.81 (0.62 - 1.06) 
P for trende     0.02   0.15   0.09 
Methionine [μmol/L]d             
1  (12.32-23.17) 225 225 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (23.18-27.39) 261 250 1.11 (0.85 - 1.46)   1.22 (0.92 - 1.61)   1.19 (0.89 - 1.58) 
3  (27.39-32.22) 279 301 0.94 (0.72 - 1.24)   1.01 (0.76 - 1.33)   0.96 (0.72 - 1.27) 
4  >32.22 335 324 1.06 (0.82 - 1.38)   1.12 (0.86 - 1.46)   1.12 (0.86 - 1.47) 
P for trende     0.97   0.88   0.67 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Smoking 
women 
1  (4.81-20.49) 17 11 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (20.50-30.82) 24 16 0.71 (0.22 - 2.26)   0.82 (0.25 - 2.7)   0.78 (0.24 - 2.51) 
3  (31.23-46.99) 22 26 0.37 (0.12 - 1.17)   0.47 (0.14 - 1.57)   0.4 (0.12 - 1.3) 
4  > 47.00 10 20 0.29 (0.08 - 1.04)   0.32 (0.09 - 1.18)   0.31 (0.08 - 1.14) 
P for trende     0.04   0.07   0.05 
Folate (Vitamin B9) [nmol/L]d           
1  (0.17-10.59) 18 20 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (10.60-15.00) 19 18 1.3 (0.39 - 4.33)   1.63 (0.46 - 5.79)   1.66 (0.46 - 5.99) 
3  (15.01-21.00) 14 24 0.65 (0.22 - 1.91)   0.59 (0.19 - 1.84)   0.78 (0.25 - 2.41) 
4  >21.01 22 11 3 (0.9 - 9.93)   3.96 (1.03 - 15.18)   3.86 (1.05 - 14.21) 
P for trende     0.17   0.16   0.11 
Methionine [μmol/L]d             
1  (12.32-23.17) 33 29 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (23.18-27.39) 21 17 1.21 (0.44 - 3.34)   1.35 (0.48 - 3.79)   1.27 (0.45 - 3.56) 
3  (27.39-32.22) 9 11 0.64 (0.2 - 2.05)   0.7 (0.22 - 2.24)   0.75 (0.23 - 2.42) 
4  >32.22 10 16 0.51 (0.2 - 1.33)   0.54 (0.2 - 1.44)   0.54 (0.2 - 1.44) 
P for trende     0.34   0.42   0.38 
a) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles) and education (in 
7 categories). 
b) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles), education (in 7 
categories), and number of years of smoking (continuous). 
c) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles), education (in 7 
categories), and number of pack-years of smoking (continuous). 
d) Quartile cut-off points were determined based on the circulating level distribution of Asian matched controls. 
e) P for trend assessed by the base 2 logarithm of the circulating levels. 
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Appendix 37- Supplementary table 4 for Article 3 
Odds ratios of lung cancer for circulating levels of vitamin B6, folate and methionine among ever smoking participants in LC3 
All cohorts 
    Model 1
a  Model 2
b  Model 3
c 
    Cases Controls OR (95%CI)   OR (95%CI)   OR (95%CI) 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
All ever       
smokers 
1  (4.37-23.93) 1300 1104 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (23.94-37.05) 911 962 0.83 (0.73 - 0.94)   0.85 (0.74 - 0.97)   0.87 (0.76 - 0.99) 
3  (37.06-62.50) 724 795 0.81 (0.7 - 0.93)   0.83 (0.72 - 0.96)   0.82 (0.71 - 0.95) 
4  > 62.51 698 772 0.78 (0.67 - 0.91)   0.83 (0.71 - 0.97)   0.81 (0.7 - 0.95) 
P for trende     0.003   0.03   0.02 
Folate (Vitamin B9) [nmol/L]d           
1  (0.17-10.92) 1154 1039 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (10.93-17.89) 948 957 0.91 (0.8 - 1.04)   0.93 (0.81 - 1.06)   0.94 (0.82 - 1.08) 
3  (17.90-34.92) 776 855 0.85 (0.74 - 0.98)   0.88 (0.76 - 1.02)   0.89 (0.77 - 1.03) 
4  > 34.97 755 782 0.87 (0.73 - 1.03)   0.92 (0.77 - 1.1)   0.91 (0.76 - 1.08) 
P for trende     0.03   0.15   0.10 
Methionine [μmol/L]d             
1  (10.63-22.89) 861 855 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.90-27.40) 902 849 1.07 (0.93 - 1.23)   1.09 (0.94 - 1.25)   1.09 (0.94 - 1.25) 
3  (27.40-31.00) 913 913 0.99 (0.86 - 1.14)   1.01 (0.87 - 1.17)   1.02 (0.88 - 1.18) 
4  > 31.01 957 1016 0.95 (0.82 - 1.09)   0.96 (0.83 - 1.11)   0.96 (0.83 - 1.11) 
P for trende     0.25   0.24   0.44 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Former 
smokers 
1  (4.37-23.93) 210 163 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (23.94-37.05) 266 279 0.74 (0.57 - 0.97)   0.77 (0.58 - 1.01)   0.77 (0.58 - 1.03) 
3  (37.06-62.50) 270 288 0.72 (0.55 - 0.94)   0.76 (0.57 - 1.01)   0.7 (0.53 - 0.94) 
4  > 62.51 378 394 0.73 (0.56 - 0.95)   0.79 (0.6 - 1.04)   0.77 (0.58 - 1.02) 
P for trende     0.17   0.41   0.31 
Folate (Vitamin B9) [nmol/L]d           
1  (0.17-10.92) 211 164 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (10.93-17.89) 200 215 0.69 (0.52 - 0.93)   0.74 (0.54 - 1.01)   0.74 (0.54 - 1) 
3  (17.90-34.92) 275 281 0.69 (0.51 - 0.92)   0.77 (0.56 - 1.05)   0.79 (0.57 - 1.08) 
4  > 34.97 438 464 0.63 (0.47 - 0.86)   0.73 (0.53 - 1.01)   0.72 (0.52 - 1) 
P for trende     0.05   0.26   0.18 
Methionine [μmol/L]d             
1  (10.63-22.89) 263 248 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.90-27.40) 279 267 0.98 (0.77 - 1.26)   1.01 (0.78 - 1.31)   1.01 (0.77 - 1.31) 
3  (27.40-31.00) 298 300 0.93 (0.73 - 1.18)   0.96 (0.75 - 1.24)   0.99 (0.76 - 1.28) 
4  > 31.01 284 309 0.86 (0.67 - 1.1)   0.86 (0.66 - 1.12)   0.87 (0.67 - 1.13) 
P for trende     0.09   0.08   0.15 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Current 
smokers 
1  (4.37-23.93) 1090 941 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (23.94-37.05) 645 683 0.85 (0.74 - 0.99)   0.87 (0.75 - 1.01)   0.89 (0.76 - 1.03) 
3  (37.06-62.50) 454 507 0.83 (0.7 - 0.98)   0.85 (0.72 - 1.01)   0.85 (0.72 - 1.01) 
4  > 62.51 320 378 0.78 (0.64 - 0.95)   0.81 (0.67 - 0.99)   0.8 (0.65 - 0.97) 
P for trende     0.005   0.03   0.01 
Folate (Vitamin B9) [nmol/L]d           
1  (0.17-10.92) 943 875 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (10.93-17.89) 748 742 0.96 (0.83 - 1.12)   0.97 (0.83 - 1.13)   0.98 (0.84 - 1.14) 
3  (17.90-34.92) 501 574 0.88 (0.74 - 1.04)   0.89 (0.75 - 1.05)   0.9 (0.76 - 1.06) 
4  > 34.97 317 318 0.97 (0.78 - 1.21)   1.01 (0.8 - 1.26)   0.98 (0.78 - 1.23) 
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P for trende     0.15   0.26   0.20 
Methionine [μmol/L]d             
1  (10.63-22.89) 598 607 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.90-27.40) 623 582 1.12 (0.94 - 1.32)   1.12 (0.95 - 1.33)   1.12 (0.95 - 1.33) 
3  (27.40-31.00) 615 613 1.02 (0.86 - 1.21)   1.03 (0.86 - 1.22)   1.03 (0.87 - 1.23) 
4  > 31.01 673 707 0.99 (0.84 - 1.17)   1 (0.84 - 1.19)   1 (0.84 - 1.19) 
P for trende     0.72   0.72   0.92 
  
 
 
 
 
 
Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d 
        
Smoking      
men 
1  (4.37-23.93) 952 789 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (23.94-37.05) 593 655 0.76 (0.65 - 0.89)   0.79 (0.67 - 0.92)   0.82 (0.7 - 0.96) 
3  (37.06-62.50) 461 497 0.81 (0.68 - 0.96)   0.84 (0.7 - 1.01)   0.82 (0.69 - 0.99) 
4  > 62.51 344 409 0.68 (0.56 - 0.84)   0.72 (0.59 - 0.89)   0.7 (0.57 - 0.87) 
P for trende     <.0001   0.001   0.001 
Folate (Vitamin B9) [nmol/L]d           
1  (0.17-10.92) 799 693 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (10.93-17.89) 677 687 0.88 (0.75 - 1.03)   0.9 (0.77 - 1.06)   0.92 (0.78 - 1.08) 
3  (17.90-34.92) 489 562 0.78 (0.66 - 0.94)   0.82 (0.68 - 0.99)   0.84 (0.7 - 1.01) 
4  > 34.97 385 408 0.78 (0.61 - 0.98)   0.86 (0.67 - 1.1)   0.82 (0.64 - 1.05) 
P for trende     0.005   0.05   0.02 
Methionine [μmol/L]d             
1  (10.63-22.89) 476 464 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.90-27.40) 538 490 1.11 (0.92 - 1.33)   1.14 (0.94 - 1.38)   1.13 (0.93 - 1.37) 
3  (27.40-31.00) 618 624 0.97 (0.81 - 1.17)   1.02 (0.84 - 1.23)   1 (0.83 - 1.21) 
4  > 31.01 718 772 0.92 (0.77 - 1.1)   0.94 (0.79 - 1.13)   0.94 (0.78 - 1.13) 
P for trende     0.16   0.17   0.32 
  Vitamin B6 (Pyridoxal 5'-phosphate) [nmol/L]d         
Smoking 
women 
1  (4.37-23.93) 348 315 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (23.94-37.05) 318 307 0.96 (0.77 - 1.2)   0.98 (0.78 - 1.23)   0.96 (0.76 - 1.2) 
3  (37.06-62.50) 263 298 0.81 (0.64 - 1.03)   0.83 (0.65 - 1.06)   0.82 (0.65 - 1.05) 
4  > 62.51 354 363 0.94 (0.74 - 1.19)   0.98 (0.77 - 1.25)   0.97 (0.77 - 1.24) 
P for trende     0.96   0.71   0.91 
Folate (Vitamin B9) [nmol/L]d           
1  (0.17-10.92) 355 346 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (10.93-17.89) 271 270 0.98 (0.77 - 1.25)   0.98 (0.76 - 1.25)   0.97 (0.76 - 1.24) 
3  (17.90-34.92) 287 293 0.99 (0.78 - 1.28)   1 (0.77 - 1.28)   1 (0.77 - 1.28) 
4  > 34.97 370 374 1.01 (0.78 - 1.31)   1.03 (0.79 - 1.34)   1.03 (0.79 - 1.33) 
P for trende     0.89   0.93   0.90 
Methionine [μmol/L]d             
1  (10.63-22.89) 385 391 1.00 (reference)   1.00 (reference)   1.00 (reference) 
2  (22.90-27.40) 364 359 1.02 (0.83 - 1.26)   1.02 (0.82 - 1.26)   1.03 (0.83 - 1.28) 
3  (27.40-31.00) 295 289 1.03 (0.82 - 1.29)   1.01 (0.8 - 1.27)   1.05 (0.83 - 1.33) 
4  > 31.01 239 244 1.02 (0.8 - 1.29)   1.02 (0.8 - 1.31)   1.02 (0.8 - 1.3) 
P for trende     0.97   0.97   0.93 
a) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles) and education (in 
7 categories). 
b) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles), education (in 7 
categories), and number of years of smoking (continuous). 
c) Assessed by conditional logistic regression, conditioning on individual case set and adjusting for circulating cotinine (in quartiles), education (in 7 
categories), and number of pack-years of smoking (continuous). 
d) Quartile cut-off points were determined based on the circulating level distribution of LC3 matched controls. 
e) P for trend assessed by the base 2 logarithm of the circulating levels. 
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